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AIM AND OUTLINE
A im
The estrogen receptor alpha (ERa) plays a role in normal physiology and development, 
but is also involved in the development and progression of diseases such as breast can­
cer. Although the ERa has been the subject of many studies, the total regulatory net­
work governed by ERa is still not well understood. Furthermore, the effect of clini­
cally relevant full or partial estrogen receptor antagonists on this network is unknown. 
The development of chromatin immunoprecipitation (ChIP) enabled the analysis of 
protein-DNA interactions, such as ERa DNA binding. The techniques for detection 
and identification of the precipitated DNA fragments have increased rapidly in the last 
few years. Initially, single sites were identified by PCR, next analyses of many promoter 
regions were performed simultaneously, later genome-wide analysis of binding through 
micro-array (ChIP-chip) became available and now next generation high throughut se­
quencing (ChIP-Seq) is applied. This has opened the possibility to study the ERa in­
teraction network in more depth than ever before. The aim of this thesis is to use these 
techniques to gain more insight in the genome-wide binding site network of the ERa 
and the effect that (partial) antagonists have on this network.
O u t l i n e
Chapter 1 gives an overview of the data available on ERa mediated regulation and 
target gene identification. The different methods and techniques that have been used 
to identify ERa target genes are reviewed, from the expression levels of single genes to 
genome-wide ChIP approaches.
In Chapter 2 we set out to identify the true genome-wide ERa binding site profile in 
response to estradiol (E2), the partial antagonist tamoxifen, or in the absence of ligand, 
using ChIP-chip. For this, true genome-wide tiling arrays are used covering the com­
plete non-repetitive part of the human genome. Thus far, no genome-wide arrays were 
employed, only e.g. promoter arrays or arrays covering only chromosome 21 and 22. 
Using genome-wide arrays will allow the identification of a great number of ERa bind­
ing sites and will enable a very thorough and statistically powerful analysis of these sites 
and the ERa binding site network as a whole. Where and to what extend the ERa binds 
outside of classical promoter regions is as of yet unknown.
In Chapter 3 ChIP coupled to Illumina high throughut sequencing (ChIP-Seq) is used
8
to detect ERa-DNA interaction sites. High throughut sequencing has great advantages 
over hybridization-based methods, such as the genome-wide arrays described in chapter 
2. Next generation high throughut sequencing allows for the unbiased, highly sensitive 
identification of all DNA sequences that interact with the ERa. A comparison of these 
methods and an analysis of the ERa ChIP-Seq data is described here.
In Chapter 4 we use the ChIP-Seq to profile ERa binding in response to E2, tamoxifen, 
the full antagonist fulvestrant or in the absence of ligand. In addition we determine 
the transcriptional output under the same conditions by profiling RNA polymerase II 
binding. This will allow us to truly see the effect of ERa binding on the transcriptional 
activity and to subsequently analyze the efficacy of different ERa antagonists on ERa 
function and assess their mechanistics.
During the course of this thesis, several ERa genome-wide binding profiling studies 
were published. Notable differences are present between the results of these data sets, 
especially regarding sequence motifs and cofactor binding. In Chapter 5 we explore a 
possible cause for these differences. We perform ChIP-Seq for the ERa using three dif­
ferent antibodies to investigate the effect of the antibody used on the subsequent ChIP 
profile.
Chapter 6 summarizes this data and the current state of ERa research and discusses the 
implications for further research.
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CHAPTER 1
Introduction
P ublished  in part a s :
W illem-Ja n  W elb o r en , H en k  G. Stu n n e n b e r g , Fred C.G .J. Sw eep , Pa u l  N . S pan 
Id en tifyin g  estro g en  recepto r  ta r g et  g en es . Mo le c u la r  O n c o l o g y , 2007 v o l . 1 
(2) pp. 138-4
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I n t r o d u c t i o n
In 1896 Beatson observed that removing the ovaries could lead to remission of breast 
cancer (Beatson 1896). Although at that time hormones were not yet discovered, his ex­
periments were the first to connect estrogens with breast cancer. More than 60 years later 
it was demonstrated that estrogens were retained in target tissues (Jensen and Jacobson 
1962), laying the foundation for the subsequent identification of steroid receptors. In­
deed, in 1968 O ’Malley described that changes in gene expression occurred after estro­
gen stimulation, indicating Estrogen Receptor alpha (ERa) functions as a transcription 
factor (O’Malley, et al. 1968). Soon after, a protein that specifically bound estrogens 
was found in breast tumors, and its quantity could predict the response of these tumors 
to endocrine disruption (Jensen, et al. 1971; McGuire 1973). With the cloning of the 
ERa in 1986 (Green, et al. 1986; Greene, et al. 1986) and subsequent identification of 
its functional domains the role for the ERa as a ligand dependent transcription factor 
became apparent (Green et al. 1986; Greene et al. 1986; Kumar, et al. 1987).
The ERa is a member of the superfamily of nuclear receptors, which are structurally re­
lated ligand-inducible transcription factors, including steroid receptors (SRs), thyroid/ 
retinoids receptors (TR, RARs and RXRs), vitamin D receptors (VDR), LXR, PPARs, 
and orphan receptors for which no ligand has been yet identified. After binding of es­
trogen to the estrogen-binding site on the ERa, the receptor dimerizes, translocates to 
the nucleus of the target cell, and binds to specific regions on chromatin, the so-called 
estrogen response elements (EREs, figure 1). Activation of genes by unliganded recep­
tor is prevented due to methylation of histone tails by H3K9 specific histone methyl 
transferases. Ligand, e.g. estradiol (E2) or the ER antagonist tamoxifen, diffuses through 
the cellular membrane and binds cytoplasmic ERa. Upon ligand binding the ERa dis­
associates from chaperone proteins such as hsp90 and translocates to the nucleus and 
dimerizes. The ERa binds chromatin and at a subset of genes recruits the histone dem- 
ethylase LSD1. LSD1 removes the methyl mark that prevents gene activation by the 
unliganded receptor and also plays a role in the interaction of distal enhancer regions via 
looping. At upregulated genes cofactors such as AIB1 (p160 family) are recruited and a 
complex containing histone acetyl transferase activity is assembled. The N-terminal his- 
tone tails are acetylated resulting in an open chromatin conformation. In addition, co­
factors with nucleosome remodeling activity (BRG1/BRM) are recruited. Finally RNA 
polymerase II and the general transcription machinery assemble at the promoter and 
the gene is transcribed. At repressed genes, either E2-repressed genes or genes repressed
12
® or e
merizes, translocates to the nucleus of the target cell, and binds to specific regions on chromatin, 
the so-called estrogen response elements (EREs).
upon tamoxifen treatment, the corepressors NCoR or SMRT are recruited and a histone 
deacetylase complex is assembled. Acetyl groups are removed from histone tails and the 
chromatin is in a closed conformation, which is not permissive for transcription to oc­
cur. In addition, the ERa can interact with other transcription factors, Sp1, AP-1 and 
NF-kB bound to their regulatory regions. These interactions, and the specific genes that 
are regulated by the interaction of the ERa with chromatin regions have been subject 
to research over the years. This review will focus on the methods and research done to 
identify ERa targets genes.
E x p r e s s i o n
Elucidating ERa target genes has for long been done on a gene-by-gene basis, measur­
ing the effect of estrogen stimulation on the expression of a single gene. By differentially 
screening cDNA libraries of induced and non-induced cells several target genes have 
been discovered e.g. pS2/TFF1 (Brown, et al. 1984; Jakowlew, et al. 1984). Recently, 
investigation of global expression changes upon estradiol induction by SAGE or micro­
array has identified many ERa target genes (Charpentier, et al. 2000; Cunliffe, et al.
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2003; Frasor, et al. 2003; Inoue, et al. 2002; Seth, et al. 2002). Interestingly, these global 
expression experiments indicated that around half of ERa target genes are downregu- 
lated upon induction with estrogen. Many of the downregulated genes are known to 
inhibit the cell cycle, are pro-apoptotic or are cytokines and growth factors that inhibit 
proliferation. This is in agreement with the view that estrogen promotes cell survival 
by downregulating pro-apoptotic genes. Although global expression profiling provides 
a wealth of information on estrogen induced gene expression, it cannot distinguish be­
tween direct and indirect ERa targets, i.e. genes that are regulated by other genes that 
are directly regulated by the ERa. For this, protein synthesis inhibitors cycloheximide or 
puromycin can be used, although unspecific effects of these drugs cannot be excluded. 
All targets that are regulated by estrogens in the presence of protein synthesis inhibitors 
should be bona fide direct ERa targets. Soulez and Parker used this to confirm that the 
P450-IIB enzyme was a direct target for the ERa in ZR75-1 cells (Soulez and Parker 
2001), and Wang et al. found EEIG1 to be a direct ERa target in MCF7 cells (Wang, 
et al. 2004). To the best of our knowledge, no genome-wide expression profile has been 
performed in breast cancer cells in the presence of protein synthesis inhibitors.
E re
Klein-Hitpass and colleagues identified an estrogen response element in the Xenopus 
vitellogenin A2 gene in 1986. They showed that this element functions in humans and 
defined a palindromic sequence (5’-GGTCACAGTGACC-3’) as the core ERE (Klein­
Hitpass, et al. 1986). W ith the sequencing of the human genome it became possible to 
search in silico for the presence of ERE’s. These computational approaches have been 
used to identify ERa target genes with limited success. From an extensive study where 
71,119 EREs were identified, only 3 were perfect ERE palindromes (Bourdeau, et al. 
2004). By narrowing down to promoter regions still 12,515 EREs were identified and 
by including conservation with mouse, 660 EREs remained of which several could be 
validated. Other authors have used similar approaches (Kamalakaran, et al. 2005). As 
the ERa can bind imperfect EREs and half sites, it is computationally very difficult to 
distinguish between real binding sites and noise. In addition, ERa can bind indirectly 
via other factors, which cannot be assessed using this approach.
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C h i p
1
Chromatin Immunoprecipitation (ChIP) is a new and very powerful technology by 
which transcription factor/cofactor occupancy of a given locus can be determined in 
its chromatin context in vivo. In brief, protein and DNA are cross-linked in the living 
cell using formaldehyde, chromatin is fragmented, and the transcription (co)factor of 
interest is immunoprecipitated with specific antibodies. The relative amount of a par­
ticular DNA fragment cross-linked to the transcription factor (and therefore present in 
the precipitate) can be determined by real-time quantitative PCR, and is a measure of 
the occupancy of the factor at that particular position in the genome. Such ChIP ap­
proaches provide valuable information about the involvement and temporal order of 
transcription factor and cofactor recruitment during activation or repression of a gene 
or locus. Furthermore, ChIP provides a means to accurately determine the epigenetic 
status of the locus.
First ChIP experiments directed at the ERa focused on a limited number of known 
binding sites and investigated binding of ERa and cofactors. For example, Shang et al. 
found that the ERa and a number of coactivators rapidly associate with chromatin at 
the c-Myc, pS2, CATD and beta-actin estrogen responsive promoters following estro­
gen treatment in a cyclic fashion (Shang, et al. 2000). More recently, a high throughput 
ChIP approach, ChIP cloning, was described by Langiere et al. (Laganiere, et al. 2005a). 
Here, the co-precipitated DNA fragments were cloned and subsequently sequenced. 
This enabled the identification of unknown ERa binding sites without any bias towards 
annotated genes and promoter regions. A disadvantage of this method is that large scale 
sequencing facility is needed and that it is difficult the discriminate between true bind­
ing sites and background DNA resulting in the necessity to do many work intensive 
validations.
Recently, ChIP has been coupled to microarray experiments, enabling the unbiased 
identification of ERa binding sites on a genome-wide scale. Initially, promoter arrays 
were used, specifically containing upstream regions from known genes as the size of the 
genome made it impossible to completely cover it sequence. These arrays are obviously 
biased and will miss a large number of binding sites as recent data shows that many 
transcription factors also bind in intergenic regions, introns and downstream of known 
genes. Despite this, this approach has been used with some success. Laganiere et al. iden­
tified 153 promoters bound by ERa in the presence of estradiol (Laganiere, et al. 2005b). 
Cheng used a promoter /CpG island array to identify ERa binding, H3K9 acetylation
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Figure 2. Overview of ChIP-chip. A. Using 
formaldehyde protein— protein and protein— 
DNA are cross-linked in vivo. The cross­
linked chromatin is subsequently isolated. B. 
The isolated chromatin is sheared in smaller 
fragments by sonication yielding fragments 
of 500 - 1000 bp. The protein or histone 
modification of interest is precipitated using 
an antibody. The cross-linked DNA is co­
precipitated. C. The unbound chromatin is 
washed away. D . The cross-linking is reversed 
and the DNA is isolated. The DNA is ampli­
fied by either LM-PCR or T7 linear amplifi­
cation of DNA. E. Total genomic DNA and 
ChIP DNA are differently labeled with Cy3 
and Cy5. F. Labeled DNA is hybridized on 
promoter arrays or arrays spanning the total 
non-repetitive genome.
and H3K9 dimethylation at different time 
points. Ninety-two ERa responsive pro­
moters were identified, and a coregulatory 
role for c-Myc at a subset of promoters was 
demonstrated. In addition, the physical in­
teraction between ERa and c-Myc via the 
bridging factor TRRAP was shown (Cheng, 
et al. 2006). Recently, a study using a ChlP- 
promoter array variant, i.e. ChIP coupled to 
a DNA selection and ligation (DSL) strat­
egy full genome promoter array, found 578 
high confidence promoter ERa gene targets 
in MCF-7 cells (Kwon, et al. 2007). In un­
supervised clustering analyses, they found 
that the 54 genes that were regulated by 
estradiol and that were directly regulated 
by the estrogen receptor as discovered by 
ChlP-DSL promoter array could inden- 
tify a subset of patients with ERa negative 
tumors, of higher grade and with a much 
poorer prognosis than the other patients.
By combining ChIP with genome-wide til­
ing arrays (ChIP-chip, figure 2), ERa bind­
ing can be investigated in a truly unbiased 
fashion. Tackling mammalian genomes is 
exceedingly more difficult and challenging 
due to its shear size, the presence of over 
30,000 protein-coding genes sprinkled 
into a bed of highly repetitive sequences. In 
mammals, the identification of transcrip­
tion factor binding sites using bioinformat- 
ic tools is complicated because regulatory 
regions are much wider spread than in yeast 
and can be located as far as hundreds of 
kb upstream or downstream or within the
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transcribed region. Indeed, by using Affymetrix tiling arrays spanning chromosome 21 
and 22, 57 E R a binding sites were identified of which the majority was located distal 
from genes and not in promoter regions (Carroll, et al. 2005). Comparing these data 
with a polymerase (pol) II ChIP-chip showed the presence of pol II at the E R a binding 
sites. Sequence analysis of the E R a binding sites showed that these were enriched with 
a Forkhead motif. FoxA1/HNF3alpha expression correlates with the presence of ER a 
in breast tumors and cell lines (Lacroix and Leclercq 2004; van ‘t Veer, et al. 2002). By 
ChIP-qPCR Carroll showed that in the absence of estradiol FoxA1 was present for most 
targets and dissociated upon ligand induction (Carroll et al. 2005). They postulate a 
role for FoxA1 as a pioneering factor whereby FoxA1 is present on the chromatin and 
facilitates the interaction o f the E R a with its binding site.
Recently, Carroll published a genome-wide ChIP-chip for the estrogen receptor and 
RNA pol II, identifying 3665 high confidence E R a binding sites and 3629 RNA pol
II binding sites (Carroll, et al. 2006). As described earlier for chromosome 21 and 22, 
mapping the location of the binding sites to nearby genes shows that only 4% is lo­
cated within 1kb upstream of a gene. Analysis of E R a binding sites for enriched DNA 
sequences identified ERE, Forkhead, AP-1, Oct and C/EBP motifs. Pair wise analysis 
showed that the ERE and AP-1 m otif occur exclusively. The Oct, Forkhead, and C/EBP 
motifs have a positive correlation. Further investigation showed a role for the coregula­
tor NRIP in E R a induced repression o f target genes. NRIP is a target of the E R a and 
can interact with E R a AP-1 complexes to repress expression of target genes.
C o n c l u s i o n s  a n d  f u t u r e  d i r e c t i o n s
Gene regulator networks regulated by E R a and identified by ChIP-chip can be com­
pared, linked and integrated with other large-scale data sets (expression array and pro- 
teomics) to unravel novel genetic and epigenetic codes and principles, and to generate 
novel hypotheses to be tested in vivo. Validated target sites can be combined to yield a 
second generation, fully annotated genomic microarray containing the sites of action 
of the ERa. This array then can be used to compare the profile of E R a targets between 
cells that are sensitive or insensitive for anti-estrogens such as tamoxifen, or can be used 
to even more accurately define the estrogen sensitivity of breast tumors. The techniques 
for detection and identification o f the ChIP-precipitated D N A  fragments have increased 
rapidly in the last few years. Initially, single sites were identified by PCR, next analyses 
of many promoter regions were performed simultaneously, later genome-wide analysis
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of binding through micro-array (ChIP-chip) became available and now next generation 
high throughut sequencing (ChIP-Seq) is applied. This has opened the possibility to 
study the E R a interaction network in more depth than ever before.
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CHAPTER 2
Genome-wide identification of 
Estrogen Receptor a  binding sites 
using ChIP-chip
W illem-Ja n  W elbo ren , Ma r c  A  van  D r iel , Eva  Ja n ssen -M eg en s , Fred  C G J Sw eep , 
Pa u l  N  S pan , H en dr ik  G  Stu n n en berg  
Ma n u sc r ip t  in preparation
2A b s t r a c t
The estrogen receptor alpha (ERa) plays an important role in both normal physiological 
as well as pathological processes such as breast cancer. Here, we used ChIP (chromatin 
immunoprecipitation) coupled to whole genome covering tiling arrays to profile E R a 
DNA binding on a true genome-wide scale and identified 1583 high confidence E R a 
binding sites. Interestingly, only a small percentage of E R a binding sites are located in 
classical promoter regions. The majority is located at great distances (>25 kb) from genes 
or within an intron, indicating the E R a also functions as an enhancer. M otif analysis of 
the binding sites sequences revealed that the full palindromic estrogen responsive ele­
ment was the most overrepresented motif. In addition, we determined the effect of the 
selective estrogen receptor modulator (SERM) tamoxifen on the E R a binding profile. 
O ur data shows that tamoxifen-bound E R a still binds to the DNA, and a total of 1224 
ERa-Tam sites were identified. Analysis revealed that the majority of these sites overlap 
with the ERa-E2 binding sites, but that there is a small group o f sites that is specific to 
tamoxifen. Comparing the minus ligand control, E2 and tamoxifen sets revealed sepa­
rate but partially overlapping populations of E R a binding sites. In conclusion, we have 
for the first time mapped the binding of unliganded, E2 and tamoxifen stimulated ER a 
on a true genome-wide scale.
I n t r o d u c t i o n
Estrogens are involved in many cellular processes such as the development and differ­
entiation of the female reproductive tract, bone metabolism, cardiovascular- and neuro­
endocrine system (Katzenellenbogen, 1996). Besides their role in normal physiology 
estrogens are also associated with the development and progression of breast cancer (An­
derson, 2002). Estrogens mainly exert their function by binding to a specific receptor, 
the estrogen receptor alpha (ERa; NR3A1) The E R a is a member o f the super family 
of nuclear receptors, i.e. ligand activated transcription factors. Upon ligand binding the 
E R a translocates to the nucleus, dimerizes and binds, either direct or via other proteins, 
to the DNA. Subsequently cofactors are recruited and transcription of a target gene is 
regulated (Shang et al, 2000). E R a has been used as a pharmacological target for the 
treatment and prevention of breast cancer by disrupting its function and signaling. Ei­
ther the level of estrogens in the body is reduced, or the estrogen receptor is targeted. 
One of the most successful therapeutics is the selective estrogen receptor modulator
24
(SERM) tamoxifen, which has been estimated to have saved the lives o f400,000 women 
(Jordan, 2003) and extended or helped palliate that of many others. Although tamox­
ifen is one o f the most successful cancer therapies a major problem is the development 
of resistance. Tamoxifen is a partial estrogen antagonist and is widely used in the clinic 
for the treatment and prevention of E R a positive breast cancer. Gene expression pro­
filing showed that tamoxifen induces a partially overlapping but different population 
of target genes compared to estradiol (Frasor et al, 2004), which could be relevant for 
understanding the development of treatment resistance.
To fully understand the role of the E R a in normal physiology as well as in cancer it is es­
sential to elucidate the binding site network. Chromatin immunoprecipitation is a pow­
erful method to assess binding o f transcription factors at specific loci. W hen coupled 
to micro-arrays, the binding of a transcription factor can be assessed at a genome-wide 
scale. We used ChlP-chip to identify the genome-wide binding site network of ERa. 
Furthermore, we determined the effect of the partial antagonist tamoxifen on the E R a 
binding site profile and performed extensive bioinformatical analysis.
R e s u l t s
M CF-7 cells were deprived of hormones for 48h followed by either mock stimula­
tion (minus ligand) or treatment with 10nM of 17^-estradiol (E2) for 1 h after which 
chromatin was harvested. To maximize enrichment o f ChIP’ed fragments we used a
ChIP-reChIP approach. The first ChIP was 
performed using the F3A6 antibody, after 
which the precipitated chromatin was sub­
jected to another round of ChIP using the 
M C-20 antibody. This approach yielded a 
very high enrichment of ~2000 fold for the 
> GREB1 promoter and ~1500 fold for the
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cus. The log ratio of ChIP vs input is plot­
ted. In green the minus ligand control, in 
red the E2 and in blue the tamoxifen data is 
shown. There is a very clear enrichment at the 
promoter region in the E2 data. Some bind­
ing can be observed in the absence of ligand, 
while tamoxifen liganded ERa shows a mod­
est enrichment at the promoter.
TFF1 promoter. The E2 treated ChIP sam­
ple and control D N A  were amplified and 
hybridized on Nimblegen genome-wide 
tilling arrays (see materials and methods). A 
total o f 41,734 putative E R a binding sites 
were called combining the results o f three
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Figure 2. Validation of ChlP-chip data. 26 randomly selected ERa binding sites were validated 
by qPCR. The x-axis depicts the fold over background, a non-ERa binding region (2nd exon of 
the myoglobin gene).
peak detection algorithms, Mpeak, TileMap and a Nimblegen in-house method to max­
imize the number of potential binding sites (Ji & Wong, 2005; Zheng et al, 2007). All 
the identified regions were combined to create a condensed, dedicated array that thus 
consisted of all putative E R a binding sites. The condensed array was used to hybrid­
ize three independent replicates of minus ligand control and E2 ChIP samples. For 
each sample enriched regions were identified as described before and final peaks were 
called by combining the individual replicates. High stringency peaks were called when 
a specific peak was present in all three replicates. A group o f lower stringency peaks was 
called containing peaks present in at least two o f the three replicates. Using the high 
stringency criteria 1583 and with the lower stringency criteria 2477 E R a binding sites 
were identified. Figure 1 shows E R a binding at the TFF1 locus. There is a clear increase 
in E R a occupancy at the TFF1 promoter upon E2 induction. In the absence o f ligand 
some residual E R a binding is observed. O ur data shows that many E2 responsive genes 
contain E R a binding sites in their promoter such as, SIAH2, CRKL, EBAG9, PGR, 
ESR1 and RARa. The E R a binding sites were validated by performing C hlP-qPCR for 
26 randomly selected sites. O f  these 26 sites, 25 were validated by ChlP-qPCR (96%) 
(Figure 2).
G e n o m i c  l o c a t i o n
In the classic model transcription factors bind to the promoter upstream o f the tran­
scription start site o f a gene to regulate transcription. Studies investigating elements
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Figure 3. Genomic location of ERa binding 
sites. A small percentage of sites, are located 
at promoter regions (6%) while the majority 
is located at great distances from know tran­
scripts (25%) or within an intron (43%).
cated within an intron (43%) or distal (>25 
functions as an enhancer.
necessary for E R a mediated transcription 
or studies identifying E R a binding sites 
have so far focused only on these promoter 
regions. However, some transcription fac­
tors might be able to regulate transcrip­
tion of genes located at great distances by 
binding to enhancer regions. We analyzed 
the locations of the E R a binding sites as 
depicted in Figure 3. Surprisingly, only a 
small percentage o f E R a binding sites are 
actually located in promoter regions (6 %). 
The majority o f E R a binding sites are lo- 
kb) from a gene (25%) indicating E R a also
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C O M P A R iT iV E  ANALYSIS OF G E N O M E -W ID E  E R a  PROFILES
Two genome-wide E R a data sets have been recently published (Carroll et al, 2006; Lin
et al, 2007). Carroll and coworkers identified 
3,665 high confidence E R a binding sites using 
the Affymetrix platform (Carroll et al. 2006). 
Lin and coworkers identified 1,234 E R a bind­
ing sites using a ChlP-PET approach (Carroll 
et al, 2006; Lin et al, 2007). Both used the 
M CF-7 breast cancer cell line. We compared 
our binding site profile with the ChIP-chip data 
from Carroll and the ChIP-PET data from Lin 
as shown in Figure 4 (Carroll et al, 2006; Lin 
et al, 2007), and found that 5 3 % of the sites 
identified in our study are also present in the 
data from Carroll and coworkers, while 39% of 
the sites from our study are also identified by 
Lin and colleagues.
Figure 4. Comparison of genome-wide 
ERa ChIP profiles. The Venn diagram 
shows the overlap of sites identified in this 
study and that of the Carroll et al and Lin 
et al data. We have identified 1583 high 
confidence sites, Carroll and coworkers 
3665, and Lin and coworkers 1234. 53% 
of the sites identified in this study were 
also detected by Carroll, 39% of the sites 
in this study were also detected by Lin.
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S e q u e n c e  m o t i f s
2 The E R a can bind as a homodimer to estrogen response elements (ERE), an inverted 
repeat sequence separated by a three-basepair spacer (GGTCAnnnTGACC). The ER a 
can also bind indirectly to the DN A  via tethering to other transcription factors such as 
AP-1 and Sp1. Furthermore, cofactors and other transcription factors can be recruited 
and can be of great influence on the transcriptional outcome. We interrogated the bind­
ing site sequences of all datasets for the presence of enriched sequence motifs. The se­
quence 200 bp up and down from the centre of each peak was interrogated using the de 
novo m otif finding algorithm M Dmodule (Liu et al, 2002). The full palindromic ERE 
was the most overrepresented and frequently occurring m otif in the data as expected, 
see Figure 5. In addition, the binding site sequences were interrogated for the presence
of known sequence motifs using TRANS- 
FAC 11. The enrichment against a random 
genomic background was calculated for 
each motif. Using this approach many mo- 
Figure 5. ERE motif. Sequence logo of the dfs were found tQ be enrich ed such as Spl 
highly overrepresented full palindromic ERE 
as identified by the MDmodule program. an .
I d
T a m o x i f e n
The SERM tamoxifen is widely used for the treatment and prevention of breast cancer. 
The effect o f tamoxifen on the binding site network of the E R a has so far not been 
determined. Three independent E R a ChIP experiments o f tamoxifen induced MCF-7 
cells were performed and subsequently hybridized on the previously established dedi­
cated array. Peak detection was performed as described before, identifying a total of 
1,224 high and 1,971 lower stringency E R a binding sites. Comparing the control, E2 
and tamoxifen sets revealed separate but partially overlapping populations o f E R a bind­
ing sites (Figure 6A). The majority of the E2 and tamoxifen interaction sites overlap, 
although there is a group of sites where E R a binds preferentially when liganded with 
tamoxifen, and a group where it binds preferentially when liganded with E2. The minus 
ligand sites overlap almost completely with both E2 and tamoxifen sites. The genomic 
distribution of the binding sites relative to genes did not differ between E2 and tamox­
ifen loaded ERa.
28
A B
Tam oxifen M inus Ligand
Figure 6. A. Venn diagram of the overlap between the binding sites induced by minus ligand 
control, E2 and tamoxifen treatment. There is a large overlap between the three conditions. 
However, a group of sites are specific to either E2 or tamoxifen alone. B. Boxplot representing 
the distribution of peak scores (binding affinity) of ERa when liganded with E2, tamoxifen or 
in the absence of ligand. E2 liganded ERa binds with the highest affinity to respective binding 
sites. Tamoxifen liganded ERa is still able to bind to the DNA but with a lower affinity. In the 
absence of ligand the ERa can bind to the DNA but the interaction is weaker.
We next assessed the binding affinity, or peak score, of unliganded, E2- or tamoxifen 
loaded E R a by calculating the sum of all probe values for each individual peak. In Fig­
ure 6B the distributions o f the peaks scores of the different ligands are depicted. Peaks 
scores for E2 loaded E R a are higher compared to unliganded or tamoxifen loaded ERa, 
indicating E R a binds with higher affinity to the chromatin when loaded with E2 com­
pared to tamoxifen. We subsequently com-
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pared the binding affinity or peak height of
sites where both E2 and tamoxifen loaded
E R a bind with sites specific for one o f the
ligands. The E2 data set was divided into
two groups, peaks where only E2 liganded
E R a binds and peaks where E2 as well as
tamoxifen liganded E R a binds (the inter­
Figure 7. Comparing the affinity of sites spe­
cific to E2 and tamoxifen, and sites where E2 section). For both groups the average peak 
as well as tamoxifen liganded ERa can bind. score was calculated. The same analysis was
In the E2 data, peaks where both E2 and ta- performed for the tamoxifen data. Figure 7__ __ __________ 1_______L:_l__ r °
E2 Tamoxifen
moxifen can bind (intersection) have a higher
shows that sites where both E2- as well aspeakscore compared to peaks where only E2 
can bind. In the tamoxifen data a similar pat- tamoxifen loaded E R a bind are generally of
tern is present. higher affinity compared to sites specific to
2
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2either E2 or tamoxifen. This indicates that tamoxifen loaded E R a is more likely to bind 
to higher affinity sites.
D i s c u s s i o n
Genome-wide ChIP-chip profiling provides a true unbiased view on the regulatory net­
work o f a transcription factor. We have profiled the binding site network of the E R a 
using ChIP-chip and identified 1,583 high stringency and 2,477 lower stringency ER a 
binding sites. E R a binding sites were identified in the promoters of previously described 
E2 responsive genes such as TFF1, EBAG9, PGR, ESR1 and RARa. The vast majority 
of the E R a binding sites, however, were not located at classical promoter regions but 
are frequently present at great distances from know transcripts or within introns, indi­
cating the E R a does not only functions as a classical transcription factor but also as an 
enhancer.
M otif analysis of the binding site sequences revealed that the full ERE is the most over­
represented m otif as expected. A total o f 29 sequence motifs were enriched, indicating 
regulation of transcription is likely to be a complex process that could involve many 
cofactors. The presence o f such a m otif however, does not necessary mean binding of 
that cofactor occurs, the presence and expression levels of cofactors can vary between 
different cell types.
Comparative analysis o f our dataset to two recently published genome-wide data sets, 
one using the Asymetrix platform and one using a ChIP-PET approach (Carroll et al, 
2006; Lin et al, 2007), showed that the two array based methods have an overlap of 
53%, while 39% of the sites are also detected by ChIP-PET. Although there is a substan­
tial overlap between the sets there are still a large number of sites that are only detected 
by one method. The differences between these data sets are probably due to lower affin­
ity sites that are more likely susceptible to differences in the experimental setup of the 
three studies. All three studies use the same cell line though incubation times, E2 con­
centrations and the antibody used are different, as well as the platform used to detect the 
precipitated fragments. These factors are likely to contribute to changes in binding site 
profile. More research is necessary to fully elucidate the exact causes for the differences 
in binding site profile and to provide a true complete set of E R a binding sites.
The use of tamoxifen in the clinic is wide spread, although its effect on the binding of
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E R a to DNA has of yet not been investigated on a large scale. We show that tamoxifen 
bound E R a is in many cases still able to bind to the DNA and that the antagonistic 
effect of tamoxifen is thus not due to inhibition of the binding of E R a to DNA. Most 
likely tamoxifen prevents the recruitment of cofactors necessary for transcriptional regu­
lation, but in many cases will still allow the E R a to interact with the DNA. We show 
that the tamoxifen liganded E R a binds with lower affinity to the DNA compared to 
E2 liganded ER a, which is in agreement with previously published data that shows 
that tamoxifen liganded E R a binds with lower affinity to an ERE (Klinge et al, 1998). 
Furthermore our data shows that the lower affinity binding o f tamoxifen liganded —ER a 
previously observed at single genes is true on a genome-wide scale.
Surprisingly, gene expression profiling of tamoxifen-induced cells show that although 
the transcription of a large number of E2 responsive genes is antagonized by tamoxifen a 
number o f genes also show an agonistic effect, indicating that the binding of tamoxifen 
liganded E R a can result in transcriptional regulation of a number of genes (Cunliffe et 
al, 2003; Frasor et al, 2006; Inoue et al, 2002). O ur results of tamoxifen specific ERa- 
DNA binding sites concurs with this notion. Comparing the profiles of E2, tamoxifen 
and unliganded E R a revealed that there is a group of sites that only show E R a binding 
when liganded with tamoxifen. These tamoxifen specific sites can be truly specific to 
tamoxifen, where it might induce a conformational change in the E R a that enables the 
receptor to bind at other regions. Alternatively, these sites are low affinity sites where we 
did not detect binding o f E2 liganded E R a because it was below the detection limit.
In the absence o f ligand ER a-D N A  binding still occurs at a small number of sites. This 
can either be residual binding due to incomplete removal o f E2 from the media or true 
ligand independent interaction. Ligand is required for maximal E R a DNA interaction 
in vivo but not in vitro (Kladde et al, 1996). In addition, it has also been described that 
ligand stabilizes the E R a DN A  interaction in vivo (Gronemeyer, 1991). Ligand bind­
ing causes a conformational change in the E R a (Brzozowski et al, 1997). W ithout this 
change proper transcriptional activation will likely not occur. More research is neces­
sary to determine whether this ligand independent interaction leads to transcriptional 
changes and if it is biologically relevant.
In summary, our work provides a global set of high confidence E R a binding sites and 
we show for the first time on a global scale that tamoxifen bound E R a is still able to 
interact with the DNA. These data provides a valuable resource and are the basis for ob­
taining insight in the tissue specific effects o f tamoxifen and development of tamoxifen
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resistance.
ChIP
MCF-7 cells were cultured in DMEM supplemented with 10% FCS at 37 °C. Cells were main­
tained in DMEM w/o phenol red and 5% charcoal stripped FCS for 48 h before induction. 
MCF-7 cells were mock treated or with 10 nM 17beta-estradiol or 1 pM 4-OH tamoxifen for 1 
h. Chromatin was harvested as described (Denissov et al, 2007). ChIP was performed using one 
of the following antibodies: F3A6 (Diagenode AC-066-100) or MC-20 (Santa Cruz, SC-542).
qPCR
The ChIP experiments were analyzed by qPCR using the Biorad MyIQ cycler and the Biorad 
SYBR green mix. Relative occupancy was calculated as fold over background, using the second 
exon of the myoglobin gene.
Amplification
The precipitated DNA was amplified using 15 cycles of LM-PCR followed by a second round of 
PCR for another 25 cycles (Ren et al, 2002). For the 3 replicate samples ChIP and total DNA 
was amplified using T7 linear amplification of DNA (TLAD) (Liu et al, 2003).
Microarray
The amplified ChIP and total DNA were differentially labeled and hybridized on a set of 19 
Nimblegen microarrays containing ~ 14.5 million 50-mer probes covering the repeatmasked 
human genome at a 100 bp resolution. We identified enriched regions by combining 3 different 
peak detection algorithms, Mpeak, Tilemap and a Nimblegen in house method (Ji & Wong, 
2005; Zheng et al, 2007). Next, the enriched regions were used to construct a dedicated array. 
Each region was extended up and down by 1 kb and the probes covering these regions were used 
to create a dedicated array.
Motif
For all sequence analysis the center of the peak was determined and extended on both sides with 
200 bp. MDmodule was used with default settings (Liu et al, 2002). Known motifs were identi­
fied using transfac 11.1 and the Match program (Matys et al, 2003). The sequence logo was cre­
ated using Weblogo (http://weblogo. berkeley.edu/). Enrichment was calculated against random 
genomic locations. using Benjamin-Hochberg multiple testing correction. Motifs with a P-value 
of > 0.001 and a enrichment score above 2 were called enriched.
Peak score
For each peak the peak score was calculated by taking the sum of all probe values present within 
a peak.
2  M e t h o d s
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CHAPTER 3
ChIP-Seq profiling of 
Estrogen Receptor a  binding sites 
using the Illumina genome analyzer
W illem-Ja n  W elbo ren , H en dr ik  G  Stu n n en berg  
P ublished  as Illum ina  A ppl icatio n  N o te
I n t r o d u c t i o n
The regulation of gene expression is a key event in development, differentiation, signal­
ing and adaptation to environmental cues. Gene expression is regulated at many levels 
such as through histone modifications and through binding of transcription factors to 
their cognate target sites in promoters and enhancers, leading to the recruitment of 
activating or repressing cofactors and ultimately in alteration of mRNA levels. To deci­
pher the network of target genes that is governed by transcription factors it is pivotal to 
identify their genomic binding site repertoire.
Currently, the presence or absence of a protein (or histone modification) at a specific ge­
nomic location is typically determined using chromatin immunoprecipitation (ChIP). 
Protein-DNA complexes are crosslinked using formaldehyde and chromatin is isolated 
and sheared into small fragments. The protein o f interest is then immunoprecipitated 
using a specific antibody and the D N A  crosslinked to that protein is co-precipitated. Af­
ter reversal o f the crosslinks, DN A  is purified and used as input for subsequent analysis 
to identify the DNA.
The application of massively parallel sequencing to ChIP has opened up new avenues at 
the genome-wide scale to elucidate entire regulatory networks and pathways. To date, 
genome-wide profiling o f DNA-associated transcription factors or individual histone 
modifications has been performed using microarray platforms. In so called ChIP-chip 
experiments, the identity o f co-precipitated genomic DNA fragments is determined 
through hybridization to immobilized oligonucleotides or PCR-amplified D N A  frag­
ments. However, a drawback of hybridization-based analysis is its inherent bias. Probes 
must be designed from a known genome sequence, and differ in melting temperature, 
nucleotide composition, and uniqueness, resulting in differential and cross hybridiza­
tion.
In experiments described below, we have used the Illumina Genome Analyzer to per­
form a comprehensive analysis of estrogen receptor alpha (ERa) binding sites in MCF-7 
cells, a model cell line for breast cancer. The Illumina sequencing platform provides the 
unique and exciting possibility to identify interaction sites by directly sequencing o f the 
co-precipitated genomic D N A fragments.
E R a is a member of the superfamily of nuclear receptors, which are ligand-dependent 
transcription factors. E R a is thought to regulate transcription o f target genes by ei­
ther directly binding to specific cis-acting DNA sequences, estrogen response elements
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(EREs), or indirectly via protein-protein interactions with other transcriptions factors 
regions, such as AP-1, Sp1 or NF-kB that are bound to D N A  via their cognate regula­
tory sites. The unsurpassed accuracy and sensitivity of the Illumina Genome Analyzer 
enabled us to comprehensively identify the ligand-dependent genomic interaction sites 
of ER a. A brief overview o f the experimental design and results is reviewed in this ap­
plication note.
M e t h o d s
M CF-7 cells were hormone deprived for 48h, followed by induction for 1 h with either
10 nM  17^-estradiol (E2) or solvent control. Proteins and D N A  were crosslinked for 30 
min at room temperature using 1% formaldehyde, quenched with 0.125 M glycine and 
washed at 4 °C. Chromatin was sheared into fragments (~500bp—1kb) using the Biorup- 
tor (Diagenode). ChIP was performed using a Red ChIP kit (Diagenode) as described 
by the manufacturer using 2.5 pl of an anti-ERa monoclonal antibody (Diagenode 
Mab-NRF3A6-050). Then, the chromatin was incubated overnight with protein A/G 
beads and antibody at 4° C with slow rotation. Subsequently, the beads were washed six 
times at increasing stringency to remove nonspecifically bound chromatin. To reverse 
the crosslinks, precipitated chromatin was incubated at 65 °C for 4 h with the addition 
o f200 mM NaCl, then phenol extracted and precipitated overnight. Three parallel ChIP 
experiments using approximately 3 x 106 cells were pooled. D NA was purified using the 
Qiagen reaction cleanup kit. The total amount of D NA  was measured using picogreen 
(Invitrogen) and/or nanodrop. To assess the quality o f the ChIP, E R a occupancy at the 
pS2/TFF1 and GREB1 promoter and a known enhancer region on chromosome 1 was 
assessed by qPCR. Primers were designed using the primer3 algorithm (http://frodo. 
wi.mit.edu/) using a product size of 50—150bp and verified to produce one amplicon 
by in silico PCR. In addition, the formation o f a single specific amplicon was assessed 
by qPCR on genomic DNA; primers that amplified more than one product were dis­
carded. The qPCR was performed using a BioRad M yIQ  light cycler. The quality o f the 
ChIP was deduced from the recovery (yield), calculated as the percentage of chromatin 
input that was co-precipitated in the ChIP assay, and from the occupancy (specificity), 
calculated as fold enrichment over an arbitrarily chosen non-binding control region. 
E R a occupancy at the pS2/TFF1 promoter, GREB1 promoter, and an enhancer region 
on chromosome 1 were 15-, 86-, and 221-fold enriched (respectively) compared to the
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control (exon 2 o f the myoglobin gene) with recoveries over 3—4%. Finally, the purified, 
co-precipitated DNA was processed for analysis on the Illumina Genome Analyzer us­
ing the Illumina ChIP-Seq sample preparation kit (IP-102-1001). Sequencing reactions 
were performed with system components and reagents available in September, 2007.
I l l u m i n a  s e q u e n c i n g  t e c h n o l o g y
Illumina DN A  sequencing technology leverages clonal cluster amplification and revers­
ible terminator nucleotides to generate high-density, high throughut sequencing runs. 
The fully automated Illumina Cluster Station amplifies adapter-ligated ChIP DNA frag­
ments on a solid flow cell substrate to create clusters of approximately 1000  clonal cop­
ies each. The resulting high-density array o f template clusters on the flow cell surface 
is sequenced by the fully automated Illumina Genome Analyzer. Tens of millions of 
template clusters present on a flow cell undergo sequencing by synthesis in parallel.
Due to this capacity for high oversampling and redundancy, binding event signals are 
readily detectable above background. Additionally, sensitivity and statistical certainty 
can be tuned by adjusting the total number of sequence reads to provide an even wider 
dynamic range and greater sensitivity to detect rare or weak DNA-protein interaction 
sites. Data collection and analysis software aligns DN A  sequence reads to a reference 
genome sequence, allowing determination of all o f the binding sites for a factor of in­
terest. Sequence read lengths of only 25—32 bases are sufficient to accurately align and 
identify millions o f fragments per run. Unlike microarray-based ChIP readout methods, 
the positional accuracy o f ChIP-Seq is ±50 bp or less.
I d e n t i f i c a t i o n  o f  e n r i c h e d  r e g i o n s
Using two lanes each for ChIP’ed D N A from E2-induced (+E2) and non-induced (-E2) 
cells, a total of ~7.5 million and ~3.3 million 32-base sequence reads were obtained. All 
32-base sequence reads were mapped to the hum an reference genome sequence (NC- 
BI36 - HG18) using the Illumina ELAND algorithm at its default setting (two or no 
mismatches allowed). Table 1 shows the total number of sequenced tags and the number 
of tags that could be aligned to the genome for the E2 induced and the non-induced 
data sets. The percentage of annotated tags is significantly higher in the +E2 data set
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as compared to the no ligand control (-E2). This is fully expected as in the presence 
of E2 ligand, E R a targets are significantly enriched in the ChIP and consequently the 
background noise is underrepresented. In the absence o f ligand, E R a does not bind 
to D N A  and hence enrichment specific genomic fragments was not obtained and the 
population of sequenced DNA fragments is a representation of the full hum an genome 
with its high proportion of repetitive elements that cannot by mapped unambiguously 
to the genome.
Total tags Two mismatches No mismatch
- E2 3375602 1736369 (51%) 977618 (28%)
+ E2 7500354 5594488 (75%) 4395434 (59%)
Table 1. Summary of sequenced and annotated tags.
To determine E R a peaks, the aligned 32-base sequence tags were computationally ex­
tended to 200 bp since DNA fragments o f ~200 bp were excised from an agarose gel 
and processed for sequencing. The 200 bp sequence strings were sorted and the overlap 
between fragments was determined. Overlapping fragments were combined into one 
peak-id, resulting in a list with one or more fragments per peak (peak value). For each 
data set, the peaks were binned according to number of tags per peak (peak value) and 
the number of peaks within each bin. Figure 1 shows the distribution of sequence tags 
over bins with the number o f tags per peak as indicated. Almost all peaks in the non­
induced set are in the bins with low number of tags, whereas the +E2 set shows peaks 
across the entire range o f peak values. Based on qPCR validation data (fpr < 5%), we 
applied a threshold of 20 overlapping fragments. This resulted in the identification of 
13,173 E R a interaction sites following ligand treatment. In contrast in the absence of 
ligand, only 191 apparent interaction sites were detected at this threshold and the ma­
jority of these apparent ‘peaks’ mapped to regions rich in repetitive sequences (145) or 
overlapped with amplified regions in M CF-7 (Shadeo & Lam, 2006).
O ur ChIP-Seq analysis resulted in the unambiguous identification of genomic E R a 
interaction sites at high signal-to-noise: peaks of 20 up to ~10,000 overlapping sequence 
tags against a background defined as fewer than 20 sequence tags. These data confirm 
that the interaction o f E R a with chromatin is strongly dependent on the presence of 
ligand.
The landscape of E R a interaction sites across the genome was determined by counting 
the number of fragments in a fixed window of 10bp and plotted on a log2 scale.
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Figure 1. Histogram of the distribution of peak value (sequence tags per peak). Peaks were 
binned according to peak value (number of overlapping sequence tags). The number of peaks 
within each bin is plotted on a log10 scale. For the ‘no ligand’ control data set the vast major­
ity of peaks are in the bins with the lowest peak value indicating that only a very low num­
ber of high confident ERa interaction sites (> 20 overlapping sequences) were detected. The 
E2-induced ERa interaction site data show peaks throughout the entire range (up to 10,000 
peaks), indicating the presence of high confidence interaction sites that are occupied in a 
strictly ligand-dependent manner.
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Figure 2. Comparison between ChIP-Seq and ChIP-chip. Screenshots of the UCSC genome 
browser (http://genome.ucsc.edu) of ERa binding sites. ChIP-Seq for ERa binding following 
E2 induction is shown in the upper track in blue; ChIP-chip in the lower track in orange. The 
UCSC ‘known gene track’ is indicated. For the Illumina ChIP-Seq data, the number of over­
lapping fragments in a 10 bp fixed window are counted and plotted in log2 scale. For ChIP­
chip, the ratio between ChIP/input is shown in log2 scale. The well known ERa target gene 
pS2/TFF1. The highest peaks in ChIP-Seq as well as ChIP-chip are observed over the promoter 
region and the upstream enhancer at -10kb. The high resolution and signal over noise ratio of 
the ChIP-Seq analysis reveals two separate peaks over the upstream enhancer.
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A comparison between ChlP-chip and ChlP-Seq profiles is shown in Figure 2 for the 
classical E R a target gene, pS2/TFF1, showing the superior signal-to-noise, read depth, 
and sensitivity of ChlP-Seq.
V a l i d a t i o n  o f  s e v e r a l  E R a  b i n d i n g  s i t e s
3
Figure 3. Validation of randomly selected 
ERa binding sites. Relative occupancy was 
assessed by qPCR versus sequence reads per 
peak. 20 randomly chosen ERa binding sites 
were validated by ChlP-qPCR. The relative 
occupancy values obtained by qPCR (average 
of 3 biological replicas) were plotted against 
the peak value. ChlP-Seq data from the Illu­
mina Genome Analyzer correlates well with 
the ChlP-qPCR data.
To confirm the accuracy of identified E R a 
binding sites, 20 peaks were randomly se­
lected for validation using ChlP-qPCR. 
ChIP-qPCR is commonly accepted as the 
“gold standard” to determine the occupancy 
of E R a at a specific site. Primers were de­
signed and a targeted ChIP was performed 
on three biological replicates as described 
above. The average relative occupancy val­
ues obtained by qPCR were plotted against 
the peak value. Figure 3 shows that the peak 
values obtained by ChlP-Seq correlated very 
well with the ChlP-qPCR data (r=0.76, 
r2=0.57) demonstrating the semi-quantita­
tive character o f the ChlP-Seq approach.
M o t i f  s e a r c h
To determine cis-acting sequence elements that facilitate binding of ligand-loaded E R a 
(either directly or via protein-protein interaction), the ChIP-Seq results were searched 
for consensus estrogen response elements (half-site or full palindrome), and for AP-1 
and Sp1 consensus motifs. The search was done using the M ATCH program and weight 
matrices from the Transfac 11 database (www.biobase-international.com). For the ERE 
full site, the Jaspar weight matrix was used (http://jaspar.cgb.ki.se). Peaks were divided 
into 10 equal bins according to their peak value. For each bin, the percentage of peaks
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Figure 4. Searching for sequence motifs. ^ e  occurrence of specific transcription factor bind­
ing motifs in the sequence underlying a peak was plotted against the peak value. Using the 
Transfac 11 database and a Jaspar Estrogen Responsive Element (ERE_ weight matrix), the 
sequence underlying a peak was scanned for the presence of ERa, Sp1, and AP-1 binding sites. 
Peaks were divided into 10 equal bins according to peak value. The percentage of peaks in a bin 
containing a specific motif is plotted on the y-axis. Peak value correlates well with the presence 
of the ERE half site and full site, and with AP-1 and Sp1 motifs.
that contain a particular m otif was calculated. Figure 4  shows that there is a good corre­
lation between peak value and the occurrence o f specific motifs. This demonstrates that 
peaks identified by a high number of sequence tags are more likely to contain an ERE 
half-site, AP-1 motif, ERE full site, or Sp1 motif.
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R e v e a l i n g  o t h e r  i n t e r a c t i o n s
Results from chromatin conformation capture assays, coined 3C and 4C (Dekker, 2006; 
Simonis et al, 2006; Zhao et al, 2006), imply that genomic transcription factor interac­
tion sites identified by our highly sensitive ChIP-Seq analysis may comprise not only 
primary sites of E R a binding (cis-acting elements such as EREs or AP-1 sites) but also 
secondary genomic sites to which E R a was crosslinked due to looping, such as be­
tween promoters and enhancers. Given the sensitivity and depths of ChIP-Sequencing, 
it seems likely that not only ‘stabile’ short- and long-range intra- and interchromosomal 
interactions, but also short-lived transient interactions, will be uncovered in the ChlP- 
Seq approach.
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Figure 5. A. Location of binding sites relative to Ensembl genes. For each ERa-binding peak 
detected, the nearest gene and the distance to that gene was determined. Binding sites were 
subsequently divided into 7 classes of functional regions. The majority of binding sites are 
located in introns (41%) or more than 25kb from a gene (21%). 9% of all sites are located in 
promoter regions (i.e., within 5kb upstream of a gene). B. Histogram depicting the binding 
of ERa relative to the closest TSS. The large peak centered at 0bp indicates ERa binding is 
enriched close to transcription start sites.
A n a l y z i n g  l o c a t i o n s  o f  b i n d i n g  s i t e s
The location of binding sites relative to the closest gene was determined using the En­
sembl 47 database (http://www.ensembl.org). Peaks were divided into 7 location classes. 
Figure 5A shows that the majority of E R a interaction sites (41%) are located in introns 
while 9% are located in promoter regions. In addition, a large number of sites (21%) are 
located distal from any annotated gene. These data emphasize that E R a can function as 
an enhancer as well as a classical transcription factor.
The distribution of binding sites relative to the transcription start site (TSS) was deter­
mined in a window of 30kb up and downstream o f the TSS. As shown in Figure 5B this 
distribution reveals that E R a binding is enriched in close proximity of the TSS.
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C o n c l u s i o n
Genome-wide ChlP-Seq analysis enables the identification of the interactome, or entire 
interaction network, of a transcription factor o f interest. Here we chose to examine the 
interactome of ER a, and with a single experiment have significantly expanded on the 
many decades of research that have focused on this factor. W ith data from two lanes of a
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flow cell (~7 million tags), we were able to identify precise genomic regions of direct, as 
well as indirect, E R a binding. With these data, we confirmed known E R a binding sites, 
revealed novel enriched regions, and provided new information on cis-acting sequences
3  that facilitate the binding of ERa.
W ith high sensitivity, low noise, and no hybridization bias, Illumina ChIP-Seq pro­
vides major advantages over microarray-based detection. In addition, it is possible to 
obtain data on binding in repeat regions, which were excluded in microarray-based 
ChlP-chip approaches. Future experiments will focus on further analysis o f  novel bind­
ing sites as well as the analysis o f  other ERa-related transcription factors.
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CHAPTER 4
ChIP-Seq of ERa and RNA polymerase II defines 
genes differentially responding to ligands
W illem-Ja n  W elbo ren , Ma r c  A  van  D riel , Eva  M Ja n ssen -M eg en s , S imon  J van  
H eer in g en , Fred  C G J Sw e e p , Pa u l  N  S pan , H en dr ik  G  Stu n n en berg  
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A b s t r a c t
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We used ChIP-Seq to map E R a binding sites and to profile changes in RNA polymerase
II (RNAPII) occupancy in M CF-7 cells in response to estradiol (E2 ), tamoxifen or ful- 
vestrant. We identify 10,205 high confidence E R a binding sites in response to E2 of 
which 6 8 % contain an estrogen response element (ERE) and only 7% contain a FOXA1 
motif. Remarkably, 596 genes change significantly in RNAPII occupancy (59% up and 
41% down) already following one hour o f E2 exposure. Although Promoter Proximal 
Enrichment of RNAPII (PPEP) occurs frequently in M CF-7 cells (17%) it is only ob­
served on a minority of E2 -regulated genes (4%). Tamoxifen and fulvestrant partially 
reduce E R a DNA binding and prevent RNAPII loading on the promoter and coding 
body on E2-upregulated genes. Both ligands act differently on E2-downregulated genes: 
tamoxifen acts as an agonist thus downregulating these genes while fulvestrant antago­
nizes E2-induced repression and often increases RNAPII occupancy. Furthermore our 
data identify genes preferentially regulated by tamoxifen but not by E2 or fulvestrant. 
Thus, (partial) antagonist loaded E R a acts mechanistically different on E2-activated 
and E2-repressed genes.
I n t r o d u c t i o n
Estradiol (E2 ) is a key regulator in the growth and differentiation o f many target tissues 
and is involved in development and progression of breast cancer (Anderson, 2002). Its 
genomic activity is to a large extend mediated by the estrogen receptor alpha (ERa; 
NR3A1), a member of the nuclear receptor super family. E R a regulates expression of 
target genes classically by binding directly to its cognate sequence, the estrogen response 
element (ERE). E R a binds to its cognate binding sites as homodimer, recruits cofactors 
and activates or represses transcription in response to E2 (Shang et al, 2000). Alterna­
tively, non-classical regulation involves protein-protein interactions with other D N A  
binding proteins such as Sp1, AP-1 and NF-kB. Identification of the E R a target gene 
network regulated by agonist and/or antagonist treatment is essential to understand the 
role o f E R a in normal physiological processes and in cancer.
Several gene expression profiling studies in M CF-7 cells identified E2 responsive genes 
in the range of 100 to 1500 (Carroll et al, 2006; Charpentier et al, 2000; Coser et al, 
2003; Frasor et al, 2003; Kininis et al, 2007; Kwon et al, 2007; Lin et al, 2007; Rae
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et al, 2005; Stender et al, 2007) whereas large scale E R a ChIP profiling showed that 
E R a interacts with many thousands genomic regions (Carroll et al, 2006; Kininis et al, 
2007; Lin et al, 2007). This discordance is in part due to the fact that mRNA levels do 
not necessarily reflect gene activity because it is subject to degradation and regulation, 
and that likely not all E R a binding sites are active under all conditions. Genome-wide 
profiling of RNA polymerase II (RNAPII) occupancy however, does provide a direct 
readout and thus could yield insights beyond what is typically obtained by mRNA ex­
pression profiling.
Recent studies have shown that the promoters of a large number of genes are preloaded 
with RNAPII with minimal occupancy over the coding body, a phenomenon referred to 
as pausing or promoter proximal enrichment (PPEP). Collectively, these studies suggest 
that control of elongation rather than or in addition to transcription initiation plays an 
important role in activation of these genes, particular for genes rapidly responding to 
developmental and cell signaling cues (Core et al, 2008; Muse et al, 2007; Zeitlinger et 
al, 2007).
Selective estrogen receptor modulators (SERMs) are (partial) E2 antagonists used for the 
treatment and prevention of breast cancer. One o f the most widely used is tamoxifen, 
which has mixed agonistic / antagonistic properties and tissue specific effects. Tamoxifen 
resistance develops ultimately in advanced breast cancer and is o f major clinical signifi­
cance (Ali & Coombes, 2002). SERMs induce an alternative conformation o f the ER a 
ligand binding domain that results in the recruitment of different cofactors and repres­
sion of transcription instead of activation. Fulvestrant (ICI 182,780) is a full antagonist 
that increases protein turn-over and results in the degradation o f ERa. Fulvestrant is 
used for the treatment of advanced breast cancer and tamoxifen resistant tumors (How­
ell, 2006). The effect of SERMs on E R a binding and subsequent RNAPII recruitment 
has not been studied at a genome-wide level.
In this study we used massive parallel sequencing o f immunoprecipitated D N A  frag­
ments to identify E R a interaction sites and RNAPII occupancy in response to E2 or 
the (partial) antagonists tamoxifen and fulvestrant. Combining E R a binding site and 
RNAPII occupancy allowed us to measure the consequence o f E2 treatment on RNAPII 
occupancy i.e. ongoing transcription. RNAPII analyses also allowed us to assess whether 
or not PPEP is a general phenomenon in rapid E2 response. We identified a large num ­
ber of E R a interaction sites and a much smaller number of direct target genes, and show 
that tamoxifen and fulvestrant alter but not abolish E R a binding, and have differential
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effects on E2-up and -downregulated genes. E2 mediated activation is antagonized by 
both compounds, while at E2-downregulated genes tamoxifen shows agonistic behavior 
in contrast to fulvestrant, which antagonizes E2 mediated repression.
Identification o f ERa interaction sites
ChIP followed by deep sequencing was performed using the M CF-7 breast cancer cell 
line, which was hormone starved for 48 h and subsequently mock treated (minus li­
gand) or stimulated for 1 h with 10 nM  E2. ^ e  numbers o f sequenced and mapped 
tags are shown in Supplementary Table SI. Classical E R a target genes e.g. TFF1 and 
GREB1 showed vast enrichment of tags over a narrow range in their promoter and en­
hancer regions in the E2 data set as compared to minus ligand (Figure 1A). Overlapping 
tags were joined into peaks and the number o f tags per peak (peak scores) was counted. 
The frequency distribution of peak scores shows a wide range in the E2 data set going 
up to nearly a 1000 tags/peak (Supplementary Figure S1). In the absence of ligand the 
vast majority of peaks are found in the bins with lower peak scores; two high peak score 
bins are observed. Because substantial E R a binding is not expected in the absence of 
ligand we visually inspected these genomic regions and observed local high tag densi­
ties over large areas reminiscent of copy number variation (CNV). Indeed, the outlier 
regions coincide with CN V as determined by arrayCGH data (Shadeo & Lam, 2006) 
and includes for example the amplified in breast cancer-1 gene (AIB1 or NCOA3) on 
chromosome 20. Regions with high CNV obviously compromise peak calling and were 
therefore corrected for prior to peak calling. Using an FD R of < 1 x 10-4, we identi­
fied 10,205 E R a interaction sites. ChIP-qPCR on three independent biological replicas 
validates the binding of E R a to randomly selected sites (20/20) (Supplementary Figure
S2). ^ e  majority o f the binding sites (41%) are located in introns and only a small per­
centage (7%) in promoter regions (Figure 1B), in good agreement with published data 
(Carroll et al, 2006; Lin et al, 2007).
Next, we compared our 10,205 E R a interaction sites with genome-wide profiles de­
termined in M CF-7 cells using either a micro-array platform or ChIP-PET identify­
ing 5,782 sites and 1,234 sites, respectively (Figure 1C) (Lin et al, 2007; Lupien et al, 
2008). O ur ChIP-Seq and the ChIP-chip data sets show a substantial overlap (57%).
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Including the less deeply sequenced ChIP-PET data set, which showed a 32% overlap 
with the ChIP-Seq targets, we obtained 615 E R a binding sites that are identified with 
all three platforms. Sites shared between all three data sets are likely to encompass high 
affinity sites. Indeed, our E R a binding sites common to all three data sets had a higher 
average peak height (84) as compared to sites present only in our data set (average 34).
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Figure 1. Overview of ERa interaction sites. A. ERa binding sites at the TFF1 and GREB1 
loci. The maximum number of overlapping tags, i.e. peak height is shown. Clear ERa peaks are 
detected in the promoter and enhancer region of the TFF1 and GREB1 gene upon E2 treatment 
whereas residual binding observed in the absence of ligand. ERa binding is strongly decreased 
although not completely abolished upon treatment with tamoxifen or fulvestrant compared to 
E2. B. Genomic location of ERa interaction sites. The majority of sites (41%) are located within 
an intron or distal from a gene (23%). 7% is located in promoter regions. C. Comparison of 
large-scale ChIP profiling data. Venn diagram of the overlap of ERa binding sites as identified in 
this study or reported by Lin et al. and Lupien et al. 3,305 and 1,089 of the ChIP-Seq interaction 
sites are overlapping with the Lupien et al. and Lin et al. analysis (57% and 88% respectively).
D. Venn diagram of the overlap between ERa binding sites induced upon E2, tamoxifen and 
fulvestrant treatment. The E2 and tamoxifen profile overlap to a large extend, but also contain 
preferential binding sites. Fulvestrant liganded ERa interacts with a small number of sites that 
largely overlap with those found upon E2 or tamoxifen induction.
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The good enrichment obtained with our E R a monoclonal antibody combined with the 
high accuracy, sensitivity and sequence depth achieved with the Illumina genome ana­
lyzer allowed for the identification of more transient and likely indirect interaction sites 
in addition to high affinity and direct DN A  binding sites. However, small variations in 
cells and culture conditions i.e. biological variation and sample handling likely also ac­
count for some o f the differences. In conclusion, our E R a binding site analysis reveals a 
very large number of sites encompassing direct as well as indirect interactions sites.
(Partial) antagonists affect ERa binding
The effect of tamoxifen and fulvestrant is hitherto only studied on a small number of 
genes. The prevailing view is that SERMs do facilitate DNA binding of E R a (Shang et 
al, 2000). We performed ChIP-Seq of E R a in M CF-7 cells treated with either tamox­
ifen or fulvestrant to assess whether this holds true on a genome-wide scale. A total of 
8,854 tamoxifen and 4,284 fulvestrant induced E R a sites are detected and representa­
tive examples of E R a binding to the TFF1 and GREB1 loci are shown (Figure 1A). 
Globally, the E2 and tamoxifen profiles overlap to a large extend (54%), whereas a 
smaller proportion of the binding sites are shared between E2 and the fulvestrant profile 
(33%) (Figure 1D). These data corroborate and extend the notion that E R a is able to 
bind to its regulatory regions in vivo when loaded with these (partial) antagonists. We 
note that binding is reduced or even abolished at some sites (Supplementary Figure
S3). The altered DNA binding of E R a in response to fulvestrant is not due to receptor 
degradation (Pink & Jordan, 1996) because we did not observe a reduction of the pro­
tein levels during the 1 h treatment applied in these experiments (data not shown). We 
conclude that E R a binding is affected, but not abolished when liganded with SERMs.
M o tif  analysis
Next we interrogated the sequence of the binding sites for overrepresentation of DNA 
motifs using the M Dmodule program (Liu et al, 2002). The full estrogen response ele­
ment (ERE) — palindromic arrangement o f half sites with a 3 bp spacer — turned out 
to be the by far most prevalent m otif (Figure 2A). Using the weight matrix generated 
by M Dmodule and an ERscan algorithm similar to that used previously (Smeenk et al, 
2008) we find that 68% o f the E R a interaction sites contain one or more ERE (motif 
score cut-off of 5, FPR o f 15%). A clear positive correlation can be observed between 
peak height and the mean of the m otif scores indicating that the E R a indeed binds
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most strongly to sites encompassing a consensus m otif (Figure 2B). Next we screened 
the E R a interaction site sequences for the presence of other motifs. In line with pub­
lished data (Carroll et al, 2006), we find significant enrichment of the Sp1, C/EBP 
and FOXA1 (HNF3alpha) motifs in addi- A
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tion to the ERE (Supplementary Table SII). s  
Although the FOXA1 m otif is statistically 0- 
enriched in our data set (p-value < 0.0001; B 8 
400 bp window), the total number of po­
tential FOXA1 sites in our data is low 
(748/10,205 or 7%). We separately exam­
ined the 3,251 sites that do not encompass 
an ERE for the enrichment of transcription 
factor motifs. Amongst others, we find the 
FOXA1 m otif in 308 peaks (9%). Given 
the apparent discordance between the Lu- 
pien and coworkers and our data, we also 
performed a peak calling using MACS to 
exclude any bias based on the peak detec­
tion algorithm (Zhang et al, 2008). MACS 
detects 7,713 peaks i.e. a 75% overlap with 
the 10,205 sites called by FindPeaks. M otif Figure 2. ERE motif and correlation with
analysis showed that the FOXA1 m otif is peak height. A  The weight matrix of the high­
ly overrepresented ERE motif. B. Correlation
present in 6.6% of peaks called by MACS. of peak height with ERa motif score. The 
To further rule out that this discordance is mean ERE motif score was determined using
due to the use of different weight matrices ERscan. ERa interartion sites were binned
according to peak height; random genomic 
and algorithms, we directly determined the . 1 1 1  1 * 1regions were used as background. A clear
overlap (400 bp window) between our E R a positive correlation is obtained between the
interaction sites and the 12,904 reported height of an ERa peak and the motif score.
The mean of the motif scores in the three 
FOXA1 binding sites and found an overlap ,, ,° r bins is significantly different as assessed by the
of 15% and 13.6% with binding sites de- Mann-Whitney test, with a p-value of < 0.01. 
termined by FindPeaks and MACS, respec- C. Percentage of interaction sites containing
an ERE. The different binding site profiles
tively. Taken together, our analysis reveals were searched for the presence of an ERE us- 
the statistical enrichment o f a number of se- ing ERscan. The ‘E2 preferential’ group con-
quence motifs including the FOXA1 motif, tains the highest percentage of  ERE motifs as
compared to the tamoxifen and fulvestrant 
but only a minor co-occurrence of E R a and /  . ,preferential groups.
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FOXA1 interaction sites was detected.
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Ligand triggers rapid changes in RNAPII occupancy
O ur and previous genome-wide analyses have provided a wealth of E R a binding sites. 
However, assigning the target genes has remained problematic because a large propor­
tion of the E R a binding sites are located at great distances from genes. To more directly 
identify genes responding to E2 treatment (1 h), we performed ChIP-Seq using an 
antibody against RNAPII and determined the log2 ratio of E2/minus ligand. RNAPII 
occupancy throughout the gene body provides a direct readout of transcriptional activ­
ity and thus yields insights beyond what is typically achieved by mRNA expression 
profiling. Classical E R a target genes such as TFF1 and GREB1 show a clear increase in 
RNAPII occupancy over their gene body already after 1 hour exposure to E2 (Figure 3). 
At a global scale, RNAPII occupancy over 596 genes significantly changes in response 
to E2 stimulation (mean +/- 1.5 x SD), with 349 genes showing an increase and 247 
a decrease in RNAPII occupancy. Comparing our E2 regulated genes with mRNA ex­
pression profiles (Kininis et al, 2007; Lin et al, 2007) revealed an overlap of 64 and 47 
genes, respectively. W hen including genes that change less than 2 fold but are signifi­
cant (p-value < 0.05) in the Kininis data set, the overlap increased to 195 genes. Note 
that with our ChIP-Seq of RNAPII occupancy and the short E2 treatment (1 h), we 
will only or predominantly identify direct and immediate/early responding target genes,
Upon treatment of M CF-7 cells with tamoxifen and fulvestrant, we observe many 
SERM-‘specific’ E R a interaction sites (Figure 1D). The selective binding of the recep­
tor in the presence o f different ligands may be dictated by the sequence composition of 
the cis-acting element. Therefore, we assessed the presence of the ERE and other known 
transcription factor motifs in the different categories of compound-specific interaction 
sites as well as of sites common to all three compounds. We find that 74% of the ‘E2- 
specific’ interaction sites contain an ERE, whereas 36% and 39% of the tamoxifen- and 
fulvestrant-specific sites contain an ERE (Figure 2C). Besides the ERE no differentially 
enriched transcription factor motifs could be detected. In addition, we assessed the evo­
lutionary conservation of the E R a binding sites. The shared as well as the compound 
specific groups are significantly more conserved compared to random regions (P-value 
< 0.01) as shown in Supplementary Figure S4. This indicates that binding sites present 
in M CF-7 cells are conserved between species and play a general role in regulation by 
ERa.
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while in gene expression profiling at 3 or 8 h 124 - 
following E2 addition delayed/late respond­
ing and indirect targets may also have been 124 - 
identified.
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Next we examined E2-responsive genes for 
the presence of nearby E R a interaction sites 
(within 50 kb). O f the 349 upregulated 
genes, 309 (89%) encompass 1,226 ER a 
interaction sites, i.e. 4 on average, whereas 
of the 247 downregulated genes, 116 (47%)
encompass 192 E R a interaction sites (1.5 Figure 3. RNA polymerase II occupancy at
\ r> -j _ 1 * j  ERa target genes. The RNAPII occupancyon average). Besides that upregulated genes
is depicted for the TFF1 (top panel) and 
more frequently encompass E R a binding GREB1 locus (lower panel) in response to 
sites than downregulated genes, the sites in solvent (green) or E2 (red).
upregulated genes more frequently contain
an ERE that conforms better to the consensus ERE and displays a higher mean m otif 
score (Supplementary Table SIII). M otif analysis shows that E R a binding sites near 
up- and downregulated genes do not contain differentially enriched transcription factor 
motifs at statistically significant p-values. Gene Ontology (GO) analysis shows that E2 
regulated genes are enriched for a diverse set o f cellular processes and functions, includ­
ing ovulation cycle process, female gonad development and female meiosis (Supplemen­
tary Table SIV).
In conclusion we show that 596 genes change in RNAPII occupancy over the gene body 
in response to E2, of which 59% are up- and 41% are downregulated. A higher number 
of E R a bindings sites are present near upregulated genes compared to downregulated 
genes and sites near upregulated genes conform better to the ERE consensus sequence 
than those o f nearby downregulated genes.
4
Promoter proximal enrichment o f RNAPII
Recent genome-wide (ChIP-chip) studies have shown that a large fraction o f the pro­
moters o f developmental and cell signaling genes as well as genes responding to exter­
nal stimuli display PPEP or pausing of RNAPII, which is thought to facilitate rapid 
upregulation o f transcription (Guenther et al, 2007; Muse et al, 2007; Zeitlinger et al, 
2007). GRO-seq (global nuclear run-on — sequencing) revealed that up to 30% of genes
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4display promoter proximal pausing (Core et 
al, 2008).
Nuclear hormone receptors such as E R a are 
regulators of rapid response par excellence 
and hence, it seemed likely that pausing of 
RNAPII might be involved in the fast regu­
lation of immediate early E2-responsive 
genes. Therefore, we determined the num ­
ber o f tags in the promoter and body of 
genes; in the minus ligand data set (i.e. be­
fore induction) of the 8,465 genes that are 
significantly enriched for RNAPII, 1,228 
(15%) display PPEP (Figure 4A). RNAPII 
enrichment in promoter regions was vali­
dated on 6/ 6  genes using the 8W G16 an­
tibody (Supplementary Figure S5. Further­
more, we validated PPEP using a number 
of phospho-specific (phosphoserine 2 , 5 
and 7) and a N-terminal RNAPII antibody 
(N-term). The transition of RNAPII from 
the initiation to the elongating form can 
be monitored by phosphorylation of spe­
cific serine residues in the CTD. Serine 5 
is phosphorylated at the initiating phase of 
transcription while serine 2 is a mark of pro­
ductive RNAPII and occurs more in the 3’ 
end of a gene. Serine 7 phosphorylation is a 
mark for elongating RNAPII (Chapman et 
al, 2007; Phatnani & Greenleaf, 2006). The 
RNAPII phosphorylation status of 3 genes 
was assessed in the absence or presence o f E2 
using ChIP in combination with phospho- 
specific antibodies. The presence of phos- 
phoserine 5 (and surprisingly 7 ) combined 
with the absence of phosphoserine 2 shows
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Figure 4. Promoter proximal enrichment of 
RNAPII (PPEP). A  Histogram of the RNAPII 
occupancy ratio at promoter versus gene body. 
The distribution of the promoter / genebody 
ratio of all genes containing RNAPII (light 
blue) and of E2 responsive genes (red). The 
dashed lines represent the mean +/- 1 x SD. 
1,228 genes display paused RNAPII of which 
only 21 are E2 responsive genes. B. RNAPII 
occupancy profile. Genes were divided into 
bins relative to the transcription start site; 
-500 to -251, -250 to TSS, TSS to +250 and 
the remaining gene body was divided into 
four equal bins. For each group of genes the 
mean number of tags per bin is plotted. E2 
regulated genes on average have less RNAPII 
at their promoter regions as compared to the 
mean of all genes. Genes above the set thresh­
old (mean + 1 x SD) have a higher RNAPII 
occupancy at their promoter as compared to 
all genes and E2 regulated genes.
B
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PPEP in the presence and absence of ligand (Supplementary Figure S6 ).
Strikingly, only 21 of the 596 E2-regulated genes (4%) display PPEP. Moreover, the 
median RNAPII occupancy profile over E2 regulated genes in the promoter region and 
the coding body does not significantly deviate from that of all genes but is very signifi­
cantly lower than the profile of PPEP genes (Figure 4B). O f the 64 E2-regulated genes 
shared between our and Kininis data sets, 8% display PPEP, a percent wise increase as 
compared to our entire data but still a minor fraction. (Kininis et al, 2007). Together 
these results demonstrate that a large fraction of all genes, but only a very minor fraction 
of E2-regulated genes display PPEP in M CF-7 cells. Nevertheless, the majority o f the 
349 E2-upregulated genes do show a rapid and highly significant increase in RNAPII 
occupancy already at 1 hour of E2 induction.
Finally, we determined the effect of ligand administration on the 21 E2 regulated genes 
that display PPEP E2 induction changes the RNAPII occupancy ratio between prom ot­
er and gene body resulting in a loss of PPEP (10/21), while tamoxifen and fulvestrant 
treatment resulted in the abolishment of RNAPII occupancy (and thus PPEP) on 21/21 
genes and 15/21 genes, respectively. The observation that (partial) antagonists induce a 
rapid loss o f RNAPII on E2 responsive promoters indicates that at large these ligands 
prevent the recruitment to and/or stabilization o f RNAPII at the promoter and thus 
preinitiation complex (PIC) formation rather than affecting the transition o f RNAPII 
into the elongating form.
4
Overlapping as well as distinct groups o f genes respond to (antago­
nists
Given that in the vast majority o f the cases the binding of E R a is not abolished upon 
(partial) antagonist treatment, we determined the effect of tamoxifen and fulvestrant on 
the RNAPII occupancy. Upon tamoxifen administration, 719 genes change in RNAPII 
occupancy; the vast majority (695/719) is downregulated as compared to the minus 
ligand control. Strikingly, more genes change their RNAPII occupancy upon (partial) 
antagonist as compared to E2 treatment (596), which has also been observed in expres­
sion profiling studies (Frasor et al, 2004). Upon fulvestrant treatment 319 genes change 
in RNAPII occupancy as compared to the minus ligand control o f which 230 are down- 
regulated. A typical example is shown in Supplementary Figure S7. In mock treated 
cells, the RNAPII occupancy o f many ERa-regulated genes was low, but in many cases 
clearly enriched for RNAPII which is likely due to incomplete ligand depletion. Col-
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Figure 5. Cluster analysis based on changes in RNAPII occupancy. A. The 1,256 genes with 
changed RNAPII occupancy in response to the various ligands were clustered into 5 groups on 
the basis of the change in RNAPII occupancy relative to ‘no ligand’ (ligand/no ligand ratio) using 
K-means clustering. B. Representative examples of RNAPII occupancy in response the various 
ligands. The number of genes in each cluster is indicated. C. Boxplot presentation of the changes 
in mRNA levels triggered by ligand treatment for 1, 3 and 8 hours of RT-qPCR analysis was 
performed on 6 randomly chosen genes out of each cluster using exonic primer pairs. Relative 
mRNA levels were normalized to that of RPS19. The number of ERa peaks and the mean ERa 
peak height is indicated. D. Enriched GO categories in each cluster.
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lectively, the total number of genes with altered RNAPII occupancy for all three ligands 
is 1,256.
To classify genes based on their response to E2, tamoxifen and fulvestrant we performed 
K-means clustering of the RNAPII ratios revealing 5 distinct clusters (Figure 5A and B). 
Using Gene Ontology we assessed whether the genes within the clusters are functionally 
related (Figure 5D). Supplementary Table SV shows an overview of the E R a binding 
sites analysis per cluster. The changes in RNAPII occupancy in response to the various li­
gand treatments were validated by ChIP-qPCR on 7-8 randomly chosen examples from 
each cluster (Supplementary Figure S8). Next we compared the changes in RNAPII oc­
cupancy o f 6 genes from each cluster with the changes in the level of primary transcript 
and mRNA levels as measured by RT-qPCR at 0, 1, 3 and 8 h after treatment using 
intron-exon and exonic primer pairs, respectively. In particular, the changes in primary 
transcript levels (Supplementary Figure S9) and to a lesser extend of mRNA levels (Fig­
ure 5C; Supplementary Figure S10) of genes in cluster 2, 3 and 4 correlate very well to 
the changes in RNAPII occupancy in response to the various ligands as determined by 
ChIP-Seq.
Cluster 1 contains a large group of genes that were strongly downregulated only upon 
tamoxifen treatment. In line with this, 4 out of 6 genes show diminishing primary 
transcripts levels whereas the mRNA levels respond later and decrease after 8 hours. O n 
average one peak per E R a binding site is present in the vicinity of these genes. Among 
the genes in this cluster is e.g. the pro-apoptotic gene Bad whose overexpression inhibits 
estrogen induced cell proliferation (Fernando et al, 2007). In addition high Bad expres­
sion levels correlate with improved disease free survival (Cannings et al, 2007). The 
cyclin A gene has a similar response to the different ligands and has prognostic value in 
early breast cancer. Overexpression of cyclin A in tamoxifen treated tumors is signifi­
cantly associated with poorer outcome (Michalides et al, 2002). Intriguingly, E R a peaks 
in the vicinity of genes in this cluster were slightly higher when liganded with tamoxifen 
as compared to E2 liganded ERa.
The second cluster contains strongly E2 downregulated genes that were derepressed by 
fulvestrant, but not or only to a limited extend by tamoxifen. Among these was cyclin 
G2, a negative regulator of the cell cycle that maintains cells in a quiescent state and is 
downregulated upon E2 induction as described previously (Stossi et al, 2006). Strik­
ingly, we observed that tamoxifen acts as an agonist on cyclin G2, in contrast to Stossi et 
al. who describe that tamoxifen antagonizes the E2 mediated downregulation. Another
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gene downregulated upon E2 treatment was the pro-apoptotic Bak gene. It has been 
described previously that Bak expression is downregulated upon estradiol treatment and 
reduction of Bak expression provides a growth advantage to cells (Leung et al, 1998). 
Bik, another pro-apoptotic gene was also present in cluster 2 and in good agreement 
with our data, it has been shown that Bik mRNA levels increase upon estrogen starva­
tion and antagonist treatment, while mRNA levels decrease upon E2 induction (Hur 
et al, 2004). Interestingly, genes in this cluster display the lowest number of E R a bind­
ing sites per gene (0.88  on average). Tamoxifen liganded E R a bound on average with 
higher affinity to sites near cluster 2 genes compared to E2 liganded ERa. Interestingly, 
the primary transcripts of cluster 2 genes do not change or are even slightly elevated 
upon tamoxifen or fulvestrant treatment, whereas the mRNA levels decrease likely due 
to regulation of mRNA stability. G O  analysis showed that cluster 2 is enriched in e.g. 
genes involved in apoptosis and cell cycle arrest.
Genes in the third cluster are upregulated by E2, which is strongly antagonized by 
tamoxifen and fulvestrant. In the absence of ligand these genes were already expressed 
as revealed by the presence of RNAPII; upon tamoxifen or fulvestrant treatment the 
RNAPII occupancy level of these genes dropped below the minus ligand level. For ex­
ample, transcription of the IGFBP4 gene is strongly boosted upon E2 addition and 
decreased upon tamoxifen treatment. IGFBP4 expression is used as a predictor of re­
sponsiveness to endocrine therapies (Walker et al, 2007). Another E2 upregulated gene 
in this cluster was the cell cycle regulator cyclin D1. Overexpression o f cyclin D1 is 
associated with better outcome for breast cancer patients but its overexpression is also 
linked to tamoxifen resistance (Ishii et al, 2008). O n average genes in cluster 3 contain 
2.7 E R a binding sites. G O  analysis revealed among others involvement in cell prolifera­
tion and insulin receptor signaling. The mRNA levels o f genes in cluster 3 and 4 (see 
below) increase upon E2 treatment, with the largest increase at 3 h o f treatment and do 
not respond or are downregulated upon tamoxifen or fulvestrant treatment.
Cluster 4 also contains E2 upregulated genes that are antagonized both by tamoxifen 
and fulvestrant, but genes in this cluster show no/m inor RNAPII occupancy in the 
absence of ligand as opposed to cluster 3 genes. Interestingly, the nuclear receptor co­
activator NCOA4 is upregulated upon E2 treatment. NCOA4 can associate with ER a 
and has been reported to increase transcription of T F F 1 (Lanzino et al, 2005). The anti- 
apoptotic Bcl-2 is present in this cluster. Bcl-2 has been shown to be upregulated upon 
E2 induction and Bcl-2 expression is linked with better outcome in hormone or che-
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motherapy treated patients (Nadler et al, 2008). Genes in the fourth cluster display on 
average the highest number o f E R a binding sites (4.2 on average per gene). In addition,
E R a binding sites found in the proximity of cluster 3 and cluster 4 have a higher peak 
score (affinity) for the E R a as compared to the other clusters. Cluster 4 was enriched 
in e.g. the G O  categories sex differentiation, ovulation from ovarian follicle and gland 
development. 4
Remarkably, cluster 5 contains genes upregulated by all three ligands which is however 
not well reflected in the mRNA levels. Among the genes was HUS1, which is part o f a 
cell cycle checkpoint in D N A  damage response (Meyerkord et al, 2008). Genes in this 
cluster contained on average 1.4 E R a binding site per gene. G O  analysis showed enrich­
ment for genes involved in stress response.
In conclusion, tamoxifen and fulvestrant have differential effects on RNAPII occupancy.
The majority of E2-upregulated genes are antagonized by both tamoxifen and fulves­
trant, while tamoxifen displayed agonistic behavior whereas fulvestrant antagonized 
E2-downregulation. Furthermore, tamoxifen specifically affects a rather large group of 
genes that are not affected by either E2 or tamoxifen.
D i s c u s s i o n
To unravel the target gene network of a transcription factor, identification of its in­
teraction sites, cis-regulatory elements and target genes is essential. We have applied 
ChIP combined with massive parallel sequencing to identify E R a interaction sites and 
to globally map changes in RNAPII occupancy in the presence and absence of three 
ligands. A small fraction of E R a interaction sites is located in promoter regions while 
the majority is found at large distances from annotated genes or in introns in line with 
previous studies (Carroll et al, 2006; Lin et al, 2007). These distal sites most likely act 
as enhancers and interact with receptive promoters via looping to regulate gene expres­
sion, as has been described for some E R a target genes such as TFF1, GREB1 and bcl-2 
(Carroll et al, 2005; Deschenes et al, 2007; Perillo et al, 2008). O ur comprehensive 
analysis of the E R a interaction site sequences showed that the vast majority of sites 
contain an ERE which is in agreement with other data (Lin et al, 2007). In line with 
observations that E R a physically and/or functionally interacts with other transcription 
factors we reveal that amongst others the Sp1, C/EBP and FOXA1 m otif are enriched
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(400 bp window). Lupien et al. reported that 50-60% of E R a binding in M CF-7 cells 
co-occurred with FOXA1. Although statistically enriched, FOXA1 is only present in a 
small fraction of all our E R a interaction sites. Use of the peak detection method em­
ployed by Zhang and coworkers (MACS) did not significantly change the percentage of 
E R a binding sites with a FOXA1 m otif (Zhang et al, 2008). The intersection between 
the FOXA1 binding sites (Lupien et al, 2008) and our E R a profile (FindPeaks) reveals a 
15% overlap. O ur m otif analysis and the limited overlap between both genomic binding 
sites indicates that the cooperativity between E R a and FOXA1 is under our condition 
much more restricted than previously reported. The discordance is substantial and may 
be due to the use of different antibodies and platforms. More research is necessary to 
fully elucidate the role of FOXA1 in E R a transcriptional regulation.
We showed at a genome-wide scale that tamoxifen and fulvestrant affect but do not 
abolish binding of E R a to chromatin. O ur analysis revealed an extensive overlap be­
tween E R a interaction profiles in the presence of the different ligands but also detect in­
teraction sites that show ligand specific E R a binding. Additionally, our analysis showed 
that a higher percentage of sites in the ‘E2-specific’ group conform to the consensus 
ERE as compared to the tamoxifen and fulvestrant specific group. One explanation of 
this ligand dependent preference is that the receptors interact or cooperate with other 
transcription factors and that this cooperativity with other transcription factors may in 
part be determined by conformational changes in the DNA binding domain instigated 
by E2, tamoxifen and fulvestrant binding. However, our m otif analysis does not lend 
support to this hypothesis and hence, the ligand specific binding is likely dependent 
on other factors. The local chromatin landscape and histone modifications likely play a 
decisive role as has been described for GR (John et al, 2008). Furthermore, it has been 
shown that E2 but not fulvestrant loaded E R a recruits SWI/SNF, an ATP dependent 
chromatin remodeler complex, to its binding sites resulting in chromatin remodeling 
and histone acetylation (Belandia et al, 2002). Likely the correct chromatin structure 
necessary for stable and recurring ERa-chrom atin interactions is not induced by (par­
tial) antagonists and as a consequence E R a binds weaker or not at all.
The dispersed and often distal localization of E R a binding sites complicates the assign­
ment o f E R a interaction sites to E2-responsive genes. We identify for the first time 
genes responding to E2 induction by using ChIP-Seq profiling of RNAPII occupancy 
in the absence and presence o f the various compounds. O f the 596 genes changing in 
RNAPII occupancy upon E2 induction around half are up- and half are downregulated
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in keeping with micro-array expression profiling (Kininis et al, 2007; Lin et al, 2007). 
The limited overlap between our E2-responsive genes and mRNA expression profiles 
maybe due to differences in the M CF-7 sublines used, the different induction times and 
inherent differences between analyses based on RNAPII occupancy and on steady state 
mRNA levels (Frasor et al, 2004).
The majority o f E2-activated genes are associated with one or more E R a binding sites, 
indicating that E R a complexes bound to multiple interaction sites probably cooperate 
to regulate expression of target genes as previously observed for e.g. TCF4 and MYC 
(Bieda et al, 2006; Hatzis et al, 2008). Nevertheless, the requirement of multiple E R a 
binding sites per E2 regulated gene alone cannot account for the striking discordance 
between the number of E2-regulated genes (596) and E R a binding sites (10,205). Most 
likely other factors besides E R a binding such as promoter accessibility, the local chro­
matin structure, epigenetic state and the presence of specific cofactors are necessary for 
transcriptional regulation to occur.
We also analyzed the RNAPII occupancy profiles to assess PPEP. Several recent studies 
have reported that between 12 and 30% of genes display PPEP RNAPII profiling in 
Drosophila showed that pausing is occurring predominantly on genes responding to 
stimuli as well as developmental genes. It is postulated that the presence of RNAPII on 
the promoter allows rapid upregulation of these genes (Guenther et al, 2007; Kim et 
al, 2005; Muse et al, 2007; Zeitlinger et al, 2007) as observed for the heat shock genes 
(Petesch & Lis, 2008). We show that 15% of all active genes in the minus ligand data 
show PPEP in M CF-7 cells in keeping with other studies(Core et al, 2008; Guenther et 
al, 2007; Kim et al, 2005; Kininis et al, 2009; Muse et al, 2007; Zeitlinger et al, 2007). 
In our data set however, the genes displaying PPEP are not significantly enriched for 
developmental genes or genes responding to stimuli, but for a broad spectrum of GO 
classes. This may be due to the developmental or differentiated state o f the cells under 
investigation (Supplementary Table SVI). We used the M CF-7 breast cancer cell line in 
contrast to the Drosophila embryos or the embryonal Drosophila S2 cell line (derived 
from late stage embryos) used by Muse et al. and Zeitlinger et al. In differentiated cells 
other genes may be poised for activation as compared to embryos/embryonic cell line. 
E2-responsive genes are responding to external stimuli par excellence and hence likely 
candidates for employing PPEP as a way of regulation. However, only a small fraction 
of genes that display PPEP are also E2-responsive, indicating that PPEP is not a general 
mechanism o f rapid E2 instigated gene regulation, although it may play a role on a lim­
4
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ited number o f E2-regulated genes.
RNAPII pausing was recently reported to play a role in the regulation of a number of 
E2-regulated genes (Kininis et al., 2007; Kininis et al., 2008). The authors assessed 
RNAPII pausing by performing ChIP-chip for RNAPII using a promoter array in ad­
dition to gene expression profiling to determine E2-responsive genes. They reported 
that 59% of E2-responsive genes are preloaded with RNAPII (Kininis et al., 2008). In 
contrast our data indicates a minor role of pausing or PPEP in E2-mediated regulation. 
It seems likely that the choice of analyzed E2-responsive genes that is selected either 
on the basis of mRNA profiling (Kininis et al., 2007) and on E2-induced RNAPII 
occupancy at very early times may have affected the respective seemingly opposing con­
clusions. As an example, the Myc and SIAH2 gene described by Kininis et al. do not 
fulfill our criteria for being E2-responsive and displaying PPEP (Supplementary Figure 
S11). In our genome-wide RNAPII ChIP-Seq analysis, the Myc gene does not exceed 
our threshold for E2-responsiveness (mean ± 1.5 x SD of log2 ratio E2/minus ligand). 
PPEP is observed in the proximity of the Myc promoter as defined by RefSeq, but the 
peak for RNAPII is not near the start site as defined by Ensembl and hence drops out 
as an E2-responsive gene displaying PPEP. SIAH2 is clearly E2-responsive, but does not 
fulfill the PPEP threshold (mean ± 1 x SD of the log2 ratio of RNAPII occupancy over 
promoter/gene body). Further research will be necessary to resolve the discordance and 
to elucidate the possible role of RNAPII pausing in E2-mediated regulation. Tamoxifen 
stimulation abolished RNAPII occupancy over the promoter and coding regions of all 
21 E2 regulated genes displaying PPEP while fulvestrant results in the abolishment 
of PPEP on 15/21 genes. Therefore we conclude that both tamoxifen and to a lesser 
extent fulvestrant inhibit RNAPII recruitment, and/or destabilization of the RNAPII/ 
PIC complex.
We show that the SERMs tamoxifen and fulvestrant have a profound effect on the 
RNAPII occupancy o f many genes. Using clustering methods, we could divide E2, ta­
moxifen and fulvestrant regulated genes into five distinct clusters based on their RNAPII 
ratio. The primary transcript levels for the clusters 2, 3 and 4 correspond very well to 
the RNAPII ChIP data validating our approach. Following tamoxifen treatment, the 
primary transcript levels of genes randomly selected from cluster 2 do not change sig­
nificantly while fulvestrant treatment increases the primary transcript levels. In contrast, 
mRNA levels show a different pattern for both tamoxifen and fulvestrant and are di­
minished indicating that mRNA stability plays a role in E R a mediated regulation of
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this gene cluster again validating our RNAPII occupancy approach. Strikingly cluster 1 
contains a group o f genes that show no or only minor downregulation upon E2 induc­
tion, but are stronger repressed by tamoxifen and not or to a lesser extend by fulvestrant.
The presence of many E R a binding sites in the vicinity o f these genes indicates that the 
tamoxifen-mediated repression may indeed be directly mediated through ERa. Tamox­
ifen preferential gene regulation has been shown on mRNA levels (Frasor et al, 2006). 4  
Cluster 2 contains genes that are most strongly downregulated by E2 and on which 
tamoxifen acts as a weak agonist; in contrast fulvestrant displays full antagonistic be­
havior. Using reporter assays it has been shown that tamoxifen antagonizes E2 induced 
upregulation but acts as an agonist at E2 downregulated genes (Ramkumar & Adler,
1995). One possible mechanism could be that on E2 downregulated genes E R a recruits 
nuclear receptor corepressors and associated HD A C’s that subsequently deacetylates the 
chromatin and prevent recruitment of RNAPII and the basal transcriptional machinery 
(Stossi et al, 2006). It seems likely that tamoxifen prevents the recruitment and load­
ing of co-activator complexes on E2-upregulated genes, as seen in cluster 3 and 4, but 
on E2-downregulated genes tamoxifen does not prevent the recruitment of repressing 
complexes, or is not able to recruit activating complexes, as seen in cluster 2. Strikingly, 
fulvestrant does antagonize both E2-upregulated as well as E2-downregulated genes. A 
small group of genes is upregulated by stimulation with all three ligands. These genes are 
enriched for among others response to stress and DNA damage, indicating that ligand 
stimulation results in activation o f stress responses.
Upon SERM treatment RNAPII is not significantly enriched over the coding body of 
most if not all E2 upregulated genes compared to background, whereas these same genes 
display clear RNAPII occupancy in the absence of ligand. O n E2-downregulated genes, 
E2-loaded E R a represses transcription probably by interfering with PIC formation and/ 
or by preventing its assembly as well as by recruiting corepressor complexes and histone 
deacetylases. Upon binding of a SERM loaded receptor, transcription is not downregu­
lated and the PIC remains present. Thus, tamoxifen or fulvestrant loaded E R a acts 
mechanistically different on E2 up- and downregulated genes. This differential behavior 
at up- and downregulated genes might relate to the direct or indirect protein-mediated 
binding of ERa. Regulation via tethering to other transcription factors such as NF-kB,
AP-1 and Sp1 might alter the properties o f SERM loaded receptor.
In conclusion our study provides novel and important insight into the regulation o f the 
E R a target gene network and serves as a resource for the further elucidation of E R a reg-
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ulated transcription. Pausing of RNAPII occurs frequently in M CF-7, but only at a very 
small number o f E R a target genes. We provide compelling evidence that tamoxifen and 
fulvestrant behave differently; tamoxifen acts as an agonist at E2 downregulated genes 
while fulvestrant antagonizes both E2 up- and downregulated genes. Strikingly, tamox­
ifen regulates a rather large number of genes that are not or much less responsive to E2
4  or fulvestrant. Furthermore, these genes might play a role in tamoxifen resistance.
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M e t h o d s
ChIP
MCF-7 cells were cultured in DMEM with 10% FCS at 37 °C. Cells were maintained in DMEM 
w/o phenol red and 5% charcoal stripped FCS for 48 h prior to induction. MCF-7 cells were 
mock treated or with 10 nM 17beta-estradiol, 1 pM 4-OH tamoxifen or 100 nM Fulvestrant 
for 1 h. Chromatin was harvested and ChIP and qPCR was performed as described (Denissov 
et al, 2007). ChIP was performed using one of the following antibodies: ERa (Diagenode AC- 
066-100), RNAPII (Diagenode AC-055-100), Ser5-P RNAPII (Abcam, ab24759), RNAPII N- 
terminus (Santa Cruz, sc-899 X), Ser2-P RNAPII and Ser7-P RNAPII, both a kind gift from 
Dirk Eick.
Illumina high throughput sequencing
Sample preparation was performed as described by the manufacturer. The 32 bp tags were 
mapped to the human genome HG18 using the eland program allowing 1 mismatch. The 32 
bp sequence reads were directionally extended to 133 bp, corresponding to the length of the 
original fragments used for sequencing. For each base pair in the genome the number of overlap­
ping sequence reads was determined, averaged over a 10 bp window and visualized in the UCSC 
genome browser (http://genome.ucsc.edu).
CNV correction and peak detection
The distribution of tags in the minus ligand dataset was determined by counting the number of 
tags in a 500 kb window. The mean and standard deviation of all windows was determined and 
a threshold was set at mean + 3xSD. Windows above the threshold were corrected by uniformly 
removing tags such that the number of tags was equal to that of the mean of all windows. All 
ERa data sets were corrected; subsequently enriched regions were identified with FindPeaks us­
ing a FDR cut-off of < 1 * 10-4, subpeaks 0.9, triangles distribution and duplicate filter (Fejes 
et al, 2008). To allow for direct comparison, datasets were uniformly equalized relatively to the 
sample with the lower number of tags.
Motif search
For all sequence analysis the highest point in a peak (FindPeaks) was used and extended on both 
sides with either 200 bp or 1500 bp. MDmodule was used with varying window sizes (Liu et 
al, 2002). Sequence logos were constructed using Weblogo (http://weblogo.berkeley.edu/). To 
search for known motifs, the MATCH software and the Transfac 11.1 database were used (Matys 
et al, 2003). Random genomic sequences were used as background. Enrichment was calculated 
using Benjamin-Hochberg multiple testing correction. Motifs with a p-value of < 0.001 and a 
score above 2 were called enriched. The presence of ERE was determined in a 400 bp window 
using ERscan, an adapted version of p53scan (Smeenk et al, 2008).
Conservation
ERa binding sites were extended from the highest point in a peak with 100 bp on both sides. 
For each binding site, the mean PhastCons28 conservation score was calculated and per group 
the mean of all sites was determined. A Mann-Whitney test was performed to determine whether 
the scores were significantly higher compared to random sequences.
GO
Enrichment of GO categories was determined with the Ontologizer software, using Topology- 
Elim, Benjamini-Hochberg and a cut-off of 0.01
RNAPII analysis
To quantitate the change in RNAPII occupancy, the data sets were uniformly equalized by re-
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moving tags relatively to the sample with the lower tag count. For each gene the number of tags 
in the gene body was counted and the log2 ratio between ligand and minus ligand control was 
calculated. A threshold was set at mean +/- 1.5 x SD of the log2 ratio. Very low expressed genes 
were removed if under all conditions the number of tags was less than 5 or the length in bp/tag 
count was less than 100. Clustering was performed using the K-means algorithm with cosine 
distance using the ARMADA program (Chatziioannou, A. et al., submitted, 2008). The heatmap 
was created using Java TreeView.
4
mRNA and primary transcript expression analysis
RNA was harvested after 0, 1, 3 or 8 h ligand treatment using the Qiagen RNeasy kit including 
on column DNase treatment. RNA was reverse transcribed to cDNA using Invitrogen super­
script III. Exon-intron and exonic primer pairs were used for primary transcript and mRNA 
analysis. Expression levels were normalized to RSP19.
Accession codes
Sequence and processed data has been submitted to National Center for Biotechnology Gene 
Expression Omnibus with GEO accession number GSE14664.
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PPEP
For each gene in the Ensembl 47 gene annotation, the number of tags was determined in the 
promoter (-250 bp to +500 bp with respect to the transcription start site) and genebody (+500 
bp to gene end). Genes with 8 or more tags in the promoter region were selected and the number 
of tags per 750 bp in the gene body was determined. Subsequently the log2 ratio of the number 
of tags in the promoter and in the gene body was calculated. A threshold was set at mean + 1 x 
SD and genes above this threshold were defined as displaying promoter proximal enrichment of
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CHAPTER 5
Antibody is key and the Achilles heel of ChIP
W illem-Ja n  W elbo ren , Fred  C G J Sw eep , Pa u l  N  S pan , H en dr ik  G  Stu n n en berg  
Ma n u sc r ip t  in preparat io n .
A b s t r a c t
Progress made in high throughput sequencing has resulted in a rapid increase in the 
number o f published genome-wide ChIP profiles. These studies are performed using 
only one antibody against the target protein or epigenetic modification. The character­
istics of the antibody are very likely influencing the resulting profile. Here, we assess for 
the first time the effect of different antibodies on the final genome-wide ChIP profile. 
For this we performed ChlP-Seq for the Estrogen Receptor alpha (ERa) using three 
different ChlP-grade antibodies, two monoclonals raised against either the C- or N- 
terminus, and one polyclonal antibody raised against the N-terminus. We show that the 
profiles o f the two monoclonal antibodies overlap to a large extend. The profile of the 
polyclonal antibody also contains the majority o f the monoclonal sites, but in addition 
contains a large group o f sites that are only detected by the polyclonal antibody. Analysis 
revealed that these sites are predominantly weak, low affinity binding sites that could be 
due to aspecific binding. ChlP-Seq with the polyclonal antibody in the E R a negative 
MDA-231 cell line however showed that these sites are not due to cross reactivity. Inter­
estingly, m otif analysis revealed that the estrogen response element occurs less frequently 
at these sites, indicating these are of lower confidence. The FOXA1 m otif however, is 
present more frequently at these low affinity sites. In conclusion, these data show that 
not all antibodies are created equal, and that the choice of antibody is of great influence 
on the final profile and the subsequent conclusions draw and insights gained.
I n t r o d u c t i o n
The decreasing cost and increasing capacity of high throughut sequencing has resulted 
in an ever-increasing number of published genome-wide chromatin immunoprecipita- 
tion (ChIP) profiles. These ChIP profiling studies have provided a wealth o f information 
on e.g. epigenetic modification patterns (Akkers et al, 2009; Barski et al, 2007; Bhan- 
dare et al, 2010; Guenther et al, 2007; Mikkelsen et al, 2007; Robertson et al, 2008; 
Rosenfeld et al, 2009; Wang et al, 2008; Zhao et al, 2007) and transcription factor 
binding profiles (Bilodeau et al, 2009; Chen et al, 2008; Lefterova et al, 2010; Nielsen 
et al, 2008; Robertson et al, 2007; Visel et al, 2009; Welboren et al, 2009). However, 
these studies are usually performed using only one specific antibody against the target 
protein, epigenetic modification or nucleosome. As a result o f this, the binding site or 
modification profile and hence the insight gained and conclusions drawn from genome-
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wide ChIP data could be influenced by the properties of the antibody chosen for the 
study. Hence, the final value of the study is completely based on the quality and proper­
ties of the antibody.
Antibody properties that are likely influencing the ChIP profile are e.g. the clonality 
of the antibody, i.e. mono- or polyclonal. In general, polyclonal antibodies will have a 
higher affinity to the target protein, but are more likely to show cross-reactivity. Fur­
thermore, polyclonal antibodies are more likely to show batch-to-batch variation. An­
other factor is the epitope to which the antibody is raised. Epitope shielding, where 
the epitope is not physically available to the antibody due to the presence of e.g. cofac­
tors, can prevent the binding of the antibody to the target protein. ^ i s  is of particular 
concern when precipitating transcription factors, which operate in large multi-protein 
complexes. Monoclonal antibodies are likely to be more sensitive to epitope shielding 
because they only recognize one epitope. Antibodies are usually tested for specificity but 
weak cross-reactivity can occur as is demonstrated by whole proteome analysis in yeast, 
which showed that a significant number of antibodies cross-reacted with other proteins 
(Michaud et al, 2003; Predki et al, 2005). ^ i s  weak cross-reactivity can hamper the 
specificity of the ChIP profile and result in false positives. This is especially the case 
for histone modifications, where e.g. antibodies against H3K9me3 and H3K27me3, 
or antibodies against different methylation states at the same residue could show cross­
reactivity.
So far, the effect of the choice of antibody on the genome-wide ChIP profile has not 
been studied. To explore this antibody effect, we used Estrogen Receptor alpha (ERa), 
for which a number of ChIP-grade antibodies are available. We performed ChIP-Seq 
for the ERa using three different antibodies, two monoclonal and one polyclonal, and 
compared the resulting profiles. We show that the genome-wide profiles of the three 
antibodies partially overlap, but that the polyclonal antibody identified a much larger 
group of binding sites. The sites specifically detected by the polyclonal antibody are 
predominantly weaker, low affinity binding sites. Motif analysis showed that the choice 
of antibody greatly influences the enrichment of specific sequence motifs and the subse­
quent conclusions drawn from the data.
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R e s u l t s
We performed ChIP-Seq using estradiol treated MCF-7 cells and three different anti­
bodies; the monoclonal F3A6 and the polyclonal HC-20, both raised against the C- 
terminus of ERa, and the monoclonal Dia050 antibody raised against the N-terminal 
part of ERa, as shown in Figure 1A. As a control input DNA was sequenced. The ERa 
binding profile for the three antibodies over the intensively studied ERa target genes 
TFF1, GREB1 and SIAH2 are shown in Figure 1B. ^ e  three antibodies showed an al­
most identical binding profile over these genes, although there was some slight variation 
in peak height between the sets. We subsequently performed peak detection using the 
MACS algorithm and compared the resulting profiles as shown in Figure 1C (Zhang 
et al, 2008). A random selection of binding sites from each set was validated by ChIP- 
qPCR. An overview of the antibody properties and resulting datasets are shown in Table 
1. ^ e  profiles of both the monoclonal antibodies, F3A6 and Dia050 overlapped to a 
large extend (85.3% of the F3A6 and 68.1% of the Dia050 set). ^ e  larger polyclonal 
HC-20 dataset overlapped very well with the both the F3A6 (91.1% of the F3A6) and 
Dia050 (90.1% of the Dia050) profile, but contained a large number of ERa binding 
sites that are not identified by the monoclonal antibodies (15,341, 60.4%).
F3A6 HC-20 Dia050
Clonality Monoclonal Polyclonal Monoclonal
Epitope C-terminal C-terminal N-terminal
Tags sequenced 6720949 8328678 8499570
Peaks 8207 25401 10270
Positive peaks 7107 24272 8997
Table 1. Antibody and data set properties.
Besides the presence or absence of a binding site, we also compared the respective peak 
heights or number of tags per peak. We normalized the three sets and calculated the 
relative peak score for each peak (see materials and methods section). Subsequently, the 
peak scores of each set were plotted pairwise as is depicted in Figure 2. In general the 
peak scores correlated well between the sets, especially between both monoclonal anti­
bodies, F3A6 and Dia050. ^ e  HC-20 peaks score correlated somewhat less with both 
the F3A6 and the Dia050 set.
Next we determined the correlation of peak scores using an alternative method by sort­
ing the peaks based on the HC-20 peak score, as depicted in Figure 3A.
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Figure 1. A. Overview of the domain 
structure of ERa. ^ e  NH2 terminal 
consists of the A/B domains, the C 
domain forms the DNA-binding do­
main (DBD) while domains D/E/F 
constitute the ligand-binding do­
main (LBD). ^ e  epitopes to which 
the F3A6, HC-20 and Dia050 anti­
bodies are raised are depicted.
B. ERa binding sites at the GREB1, 
TFF1 and SIAH2 loci. Peakheight is 
on the y-axis. Clear ERa peaks are de­
tected in the promoter and enhancer 
regions of GREB1 and TFF1 and in 
the promoter and intron of SIAH2. 
^ e  binding pattern and peakheights 
are comparable between the three 
data sets.
C. Venn diagram of the overlap be­
tween the binding site profiles of the 
F3A6, HC-20 and Dia050 antibody. 
^ e  F3A6 and Dia050 profiles over­
lap to a large extend. ^ e  HC-20 pro­
file encompasses almost completely 
the profiles of the F3A6 and Dia050 
antibody, but in addition contains a 
large number of sites not detected by 
the other antibodies.
5
The general trend between the three sets was similar, that is, a high peak in one set was 
usually also high in the other sets. However, there was a group of peaks with a low peak 
score in the HC-20 set but a higher score in the F3A6 or Dia050 set. Taken together this 
shows that, especially for the F3A6 and Dia050 sets, not only the number and location 
of binding sites was similar, but also the relative peak scores within the sets. However,
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Figure 2. Peak height correlation. Scatter 
plot depicting the pairwise comparison 
of ERa binding sites. For each peak the 
height was determined in all three data 
sets and potted per peak. The R-square 
was calculated and plotted. There is a clear 
correlation between the data sets, where 
the F3A6 and Dia050 show the best cor­
relation, while the HC-20 and Dia050 
show the lowest correlation.
HC-20 showed a somewhat lesser correlation and contained a large number of sites not 
detected by the two monoclonal antibodies.
There are several possible explanations for the large number of HC-20 specific peaks. 
Due to their nature polyclonal antibodies are more prone to cross-reactivity. To assess 
whether the HC-20 specific sites are true ERa binding sites or caused by cross-reactivity, 
we first looked at the presence of the ERa binding motif, the estrogen response element 
(ERE) in the sequences underlying the peaks. Motif analysis revealed that 70% of the 
F3A6 sites, and 68% of the Dia050 sites contained an ERE, but only 57% of the HC-20 
sites, a significantly lower percentage of EREs compared to both monoclonal antibodies. 
We next looked at the distribution of EREs within the HC-20 set. We separately ana­
lyzed the peaks identified only by HC-20 (HC-20 specific) and sites detected by HC-20 
and at least one other antibody (HC-20 shared). Analyses revealed that 50% of the HC- 
20 specific peaks contained an ERE, while an ERE was present in 70% of HC-20 shared 
peaks. Combined the motif analysis indicated that the percentage of false positives in
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Figure 3. A. Peak height correlation. For each 
dataset a relative peakscore was calculated (see 
materials and methods). Peaks were sorted 
based on the relative peak height in the HC- 
20 data set and plotted. The three datasets 
clearly follow the same trend, although there 
are a number of peaks that are higher in ei­
ther the F3A6 or Dia050 sets compared to the 
HC-20 set.
B. Boxplot of HC-20 peaks in MCF-7 and 
MDA-231 cell line. For each peak in the 
MCF-7 HC-20 set the number of tags per 
peak was calculated and plotted in a box plot. 
The number of tags at the same location in the 
MDA-231 data was calculated and plotted. 
As a control the number of tags in a random 
selection of locations in the MDA-231 was 
calculated and plotted. This clearly shows that 
there is only very limited binding of HC-20 
in the ERa negative MDA-231 cell line.
C. Peak height in the HC-20 shared and HC- 
20 specific group. For each peak the number 
of tags were calculated in the HC-20 shared 
and the HC-20 specific group. The tags per 
peak for both sets were plotted in a box plot. 
This shows clearly that the peaks in the HC- 
20 specific groups are comprised of a lower 
number of tags and are weaker, low affinity 
binding sites compared to the HC-20 shared 
group.
5
the HC-20 set was higher compared to the F3A6 and Dia050 sets, and that the major­
ity of these false positives were HC-20 specific. We next assessed whether the HC-20 
antibody cross-reacted with other proteins by performing ChlP-Seq using HC-20 and 
the ERa negative breast cancer cell line MDA-231. We first looked at the locations of 
the H C -20 peaks identified in the ERa positive MCF-7 cell line. The number of tags 
at these locations in the MDA-231 data was calculated. Figure 3B shows a boxplot with
Shared Specitic
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5FOXA1
It has been reported that FOXA1 is involved in ERa mediated regulation and co-occurs 
with ERa binding (Carroll et al, 2005; Fullwood et al, 2009; Lupien et al, 2008). This 
is in contrast with our previous ChIP-Seq data that only showed a minor co-occurrence 
(Welboren et al, 2009). An important difference between our and other studies is that 
we have used the F3A6 antibody, while a number other studies used the HC-20 anti­
body. Here, we find that the antibody is of great influence on the binding site profile and 
we expect that the choice of antibody could also determine the presence and enrichment 
of specific sequence motifs. To assess this we performed sequence analysis by interrogat­
ing the binding site sequences of the three datasets using a combination of de novo motif 
finding algorithms and identified a FOXA1 motif. We subsequently used this motif as 
well as the transfac and Lupien FOXA1 motif to interrogate the three data sets (Lupien 
et al, 2008). Interestingly, we find that the FOXA1 motif occurred more frequently in 
the HC-20 data compared to the F3A6 and Dia050 data (see table 2). Furthermore, the 
percentage of peaks with a FOXA1 motif was higher in the HC-20 specific compared to 
the HC-20 shared (see table 3).
the distribution of the HC-20 peak score in the MCF-7 data, the MDA-231 data and 
a random set of peaks in the MDA-231 data. Clearly, there was only a limited signal 
in the MDA-231 data. Next, we performed peak detection on the MDA-231 data and 
identified 90 peaks, of which 29 overlapped with the HC-20 MCF-7 data. Combined, 
this indicates only a minor part of the HC-20 specific peaks are due to cross-reactivity. 
However, cross-reactivity cannot be completely excluded, other proteins recognized by 
the antibody could be expressed in MCF-7 and not in the MDA-231 cell line. A third 
possibility is that these HC-20 specific sites are weak, low affinity binding sites that 
were below the detection limit of the monoclonal antibodies. Since polyclonal antibod­
ies recognize multiple epitopes, multiple antibody molecules will bind the same target 
protein resulting in a higher signal. We determined the peak scores of the sites that were 
only detected by HC-20 (HC-20 specific) and the peak scores of sites detected by HC- 
20 and at least one other antibody (HC-20 shared) (Figure 3C). Clearly, the sites that 
were only detected by HC-20 had a much lower peak score compared to the sites also 
detected by another antibody and are hence low-affinity binding sites.
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F3A6 HC20 D ia050
% enrichment % enrichment % enrichment
ERE 69.6% 7.734 57.4% 6.497 68 .0% 7.417
Transfac 9.6% 3.041 11.7% 3.584 9.9% 2.960
FOXA1 W elboren 20.4% 3.461 20 .7% 3.544 19.4% 3.322
FOXA1 Lupien 45.9% 2.511 51.7% 2.794 45.8% 2.517
Table 2. Frequency and enrichment of identified motifs
ERE Transfac FOXA1
Wfelboren
FOXA1
Lupien
HC-20 shared 69.8% 12.0% 19.3% 46.4%
HC-20 specific 49.8% 15.4% 21 .5% 54.9%
Table 3. Motif frequency in HC-20 shared and HC-20 specific peaks.
D i s c u s s i o n
The number of published genome-wide ChIP profiles is increasing rapidly. Many con­
clusions about the biological function of a transcription factor or histone modification 
are drawn based on ChIP data generated with a singular antibody. Until now the effect 
that a specific antibody has on the final profile has not been studied. Here, for the first 
time we performed ChIP-Seq using three different antibodies against the same tran­
scription factor (ERa) and compared the resulting binding site profiles. The profiles of 
the three antibodies overlap to a large extend, but HC-20 detects a large number of sites 
not detected by the two other antibodies (F3A6 and Dia050).
There are several possible explanations for this large group of HC-20 specific sites. 
First, at the sites specific for the polyclonal ERa antibody HC-20 the epitopes could be 
masked or occluded by other proteins like e.g. cofactors, thereby preventing the binding 
of monoclonal antibodies F3A6 and Dia050. This is less likely for polyclonal antibodies 
due to the fact that these are comprised of a heterogeneous mixture of antibodies recog­
nizing different epitopes of the target protein. However, both the monoclonal F3A6 and 
Dia050 antibody are raised against different domains of the ERa, a N- and C-terminal 
fragment respectively. Furthermore, the epitopes of the HC-20 and F3A6 are overlap­
ping, as shown in Figure 1. Therefore, it is highly unlikely that both the epitopes for the
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monoclonal antibodies are masked while the HC-20 epitope is still available, so the large 
number of HC-20 specific sites cannot be attributed to epitope masking.
A second explanation could be that a large number of sites detected by HC-20 are false 
positives. Analysis showed that the group of HC-20 specific sites were predominantly 
low affinity sites, and the lower frequency of EREs in this group suggests that there could 
be more false positives present. However, ChlP-Seq using HC-20 in an ERa negative 
cell line showed that the number of false positives was low, indicating cross reactivity of 
the antibody is not a major contributor, but it can not be excluded completely. To com­
pletely rule out cross reactivity, a ERa knockdown in MCF-7 cells could be performed 
followed by ChIP or western blot, or ideally mass spectrometry of precipitated protein, 
but this is beyond the scope of the current study.
The third and most likely explanation of the large number of HC-20 specific peaks is 
that because it is a polyclonal antibody, it is better suited to detect weak ERa binding 
sites. Analysis showed that the HC-20 specific peaks were comprised of a lower number 
of tags compared to peaks also detected by the monoclonal antibodies and were hence 
low affinity sites. Compared to monoclonal antibodies, polyclonal antibodies have a 
higher avidity because multiple antibody molecules bind the same target protein, which 
enables the detection of weak sites that are below the detection limit of monoclonal 
antibodies (Lipman et al, 2005).
Global ChIP profiles are frequently used to discover new and refine existing transcrip­
tion factor binding motifs. The choice of antibody will also have its effect on the pres­
ence and the enrichment of specific sequence motifs. We interrogated the three profiles 
for the presence and enrichment of the ERE and the FOXA1 motif, that has been previ­
ously implied to co-occur with ERa binding. The ERE was enriched in all three sets, 
but showed a lower enrichment in the H C -20 set compared to the F3A6 and Dia050 
set while the reverse was true for the FOXA1 motif. The enrichment of certain sequence 
motifs is thus dependent on the choice of antibody, as antibodies differ in their ability 
to detect different affinity binding sites as we show here.
The question what the true binding sites are still remains however. Sites detected by all 
three antibodies are true, high confidence binding sites. However, determining whether 
a site detected by one of three antibodies is a true binding site is not straightforward. It 
is a choice between identifying as many binding sites as possible and accepting a higher 
false positive rate, or getting a lower number of sites, but with a higher confidence. Ac­
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cepting a high false positive rate will influence the subsequent motif analysis and will 
result in a lower enrichment of specific sequence motifs. If the option to use more than 
one antibody is available the analysis could be done separately for just the high confi­
dence sites and for all the sites. The optimal situation would be to use multiple very well 
characterized antibodies, thereby avoiding antibody specific effects. Antibodies should 
ideally be characterized by mass spectrometry of precipitated peptides and by knock­
down of the transcription factor or in the case of histone modifications enzymes that are 
predicted to apply the modifying group (Park, 2009). Especially with the recent efforts 
undertaken to sequence epigenomes it is paramount to thoroughly assess antibody qual­
ity prior to performing the profiling.
Taken together, our data shows that in case of the ERa, the antibody used is of great 
influence on the final binding site profile and that a significantly higher number of sites 
are detected with the polyclonal HC-20 antibody compared to the monoclonal anti­
bodies. In this case the clonality of the antibody has more impact on the binding site 
profile and enrichments of sequence motifs than the epitope to which it is raised. The 
lower occurrence of the ERE in the HC-20 sites however raises the question what the 
biological relevance of these sites is. The choice of antibody is thus of major influence 
on the identified binding site profile, enriched sequence motifs and hence conclusions 
and insights gained from the study. The antibody is thus both key and Achilles heel of 
ChIP-profiling.
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M e t h o d s
ChIP
MCF-7 cells were hormone starved for 48 h followed by treatment with 10 nM E2 for 1 h. Chro­
matin harvest and ChIP was performed as described elsewhere (Denissov et al, 2007). For each 
of the three anti-ERa antibodies ChIP was performed on the same batch of chromatin. ChIP 
samples were according to Illumina protocols and analyzed on the Illumina Genome Analyzer 
(Welboren et al, 2009). As a control input DNA sample was sequenced.
Peak detection
The number of tags in each of the three data sets was equalized by randomly removing tags from 
the larger data sets, until the number of tags in all sets was the equal. ERa binding sites were 
identified in the data by the MACS peak detection program, using a p-value cut-off of 1e-07 and 
the input track as a control (Zhang et al, 2008).
Correlation
We first normalized the peak scores within each dataset. For each individual peak, the peak score 
was divided by the sum of all peaks score in that set, resulting in a relative peak score.
Motif analysis
A de novo search for motifs was performed using the MDmodule, Weeder and MotifSampler 
motif finding algorithms (Liu et al, 2002; Pavesi et al, 2001; Thijs et al, 2001). Subsequently, for 
each identified motif the enrichment compared to a matched background set was calculated and 
matching motifs were clustered.
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Estrogens regulate many cellular processes in a wide variety of target tissues during 
growth, development and differentiation. Estrogens are mainly involved in the regula­
tion and development of the female reproductive tract but also play a role in the cen­
tral nervous system, cardiovascular systems and in bone metabolism (Katzenellenbogen, 
1996). In addition to their role in physiology, estrogens are also associated with the 
development and progression of breast cancer (Anderson, 2002). In 1896, Beatson dis­
covered that removal of the ovaries resulted in breast cancer remission, connecting for 
the first time hormones with breast cancer, decades prior to the discovery of estrogens 
or estrogen receptors (ERs). Seventy years later, O ’Malley observed changes in hybrid- 
izable RNA upon estrogen stimulation of the chick oviduct, indicating that estrogens 
regulate transcription (O’Malley et al, 1968). Again several years later a specific estrogen 
binding protein was discovered that was present in breast tumors and its expression level 
could predict the response to endocrine disruption. Thereby making the link between 
cancer and estrogens that was described almost a century before (Jensen et al, 1971; 
McGuire, 1973). The subsequent cloning of the ERa gene and the identification of 
specific domains demonstrated that ERa functions as a ligand dependent transcrip­
tion factor (Green et al, 1986; Greene et al, 1986; Kumar et al, 1987). The structure of 
ERa and its non-genomic regulation have been reviewed extensively (Ruff et al, 2000; 
Warner & Gustafsson, 2006). This review will focus on the regulation of ERa-mediated 
transcription and on the advances made in the elucidation of its target gene network. 
Furthermore, the clinical significance and implications of ERa expression and genome- 
wide ChIP profiling is discussed.
Estrogen receptor
The ERa (NR3A1) is a member of the super family of nuclear receptors, which are 
ligand dependent transcription factors. In addition to ERa, the family includes other 
steroid hormone receptors such as the androgen receptor (AR, NR3C4) and the gluco­
corticoid receptor (GR, NR3C1), and other nuclear receptors such as the retinoic acid 
receptor (RAR, NR1B), retinoid X  receptor (RXR, NR2B) and peroxisome proliferator 
activated receptor (PPAR, NR1C). Estrogens are small lipophilic molecules that traverse 
the cell membrane and bind to cytoplasmic ERa associated with chaperone proteins 
such as hsp90. Upon binding a cascade of events occurs; the receptor dissociates from
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the chaperone proteins, dimerizes and associates with chromatin. ERa can either bind 
directly to DNA (classical pathway) or indirectly via protein-protein interactions (non- 
classical pathway). In the classical pathway, ERa homodimers bind to a specific DNA 
sequence motif, the estrogen response element (ERE). The ERE is a 15 bp palindrome 
consisting of two PuGGTCA half sites separated by a 3 bp spacer. ERa is also able to 
bind to imperfect EREs. Recent genome-wide studies show that the ERE is the most 
predominant motif in ERa binding sites (Carroll et al, 2006; Lin et al, 2007; Welboren 
et al, 2009). In the non-classical pathway the ERa binds indirectly to the DNA via 
tethering to other transcription factors such as Sp1 (specificity protein 1), AP-1 (acti- 6  
vating protein 1) or NF-kB (nuclear factor kappa b), and regulates transcription in an 
ERE independent manner. The Sp1 family of transcription factors plays an important 
role in proliferation, differentiation, survival and angiogenesis (Kaczynski et al, 2003;
Safe & Abdelrahim, 2005). Sp1 can bind to GC rich regions, which are present in many 
estradiol (E2) responsive promoters. For example, mutational analysis revealed that the 
GC rich region in the promoter of the TGFa (transforming growth factor alpha) gene 
is required for E2-mediated gene activation (Vyhlidal et al, 2000). Several other genes 
have been identified that are activated by the ER/Sp1 pathway including e.g. the c- 
Myc and progesterone receptor genes (Miller et al, 1996; Petz & Nardulli, 2000). The 
transcription factor AP-1 is a complex containing fos, jun and other family members.
Several E2-regulated genes are dependent on AP-1, such as IGF-I (insulin-like growth 
factor I), ovalbumin, progesterone receptor and pS2/TFF1 (Barkhem et al, 2002; Gaub 
et al, 1990; Savouret et al, 1994; Umayahara et al, 1994). The AP-1 complex binds to 
promoters of genes involved in growth, differentiation and development. Many ER/ 
AP-1-responsive genes have been identified using microarray studies, indicating that 
E2-mediated regulation via the non-classical pathway occurs frequently (DeNardo et 
al, 2005; Glidewell-Kenney et al, 2005). The NF-kB family of transcription factors are 
involved in the immune and the skeletal systems and in inflammatory response (Kalaitz- 
idis & Gilmore, 2005). NF-kB binds to kB elements and regulates expression of target 
genes. ERa has been shown to inhibit NF-kB in an E2-dependent manner. The ERa 
can directly inhibit the binding of NF-kB transcription factors to the DNA, but the 
mechanism is poorly understood.
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T a r g e t  g e n e  n e t w o r k
Single gene analysis
To fully elucidate ERa function, the identification of its target gene network is essen­
tial. Many strategies have been employed to gain insights in the target gene network 
governed by the ERa. Classically target genes have been identified using “single gene” 
experiments. The egg-white proteins in the chicken oviduct and the Xenopus laevis 
6  vitellogenin gene are among the first ERa target genes to be identified (Chambon et 
al, 1984; Hayward et al, 1982; Jost et al, 1984; Lai et al, 1983). Later, by comparing 
cDNA libraries of non-treated and E2-treated MCF-7 human breast cancer cells several 
other ERa-responsive genes were identified such as the classical and intensively studied 
ERa target gene pS2/TFF1 (Brown et al, 1984; Jakowlew et al, 1984). ERa-regulated 
genes identified using differential cloning are e.g. the cell cycle regulators c-Myc and 
cyclin D1, connecting proliferation with E2 signaling (Altucci et al, 1996; Dubik et al, 
1987).
Estrogen response elements
The first estrogen response element was identified in 1986 in the promoter of the Xeno­
pus vitellogenin gene. Transfection experiments showed that this element also functions 
in human cells, and that the core ERE could be defined as a 13 bp palindrome (GGT- 
CANNNTGACC) (Klein-Hitpass et al, 1986). The availability of the entire human 
genome sequence allowed the computational search for EREs and ERa target genes. 
This approach led to the interesting observation that approximately 70,000 EREs are 
present in the human genome, i.e. one in every 43 kb of DNA (Bourdeau et al, 2004). 
By comparing these with the merely 9,944 EREs identified in the mouse genome, a total 
of 660 evolutionary conserved elements were found. The large number of EREs pres­
ent in the genome and the limited conservation between human and mouse indicates 
that a large fraction of the EREs may not be “true” ERa binding sites. These in silico 
studies suggested that actual binding by ERa is dependent on more factors than just 
the DNA sequence. The hypothesis was put forward that the chromatin structure and 
hence accessibility of the binding sites plays a major role. Furthermore, the notion that 
sequence is not the only or decisive determinant in ERa binding is underscored by the
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observation that ERa can bind indirectly via tethering to other transcription factors and 
subsequently regulate target genes in an ERE independent manner.
Expression profiling
Microarrays, either cDNA or oligonucleotide, and SAGE (serial analysis of gene expres­
sion) are powerful tools that can be used to assess global changes in gene expression. 
Many gene expression profiling studies have been performed identifying E2-responsive 
genes, the number ranges from 100 to 500 (Carroll et al, 2006; Charpentier et al, 2000; 
Coser et al, 2003; Frasor et al, 2003; Kininis et al, 2007; Kwon et al, 2007; Lin et al, 
2004; Lin et al, 2007; Rae et al, 2005; Stender et al, 2007). The large quantitative and 
qualitative differences between the various profiling studies are most likely due to the 
use of different cell lines, treatment times, platforms and analysis methods. Collectively, 
expression profiles show that E2 activates as well as represses a large variety of targets 
including genes involved in cell cycle regulation and proliferation (e.g cyclin D1 and 
cyclin G2), apoptosis (bcl-2 and survivin) and transcriptional regulation (c-fos and c- 
jun). Upregulated genes include amongst others activators of proliferation and down- 
regulated genes include negative proliferation regulators.
Frasor and coworkers observed that at early time points following E2 induction a greater 
proportion of genes are upregulated, while at later time points more genes are down- 
regulated (Frasor et al, 2003). This was also observed by Carroll and colleagues, who 
postulated that early ERa-mediated downregulation may be due to squelching while 
the increase in the number of downregulated genes at later time points may depend on 
the upregulation of the corepressor NRIP which mediates the repression of ERa target 
genes (Carroll et al, 2006).
The number of E2-responsive genes identified by these transcriptome studies differs 
significantly even though the majority was performed using the MCF-7 cell line. The 
platform and specific conditions used certainly will have contributed to these differ­
ences, but other factors may also play a role. First of all, the experimental or technical 
differences between the profiling studies such as platforms, ligand concentration, treat­
ment time and statistical thresholds used. Secondly, the biological differences, i.e. the 
handling of the cells and the differences between MCF-7 sublines. MCF-7 cells have 
been in culture for many decades and as a result the cell lines used in different laborato­
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ries may not be the same anymore. Differences in karyotype, hormone receptor content 
and growth rate have been observed although morphologically the cells look(ed) identi­
cal (Bahia et al, 2002; Burdall et al, 2003; Osborne et al, 1987).
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It is important to note that a disadvantage of expression profiling is that indirect effects 
that affect the mRNA level are also measured which could be a major source of the 
observed differences. Lin and coworkers used the translation inhibitor cycloheximide 
combined with the ERa antagonist ICI 182,780 to show that only a relatively small 
number (23%) of E2-responsive genes are actually direct targets. More recently changes 
in RNA polymerase II (RNAPII) occupancy over the gene body has been used as a di­
rect measure of gene activity (Nielsen et al, 2008; Welboren et al, 2009). We have used 
this method to identify 596 genes directly responding to 1 h of E2 treatment (Nielsen 
et al, 2008; Welboren et al, 2009). Profiling RNAPII occupancy has the advantage that 
direct effects on target genes are observed, whereas transcriptome profiling is the sum of 
changes in transcriptional activity and regulation at mRNA level as observed by mRNA 
profiling. Both methods are complementary.
Chromatin immunoprecipitation analysis
Chromatin immunoprecipitation (ChIP) assesses the binding of chromatin interacting 
proteins such as a transcription factors, cofactors or histone modifications at a specific 
genomic position in living cells. Proteins and DNA are crosslinked with formaldehyde 
and the chromatin is fragmented by sonication. The protein of interest is precipitated 
using a specific antibody and the DNA to which it is bound is co-precipitated. In both 
the input and the precipitated fraction the relative concentration of specific DNA frag­
ments is determined by qPCR and from this the occupancy of the protein of interest 
at any specific locus can be calculated. ChIP thus allows the identification of transcrip­
tion- and cofactor recruitment to a specific locus upon ligand induction, as well as the 
order of recruitment. Furthermore, specific histone modifications present at a locus 
can be measured by ChIP, providing information on the local chromatin structure and 
epigenetic state. Shang and colleagues conducted early ERa ChIP experiments assessing 
ERa and cofactor occupancy at the cathepsin D  (CATD), c-Myc and pS2/TFF1 gene 
over time (Shang et al, 2000). They observed a step wise recruitment of cofactors and 
found that the ERa transcriptional complex repeatedly cycled onto and off promoters. 
Metivier and coworkers used ChIP to extensively analyze the occupancy of a large panel
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of transcription factors and histone modifications at the pS2/TFF1 promoter over time 
at 5 minute intervals (Métivier et al, 2003). A cyclic recruitment of cofactors, histone 
modifications, histone acetyl transferases, histone methyl transferases and chromatin re­
modelers was observed. The authors concluded that ERa-mediated transcription occurs 
in ‘waves’ that allow the cell to respond to environmental and others cues by continu­
ously adjusting the rate of transcription of a gene.
ChIP-chip
Single ChIP, using sequence-specific primer sets combined with qPCR, is obviously not 
suited to gain genome-wide insight in transcription factor binding or histone modifica­
tions. By combining ChIP with microarray platforms (ChIP-chip), binding sites can be 
identified at a much broader scale. In ChIP-chip, the precipitated DNA is amplified, 
fluorescently labeled and directly hybridized to a microarray or mixed with differential 
labeled input DNA. Initially promoter arrays were used that contain the upstream re­
gions of known genes including CpG islands that are often overlapping with promoter 
regions. These custom arrays have been used successfully by several laboratories resulting 
in the identification of many ERa binding sites and in some cases histone modifications 
or cofactor occupancy (Cheng et al, 2006; Jin et al, 2004; Kininis et al, 2007; Kwon et 
al, 2007; Laganiere et al, 2005). Microarrays comprising the entire non-repetitive hu­
man genome enabled a true genome-wide identification of ERa binding sites. The first 
study has been performed on Affymetrix arrays covering chromosome 21 and 22, and 
resulting in the identification of 57 ERa binding sites (Carroll et al, 2005). The major­
ity of these sites turned out to be located in introns or distal to genes and only a small 
percentage were located in promoter regions. The authors showed that the distal ERa 
binding sites functioned as enhancers as demonstrated for the pS2/TFF1 gene and that 
the enhancer interacted with the promoter via looping. Sequence analysis of the ERa 
binding sites also revealed an enrichment of the FOXA1 motif and it was postulated that 
FOXA1 might act as pioneering factor that facilitates ERa binding. More recently, the 
same investigators published a genome-wide ERa and RNA polymerase II (RNAPII) 
ChIP-chip analysis using Affymetrix arrays identifying 3665 ERa and 3629 RNAPII 
binding sites (Carroll et al, 2006). Re-analysis of the ERa ChIP-chip data revealed that 
the number of ERa sites was as high as 5782 (Lupien et al, 2008). As observed for 
chromosome 21 and 22, the number of ERa sites that is located in promoter regions is
6
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as low as 4%. Sequence analysis of all binding sites revealed several enriched motifs and 
showed that the co-occurrence of the ERE and the AP-1 motif is negatively correlated, 
suggesting the AP-1 and ERE motif occur mutually exclusively while the Oct, FOXA1 
and C/EBP motif are positively correlated. In addition, a role for the nuclear receptor 
corepressor NRIP1 in ERa-mediated repression was reported.
In a later study the ERa ChIP-chip experiment was repeated and 8,525 sites were iden­
tified, of which 86% overlapped with the previously published dataset (Hurtado et al, 
2008). A newly identified site was present in the ERBB2 gene. Tamoxifen resistant 
tumors have increased ERBB2 expression levels and cell lines overexpressing ERBB2 
acquire resistance to tamoxifen. Binding site sequence analysis showed an enrichment 
of the PAX transcriptionfactor binding motif. PAX2 is expressed in a subset of breast 
tumors and is regulated by tamoxifen in endometrial cancer cells. ChIP-qPCR showed 
that PAX2 was recruited to ERa binding sites upon tamoxifen but not upon E2 treat­
ment. However, PAX2 recruitment to the ERBB2 gene was observed in the presence 
of tamoxifen as well as E2. Furthermore, the authors show that PAX2 competes with 
the co-activator AIB-1 for binding at the ERBB2 gene. Increasing levels of AIB-1 block 
PAX2 binding and result in upregulation of ERBB2 and subsequent cell proliferation, 
reversing the antiproliferative effects of tamoxifen. Interestingly, in tamoxifen resistant 
cells PAX2 levels are decreased, resulting in increased expression of ERBB2. Reintroduc­
tion of PAX2 restored the ability of tamoxifen to inhibit cell growth indicating PAX2 is 
an important factor in mediating SERM action.
A more recent ChIP-chip paper investigated the tissue specific behavior of estrogens. 
Krum and colleagues compared the expression and ERa binding site profile in the breast 
cancer cell line MCF-7 with that of exogenous ERa in the U2OS osteocarcoma cell line 
to determine how estrogens exert this tissue specificity (Krum et al, 2008). Strikingly, 
fewer than 10% of the genes responding to E2 in MCF-7 are responsive in U2OS cells. 
Furthermore, ChIP-chip analysis on chr1 and chr6 showed that fewer than 15% of the 
ERa binding sites were common between both cell types. To unravel the cell type spe­
cific binding of ERa, the presence of specific chromatin modifications at putative en­
hancers was determined. The authors showed that before E2 treatment some enhancers 
contained the active mark H3K4me2 while others contained the heterochromatic mark 
K3K9me2, and that these marks correlated with the binding of ERa. Interestingly, 
FoxA1 does not seem to play a role in the U2OS cells.
ChIP-chip has also been used to assess the effect of post-translational modifications of
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ERa on genome-wide binding and target gene profile (Bhat-Nakshatri et al, 2008). 
The authors focused on the serine/threonine kinase AKT and compared ERa binding 
in parental MCF-7 cells with AKT overexpressing MCF-7 cells. More than half of the 
ERa binding sites are present in both data sets and gene expression profiling showed 
that AKT increased the number of E2 responsive genes from 833 to 1063. Analysis 
of the target genes revealed that AKT induces changes in the TGF-8 , NF-kB/TNF, 
retinoic acid and E2F pathways. Besides directly influencing ERa binding, AKT also 
induces secondary effects due to changes in the expression of E2F2 and E2F6, which 
subsequently change the expression of estrogen-induced or estrogen-repressed second­
ary target genes either in the presence (E2F6) or absence of E2 (E2F2). In conclusion, 
the authors postulate that AKT alters ERa and / or coactivator binding resulting in 
changes in binding occupancy and target gene expression.
Liu and colleagues compared the binding of ERa and ERp using ChIP-chip and an in­
ducible ERp system. Although there was a high degree of overlap between both profiles, 
a group of sites showed selective binding by either ERa or ER^ (Liu et al, 2008). Inter­
estingly, ERp binding sites were located closer to the transcription start site compared to 
ERa. In addition ERp binding site sequences included CG-rich motifs, while ERa sites 
were enriched for TA-rich motifs. Together these differences could explain the different 
expression profile of ERa and ERp (Liu et al, 2008).
ChIP deep sequencing
With next generation high throughput sequencing platforms millions of fragments 
can be sequenced simultaneously. DNA fragments can be identified at significantly de­
creased costs and with much higher sensitivity, resolution and accuracy as compared 
to microarrays. Lin and coworkers used a chromatin immunoprecipitation-paired end 
diTag cloning and sequencing strategy (ChIP-PET) to map ERa binding sites. 635,371 
tags have been sequenced (454 platform), of which 361,241 (57%) could be unam­
biguously mapped to the human genome. In total 1,234 high-confidence ERa binding 
sites were identified. O f these, 71% contained an ERE-like sequence and many other 
transcription factor motifs were enriched, including Sp1, AP-1 and FOXA1. Illumina 
high throughput sequencing has also been successfully combined with ChIP for the 
identification of precipitated fragments. Recently, we identified 10,205 ERa binding 
sites in MCF-7 cells using ChIP-Seq and assessed the effect of tamoxifen and fulvestrant
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on ERa binding. Fulvestrant is a full E2 antagonist that increases ERa protein turnover 
and results in degradation of ERa, although at the 1 h time point no degradation was 
observed. We showed that both tamoxifen as well as fulvestrant affect but do not abolish 
ERa binding (Welboren et al, 2009). Also, the effect of different ligands on the RNAPII 
occupancy over target genes was investigated using ChIP-Seq. Upon E2 treatment 596 
genes show changes in RNAPII occupancy. Tamoxifen and fulvestrant treatment abol­
ished RNAPII occupancy over E2-upregulated target genes. On E2-repressed genes ta­
moxifen acts as an agonist, downregulating these genes while fulvestrant antagonizes the 
6  E2-induced repression and often increases the RNAPII occupancy. Thus, both antago­
nists act differentially on E2-induced and E2-repressed genes.
C O M P A R IS O N  OF CHIP-PROFILES
Different ERa ChIP profiling studies i.e. ChIP-chip, ChIP-PET and ChIP-Seq have 
identified a multitude of ERa interaction sites. The number of sites detected in each 
study however is significantly different and the profiles show a limited overlap, even 
though all studies used the MCF-7 breast cancer cell line and performed a similar E2 
treatment.
Clearly, ChIP profiling is a relatively new development and it is likely that as the ap­
proach matures the variation between experiments and laboratories will disappear over 
time. In this light, the transition from microarray to sequencing based detection of 
ChIP DNA fragments seems to be an important step in that direction.
Comparing the existing ChIP-chip and ChIP-Seq ERa sets shows that around half of 
the binding sites overlap and that both sets contain a considerable number of specific 
sites. Both sequence-based profiles (ChIP-Seq and ChIP-PET) show a larger overlap, al­
though one has to keep in mind that the ChIP-PET set is much smaller (Figure 1). One 
obvious factor that will certainly have contributed but is unlikely to be the main course 
is the biological variation in the MCF-7 (sub)lines used and / or handling of the cells.
One of the main differences between these profiles however is that different antibodies 
against the ERa were used, which is likely to affect the ChIP and thus the ERa binding 
profiles. Different antibodies, or even antibody batches, will have different specificities 
and avidities for the target protein. Antibodies raised against different peptides will 
recognize different epitopes. As a consequence, epitope masking due to conformational
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shielding or binding and crosslinking of an interactor may block or hinder the binding 
of some but not other antibodies. For polyclonal antibodies, epitope masking is less 
likely to affect the outcome as multiple epitopes can be recognized. On the downside, 
polyclonal antibodies may display more cross-reactivity.
Another factor contributing to the differences in ERa binding profile is the platform 
used to identify the precipitated DNA fragments. Microarray based detection has been 
widely used and provided the first genome-wide views of transcription factor binding and 
histone modifications. Microarray approaches do however have intrinsic disadvantages 
related to the sequence composition of probes, differences in melting temperature, an­
nealing efficiency and cross-hybridization which are discussed in detail elsewhere (Buck 
& Lieb, 2004; Bulyk, 2006; Graf et al, 2007; Hanlon & Lieb, 2004; Wu et al, 2006). 
ChIP-Seq, in which co-precipitated fragments are identified by high throughput se­
quencing, has important advantages over microarrays. Firstly, ChIP-Seq is unbiased and 
enables a higher resolution and accuracy. Furthermore, the fabulous sequencing depth 
allows the identification of binding sites that are moderately enriched that likely would 
not have escaped detection using an array approach. Because sequencing based methods 
are not dependent on hybridization the ‘background’ is significantly lower compared to 
microarrays. An additional important advantage of ChIP-Seq is that information on re­
petitive sequences can be obtained which is 
not possible on microarrays, because these 
contain only non-repetitive regions (Marks 
et al, 2009).
Notwithstanding the differences, the com­
bined ERa binding site profiles identify a 
large number of stable, high affinity ERa 
interaction sites and a set of more transient 
ERa interaction sites. High affinity sites are 
more likely to be detected by all techniques,
while lower affinity sites may only be de­
Figure 1. Comparison of the ChIP-Seq 1 1 1
(10,205), ChIP-chip (8,525) and ChIP-PET tected when using the more sensitive and
(1,234) ERa bmdmg site profile. The CMP- accurate sequencing based approaches i.e. 
Seq data is compared with the new ChIP-chip 
data from Carroll and coworkers (Hurtado et 
al, 2008) and the ChIP profile from Lin and
Collectively, ChIP profiling studies have re­
colleagues. The overlap between all profiles is
limited. vealed that the number of ERa interaction
6
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sites is much larger than the number of E2-responsive genes hitherto identified by gene 
expression profiling. The biological implications of the discrepancy remain one of the 
questions to be answered. One assumption is that a large number of ERa binding sites 
may not be functional, i.e. ERa binding has no consequence on the transcription of 
closely positioned genes in the particular cell investigated. It is likely that at these sites 
conditions for transcriptional regulation are not favorable i.e. a cofactors or transcrip­
tion factors are not co-recruited or a specific post-translational modification of the chro­
matin is absent and hence the level of transcription from the gene is not affected. An 
alternative hypothesis is that multiple ERa sites cooperate and interact via looping to 
regulate expression of one or more target genes. More research is necessary to elucidate 
this aspect of ERa-mediated regulation. A recently developed technique, ChIA-PET 
(Chromatin Interaction Analysis using Paired-End Tag sequencing), may shed light on 
this issue (Fullwood & Ruan, 2009).
C O F A C T O R  CHOICE
ERa mediated gene regulation is controlled by the interplay of ligand, receptor, DNA 
(ERE) and cofactors. Cofactors interact with the receptor in a ligand dependent man­
ner and are often part of large multi protein complexes that regulate transcription by 
recruiting components of the basal transcription machinery, regulating chromatin struc­
ture and/or modifying histones (reviewed by Klinge 2000)(Klinge, 2000). Coactivators 
are required for transcriptional activation, while corepressors decrease the transcriptional 
activity. The presence and levels of cofactors will, to a large part, determine the transcrip­
tional outcome and are vital in ERa mediated regulation. Protein—protein interaction 
studies have revealed a multitude of nuclear receptor cofactors.
The best characterized are the p160 family of steroid receptor cofactors; SRC-1 (steroid 
receptor coactivator 1), SRC-2 (TIF2/GRIP1) and SRC-3 (AIB1/RAC3/ACTR). An 
increase in the level of SRC-3/AIB1 has been observed in breast and prostate tumors 
(Anzick et al, 1997; Gnanapragasam et al, 2001). A limited number of SRC binding 
sites have been identified using a ChIP-cloning approach (Labhart et al, 2005) while 
more recently ChIP-chip has been used (Kininis et al, 2007). Both studies show that 
the binding of SRC cofactors correlated very well with ERa binding. The p160 family 
and many other nuclear receptor cofactors contain an LXXLL (NR-box) motif, which 
facilitates the interaction of the cofactor with the AF-2 domain of the ERa. One func­
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tion of these cofactors is to recruit other proteins such as CBP/p300 and pCAF that 
have histone acetyl transferase (HAT) activity. The CBP (CREB binding protein) is a 
not only a coactivator of ERa but also of other nuclear receptors and many other tran­
scription factors such as p53 and NF-kB (Avantaggiati et al, 1997; Chakravarti et al, 
1996; Fr0nsdal et al, 1998; Kamei et al, 1996; Perkins et al, 1997). p300 shares many 
functional properties with CBP, nevertheless, CBP and p300 are not completely redun­
dant as shown by targeted deletion studies (Yao et al, 1998). Another group of factors 
recruited by the p160 family are the PRMT (protein arginine methyl transferase) fam­
ily of proteins that are able to methylate histone H3 and H4. The first PRMT family 
member to be discovered, CARM1 (coactivator associated arginine methyltransferase 
1, or PRMT4) (Chen et al, 1999), enhances ERa-mediated transcriptional activity by 
interacting with GRIP1, a p160 family cofactor and p300 (Chen et al, 2000). CARM1 
methylates several arginines in histone 3 i.e. H 3R2 , H3R17 and H3R26 upon nuclear 
receptor mediated activation (Ma et al, 2001; Schurter et al, 2001). Another family 
member, PRMT1, methylates H4R3, which in turn facilitates the acetylation of H4 by 
p300 (Wang et al, 2001). PRMT1 is an essential cofactor for ERa-mediated pS2/TFF1 
regulation (Wagner et al, 2006). Yeast two-hybrid studies have shown that PRMT2 
can also interact with the ERa and that it enhances ERa transcriptional activity upon 
ligand binding (Qi et al, 2002). Other cofactors that possess chromatin remodeling 
activity are for example BRM (Brahma) and BRG-1 (Brahma related gene -1). They are 
subunits of an ATP dependent chromatin remodeling complex and are recruited to E2 
responsive promoters upon induction (Belandia et al, 2002; DiRenzo et al, 2000). These 
remodelers alter the local chromatin structure to a more open conformation, permitting 
transcription as is elegantly shown for GR (John et al, 2008).
Nuclear receptors that bind DNA in the absence of ligand, antagonist loaded receptors 
or receptors causing gene repression interact with corepressors proteins such as NCoR 
(nuclear receptor corepressor) and SMRT (silencing mediator of retinoid and thyroid 
hormone receptors). Corepressors interact with helix 3 and 5 of the ERa via so called 
CoRNR boxes (LXXI/HIXXXI/L) (Hu & Lazar, 1999). NCoR and SMRT in turn re­
cruit large repressor complexes including histone deacetylases that repress gene activity 
by maintaining or reinforcing a repressive chromatin state. Antagonist loaded ERa does 
bind regulatory regions (Welboren et al, 2009) and recruits corepressor complexes, as 
shown for the pS2/TFF1 and c-Myc genes where NCoR, HDAC3 and the nucleosome 
remodeling complex NURD are recruited, leading to a repressive chromatin state (Liu 
& Bagchi, 2004). Low levels of NCoR expression have shown to have predictive value
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6in tamoxifen resistance and NCoR levels decrease during progression of breast cancer 
(Girault et al, 2003; Kurebayashi et al, 2000). Another factor involved in ERa medi­
ated regulation is the histone demethylase LSD1. Using ChIP-DSL Garcia-Bassets and 
coworkers showed that LSD1 is recruited to a subset of E2-responsive genes upon treat­
ment and subsequently demethylates H3K9, hence counteracting the repressive effect of 
methylation (Garcia-Bassets et al, 2007).
To gain insight into cofactor choice on ERa-mediated regulation genome-wide cofac­
tor profiling will be essential. Hitherto, data obtained at a single gene level has been 
reported and has been extrapolated to hold true for all or a large number of similarly 
regulated genes. Genome-wide profiling of nuclear receptor cofactors will show whether 
or not the model of regulation that was determined on single or at best a handful of 
genes does apply genome-wide.
E p i g e n e t i c  m a r k s
Genome-wide epigenetic profiling studies have revealed that the chromatin structure 
and epigenetic marking of a promoter, enhancer and coding body of a gene correlates 
with the transcriptional state. Epigenetic marks consist of covalent post-translational 
modifications of N-terminal histone tails (Barski et al, 2007; Bernstein et al, 2005; 
Pokholok et al, 2005; Roh et al, 2004; Schubeler et al, 2004). Epigenetic marks such 
as acetylation, phosphorylation, methylation and ubiquitination are deposited and re­
moved by coregulatory complexes in a serial and combinatorial manner. Modification of 
histone tails results in dynamic changes in the chromatin structure and restrict or permit 
binding of transcription factors (Jenuwein & Allis, 2001; Rosenfeld et al, 2006). Sev­
eral studies have been performed investigating the role of epigenetics in ERa-mediated 
regulation. Bauer and coworkers showed that the arginine methyltransferase CARM1 is 
recruited to the pS2/TFF1 promoter upon E2 induction, and that this event correlates 
with the methylation of arginine 17 of histone H3 and transcriptional activation (Bauer 
et al, 2002). Kwon and colleagues profiled ERa binding, histone methylation and acety- 
lation (Kwon et al, 2007). Histone H3K9 acetylation, which is associated with an open 
chromatin structure and increased transcriptional output, was observed at the promot­
ers and enhancers of the active pS2/TFF1 and GREB1 gene. In addition, the promoter 
regions contained H3K4 tri-methylation, a mark that is widely associated with active 
promoter regions. H3K4 mono-methylation was associated with active genes, while
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H3K4 di-methylation was observed primarily on the promoters of active genes and to 
a lesser extent on enhancers. Both H3K27 di- and tri-methylation showed distinct pat­
terns over the GREB1 and pS2/TFF1 gene (Kwon et al, 2007). Kininis and coworkers 
assessed histone H3 and H4 acetylation using a custom promoter array and revealed a 
correlation between histone acetylation and RNAPII occupancy, reinforcing the notion 
that histone acetylation correlates with gene activity (Kininis et al, 2007). Métivier and 
colleagues performed a detailed time course analysis of the pS2/TFF1 promoter and 
showed that H3 and H4 acetylation and di-methylation are deposited and removed in a 
cyclical fashion (Métivier et al, 2003). The recruitment of cofactors, ERa and RNAPII 6  
also occurred in a cyclical manner, producing transcriptional “waves”. Interestingly, two 
recent publications showed that besides histone modifications DNA methylation also 
takes place in a cyclical fashion at the pS2/TFF1 promoter (Kangaspeska et al, 2008;
Métivier et al, 2008). The authors observed DNA methylation at the end of each pro­
ductive transcription cycle. DNA methylation correlated with the occurrence of the 
methylated CpG binding proteins MeCP2, DNMT3a/b, DNMT1 and the chromatin 
remodeler SWI/SNF. Furthermore, the authors suggest that DNMT3a/b are involved 
in both methylation and demethylation of the promoter. These data suggest that both 
histone modifications and DNA methylation may be intricate parts of the “normal” 
transcriptional cycle.
Histone methylation has been reported to prevent gene activation by unliganded recep­
tors (Garcia-Bassets et al, 2007). Using ChIP-DSL and a promoter array the authors 
show that the histone demethylase LSD1 is recruited to a subset of ERa target genes 
upon E2 treatment. In the absence of ligand these genes show H3K9 methylation. The 
H3K9 methylation prevents the effective binding of unliganded ERa. The binding of 
liganded ERa permits LSD1 recruitment and the removal of the inhibitory marks al­
lowing transcription to occur. Most current models on ERa-mediated regulation, how­
ever, are based on analysis of single genes and the question arises as to whether these 
reported deposition of marks and the inferred mechanisms are the rule or the exception 
in regulation by ERa.
Yet another intriguing layer of complexity to ERa target gene regulation has been re­
ported recently. The occurrence of controlled and local DNA damage and repair has 
been shown to play a role in the ERa-mediated regulation of bcl-2 (Perillo et al, 2008).
E2 treatment results in the demethylation of H3K9 by LSD1, methylation of H3K4 
and the formation of a loop between the enhancer and promoter of bcl-2. Demethyla-
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tion of lysine H3K9, in this case by LSD1, is an oxidative process that produces H 2O 2 . 
H2O2 causes local DNA damage by formation of 8-oxo-guanine. The 8-oxo-guanine is 
removed via base excision repair by OGG1 (8-oxo-guanin DNA glycosylase 1). In addi­
tion, topoisomerase II^, which is capable of repairing single stranded breaks in double 
stranded DNA, is also recruited. These data show that local DNA damage and repair 
induced by E2-dependent demethylation of H3K9 may also play an important role in 
ERa signaling. Double strand DNA breaks, induced by topoisomerase IIp, have been 
reported previously in the regulation of transcription of the pS2/TFF1 gene previously 
(Ju et al, 2006). The question is whether transient DNA breaks and the DNA repair 
machinery plays a general role in transcriptional regulation. The plethora of post-trans­
lational modifications, the vast number of histone modifying enzymes and the serial 
and combinatorial fashion in which these modifications are applied, points to a very 
complex process to ensure tight and timely regulation.
L o o p i n g
Genome-wide ERa ChIP profiling studies hitherto revealed that only a minor frac­
tion of ERa binding sites are located in promoter regions and that the vast majority 
is located at great distances (> 20 kb) from genes. (Carroll et al, 2006; Lin et al, 2007; 
Welboren et al, 2009). Because of these large distances to genes, assignment of binding 
sites to target genes is often rather arbitrary. Moreover, the number of identified ERa 
binding sites is much larger than the number of E2-regulated genes identified by expres­
sion or RNAPII profiling, indicating that many binding sites are idle or that multiple 
ERa binding sites cooperate to regulate transcription. Using 3C it has been shown that 
at the classical ERa target genes pS2/TFF1, GREB1 and bcl-2, multiple ERa bind­
ing sites interact via looping to regulate transcription (Carroll et al, 2005; Deschenes 
et al, 2007; Perillo et al, 2008). Pan and colleagues further investigated the interaction 
between the TFF1 promoter region and the upstream enhancer (Pan et al, 2008). They 
show that both the enhancer and the promoter region are occupied by the same suite of 
transcription factors consisting of ERa, cofactors and RNAPII. Furthermore, the pro­
moter and upstream enhancer interact via looping in an E2 dependent manner and the 
transcriptional output of the interaction is dependent on the ERE sequence.
Long-range chromosomal interactions are likely a general mechanism in transcriptional 
communication and regulation by ERa and many other transcription factors. Recently,
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a combination of 3C with ChIP-DSL, the 3D assay (deconvolution by of DNA interac­
tions by DSL), was used to identify regions that interact with the enhancer of the TFF1 
gene on a genome-wide scale (Hu et al, 2008). Strikingly, the GREB1 promoter and en­
hancer on chr2 interacted with the TFF1 enhancer on chr21. Subsequent FISH analysis 
showed that indeed both loci interacted upon E2 induction. The knock down of CBP/ 
p300 or SRC1 abolished the GREB1:TFF1 interaction. Furthermore, inhibition or 
knockdown of nuclear myosin-I abolished the interaction, as did the knockdown of dy­
nein light chain-1 and the chromatin remodeler BAF53. The histone demethylase LSD1 
has previously been shown to be essential for E2 mediated regulation. Interestingly, 6  
LSD1 knockdown had little effect on interchromosomal interaction of GREB1:TFF1.
Further FISH analysis showed that the sites of the interchromosomal interactions are 
spatially related to nuclear speckles, regions that are enriched for key transcriptional 
elongation factors, chromatin remodelers and splicing factors. LSD1 knockdown pre­
vented the interaction of the GREB1:TFF1 loci with these nuclear speckles. Liganded 
ERa thus initiates interchromosomal interactions that are important for enhancement 
of ligand dependent transcription (Hu et al, 2008).
High throughput alternatives of the 3C method have been developed to study interac­
tions on a genome-wide scale. 4C (circular chromosome conformation capture) identi­
fied more than hundred regions that interacted with the H19 imprinting control region 
(Zhao et al, 2006). An alternative high throughput technique named 5C (carbon copy 
chromosome conformation capture) has been used to identify looping in the P-globin 
locus (Dostie et al, 2006). More recently a new approach has been announced, ChIA- 
PET (Chromatin Interaction Analysis using Paired-End Tag sequencing) (Fullwood &
Ruan, 2009). Using this technique all chromatin interactions can be detected in one 
experiment. In ChIA-PET chromatin is crosslinked and sheared in small fragments. A 
linker sequence is introduced in the junction of two DNA fragments that are in close 
proximity due to chromatin interaction. The linker-connected ligation products are sub­
sequently extracted and sequenced. Mapping the two paired fragments onto the genome 
reveals the interacting regions.
Applying these technologies to ERa will enable the detection of “all” chromatin in­
teractions taking place upon ligand or antagonist binding and may shed light on the 
difference in the number of ERa binding sites and number of genes changing upon E2 
treatment.
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F o x a !
Recently, the forkhead box protein FOXA1 was identified as a factor intimately associ­
ated with ERa-mediated transcriptional regulation. The FOXA1 motif was found to be 
highly enriched in ERa binding sites (Carroll et al, 2005; Carroll et al, 2006; Laganiere 
et al, 2005). ChIP-chip of FOXA1 showed that 50-60% of the FOXA1 binding sites 
overlap with ERa binding sites. The authors postulated that FOXA1 acts as a pioneer­
ing factor that binds H3K4me1/2-rich and H3K9me2-poor regions and facilitates ERa 
binding (Lupien et al, 2008). ERa ChIP-Seq data from our laboratory, however, shows 
that only a small number of ERa binding sites (7%) contain the FOXA1 motif (Wel- 
boren et al, 2009). In addition, in the ChIP-DSL study by Kwon and coworkers no sig­
nificant association of ERa binding sites and the FOXA1 motif was observed. However, 
only promoter regions were assessed by ChIP-DSL, which could contribute to the lack 
of FOXA1 enrichment because only a relatively small fraction of ERa binding sites are 
located in promoter regions (Kwon et al, 2007). Taken together the question remains to 
what extend FOXA1 plays a role in ERa-mediated regulation.
E R a  ANTAGONISTS
The growth of many breast tumors is E2 dependent, and hence blocking E2 binding 
to ERa by antagonists is used as a therapeutic treatment. The successful application of 
tamoxifen has triggered vivid interest in the development of many (partial) antagonists, 
so called SERMS (selective estrogen receptor modulators). SERMs bind in the same 
pocket as E2, but the compound loaded ERa ligand binding domain adopts a different 
conformation. The crystal structure of the compound loaded ligand binding domain 
has been solved and shows that binding of antagonist elicits a re-positioning of helix 
12 that prevents / disrupts the transcriptional activity of AF-2 and inhibits interaction 
with coactivators (Brzozowski et al, 1997). SERMs operate either as agonist, antagonist 
or mixed agonist/antagonist based on a set of variables such as type of drug or target 
tissue. The transcriptional outcome of SERM loaded ERa is mostly determined by the 
conformation of ERa upon ligand binding, the presence or absence of coregulatory 
proteins and the effector site/promoter. The most successful and widely used SERM 
is tamoxifen, which is applied in the clinic for the treatment and prevention of breast 
cancer. Notwithstanding its great beneficial effects, tamoxifen has some disadvantages, 
namely induction of resistance. Tamoxifen resistance will eventually occur in all cases of
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advanced breast cancer and enables the tumor to grow in the presence of tamoxifen. The 
mechanism by which this occurs is still not clear; it has been reported that growth factor 
signaling might play an important role. Changes in the levels of epidermal growth fac­
tor receptor (EGFR), human epidermal growth factor receptor type 2 (ERBB2/HER2) 
and insulin-like growth factor receptor type 1 (IGF-IR) and their downstream signaling 
pathways are associated with tamoxifen resistance (Massarweh et al, 2008). Recently,
PAX2 has been shown to mediate repression of ERBB2 upon tamoxifen treatment, 
connecting ERa with the ERBB2 pathway (Hurtado et al, 2008). An additional disad­
vantage of tamoxifen is its tissue specific effect; tamoxifen acts as an antagonist in breast, 6  
but as an agonist in the uterus, resulting in an increased risk of endometrial cancer. The 
expression pattern and abundance of activated cofactors in the different tissues may very 
well determine the tissue specific effects of SERMs (Smith & O ’Malley, 2004).
Interestingly, our recent ChIP-Seq data (Welboren et al, 2009) shows that tamoxifen in­
duces ERa binding to a subset of the E2-induced ERa binding sites, indicating that the 
DNA sequence or chromatin structures may in part determine the tamoxifen response.
We have also shown that tamoxifen has a repressive effect on a large set of genes that 
appear not to respond to E2. The observed repression by tamoxifen may therefore be 
independent of the presence of ERa protein.
E R a  T A R G E T  G E N E S  A N D  B R E A S T  C A N C E R
Considerable effort has gone into gene expression profiling to diagnose, monitor and 
to predict disease progression and response to chemo- and endocrine therapy. Routine 
pathological tumor assessment of lymph node status, tumor size and histological tumor 
grade do not accurately predict the response to therapy or determine whether or not me­
tastasis will occur. Based on histological and clinical guidelines, almost 90% of lymph 
node negative patients now receive adjuvant systematic treatment. The use of a tumor 
type specific molecular signature is generally seen as of great benefit to tailor treatment. 
Gene expression profiling studies have aided the selection of breast cancer patients that 
would not need adjuvant chemo- and/or endocrine therapy (van ‘t Veer et al, 2002). The 
gene expression signature predicts that 70-80% of these patients are unlikely to develop 
metastasis, so these patients are currently over-treated. Several other gene expression 
profiles predict recurrence and overall survival and/or tamoxifen resistance (Chanrion et 
al, 2008; Frasor et al, 2006; Graf et al, 2007; Jansen et al, 2005; Kok et al, 2009; Lipp-
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man et al, 2008; Ma et al, 2004; Oh et al, 2006; Paik et al, 2004; Wang et al, 2005; 
Zhang et al, 2009).
Epigenetic silencing of loci is frequently observed in cancer. HDAC inhibitors can al­
leviate the epigenetic repression of genes and has been shown to inhibit cell growth and 
activate apoptosis in the MCF-7 breast cancer cell line, indicating that epigenetic silenc­
ing plays an important role in breast cancer (Im et al, 2008; Pledgie-Tracy et al, 2007). 
Alterations in the DNA methylation profile are observed in many cancers (Baylin, 2005). 
Genome-wide profiling of DNA methylation, e.g. MeDIP (methylated DNA immuno- 
precipitation using a specific antibody) or MethylCap (methylated DNA precipitation 
using protein affinity columns), provides detailed information on the methylation state 
of loci and can identify epigenetically silenced loci (Wilson et al, 2006). So far, gene 
expression profiles are based on the expression level of a small group of genes. However, 
a wealth of information on ERa regulation and the network of target genes governed by 
ERa have become available in recent times and awaits its translation into clinic applica­
tions. Furthermore, several genomic regions important for the development of breast 
cancer have been identified recently using genome-wide association studies (Ahmed et 
al, 2009; Thomas et al, 2009; Zheng et al, 2009). These regions identify new pathways 
contributing to the development of breast cancer and can be combined with profiling 
data. Gene expression profiling using high throughout sequencing of the transcriptome 
(RNA-Seq) has much improved sensitivity, resolution and accuracy. Sequencing of the 
transcriptome has the big advantage that mutations and translocations can be detected 
because the sequence of “each” transcript is determined. Furthermore, RNA-Seq is much 
more quantitative as compared to array based gene expression profiling, RNA-Seq can 
distinguish/detect different isoforms and can determine transcript boundaries. In addi­
tion, tumor specific and driver mutations can be determined (Nagalakshmi et al, 2008; 
Sultan et al, 2008; Wilhelm et al, 2008). The ever increasing sequencing capacity and 
decreasing costs hold great promises for the application of RNA/ChIP-Seq profiling to 
assist in diagnosis and prognosis. The presence or absence of genomic alterations such as 
copy number variation, inversions and deletions, the gene expression profile and the epi­
genetic state of loci are likely to be of high predictive value. Combined ChIP, epigenetic, 
RNA profiles or signatures and genome-wide association studies are likely to improve 
the monitoring of disease progression and may lead to a more tailored and personalized 
approach in endocrine treatment selection of breast cancer patients.
112
F u t u r e  d ì r e c t ì o n s  a n d  c o n c l u s i o n s
A comprehensive and detailed picture of ERa-mediated transcriptional regulation is 
beginning to emerge (Figure 2). Several regulatory and signaling pathways converge to 
ultimately regulate expression of an ERa target gene. Genome-wide ChIP and RNA 
profiling combined with deep sequencing has greatly increased our knowledge of the 
ERa target gene network. Hitherto the majority of data has been generated using one
© or e
ganded receptor is prevented due to methylation of histone tails by H3K9 specific histone methyl 
transferases. Ligand, e.g. estradiol or the SERM tamoxifen, diffuses through the cellular mem­
brane and binds cytoplasmic ERa. Upon ligand binding the ERa disassociates from chaperone 
proteins such as hsp90 and translocates to the nucleus and dimerizes. The ERa binds chromatin 
and at a subset of genes recruits the histone demethylase LSD1. LSD1 removes the methyl mark 
that prevents gene activation by the unliganded receptor and also plays a role in the interaction 
of distal enhancer regions via looping. At upregulated genes cofactors such as AIB1 (p160 fam­
ily) are recruited and a complex containing histone acetyl transferase activity is assembled. The 
N-terminal histone tails are acetylated resulting in an open chromatin conformation. In addi­
tion, cofactors with nucleosome remodeling activity (BRG1/BRM) are recruited. Finally RNA 
polymerase II and the general transcription machinery assemble at the promoter and the gene 
is transcribed. At repressed genes, either E2-repressed genes or genes repressed upon tamoxifen 
treatment, the corepressors NCoR or SMRT are recruited and a histone deacetylase complex is 
assembled. Acetyl groups are removed from histone tails and the chromatin is in a closed confor­
mation, which is not permissive for transcription to occur.
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cell line and rather similar conditions. The effect of signaling pathways, the presence 
and levels of cofactors on the global target gene network can now be determined with 
relative “ease”. In addition, the role of the ERa in different cell lines and tissues can be 
studied and most importantly, the application of the profiling approaches to tumors 
may provide the real in vivo picture. The sequencing of tumor genomic DNA and the 
determination of DNA methylation and RNA profile, as planned in the International 
Cancer Genome Consortium (ICGC), will provide invaluable insight in tumor devel­
opment and progression. W ith the decreasing cost, and increasing accuracy and capacity 
of high throughput sequencing platforms, the amount of data is explosively increasing. 
The expectation is that our understanding of ERa-mediated regulation will greatly in­
crease and will ultimately lead to new diagnostic/prognostic tools, to therapeutic targets 
and a more tailored treatment. The integration of all this genomic data and its clinical 
application will be the challenge of the near future.
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A b s t r a c t
Genomes are organized into high-level three-dimensional structures, and DNA ele­
ments separated by long genomic distances can in principle interact functionally. Many 
transcription factors bind to regulatory DNA elements distant from gene promoters. 
Although distal binding sites have been shown to regulate transcription by long-range 
chromatin interactions at a few loci, chromatin interactions and their impact on tran­
scription regulation have not been investigated in a genome-wide manner. Here we 
describe the development of a new strategy, chromatin interaction analysis by paired- 
end tag sequencing (ChIA-PET) for the de novo detection of global chromatin interac­
tions, with which we have comprehensively mapped the chromatin interaction network 
bound by oestrogen receptor a  (ERa) in the human genome. We found that most high- 
confidence remote ERa-binding sites are anchored at gene promoters through long- 
range chromatin interactions, suggesting that ERa functions by extensive chromatin 
looping to bring genes together for coordinated transcriptional regulation. We propose 
that chromatin interactions constitute a primary mechanism for regulating transcription 
in mammalian genomes.
I n t r o d u c t i o n
Although genomic information is usually presented as a linear series of bases, genomes 
are known to be organized into three-dimensional structures in vivo through interac­
tions with protein factors for nuclear process such as transcription (Fraser 2006). The 
precise and coordinated regulation of transcription requires the binding of transcription 
factors to specific regulatory DNA sequences in the genome. Chromatin immunopre- 
cipitation (ChIP) microarray (Collas & Dahl 2008) (ChIP-Chip) and ChIP-Sequenc­
ing (Wei et al. 2006, Wold & Myers 2008) (ChIP-PET and ChIP-Seq) have identified 
global transcription-factor-binding sites (TFBSs) and revealed that many TFBSs are 
far from gene promoters (Massie & Mills 2008). For example, most TFBSs bound by 
ERa in the human genome are distal to transcription start sites (TSSs) of target genes 
(Carroll et al. 2005, 2006, Lin et al. 2007, Lupien et al. 2008, Welboren et al. 2009). A 
major question arising from this observation is which distal TFBSs are non-functional 
fortuitous binding sites, and which are involved in transcriptional activity through a 
remote control mechanism. Long-range chromatin interactions between DNA elements
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engaged in transcriptional regulation (West & Fraser 2005, Woodcock et al. 2006) have 
been observed with the use of chromosome conformation capture (3C) (Dekker et al.
2002, Hagege et al. 2007) and variants including ChIP-3C (Horike et al. 2005, Cai et 
al. 2006), 4C (Zhao et al. 2006, Ling et al. 2006, Simonis et al 2006, Wurtele & Char­
trand 2006), 5C (Dostie et al. 2006) and 6C (Tiwari et al. 2008), and also RNA tagging 
and recovery of associated proteins (RNA TRAP) (Carter et al. 2002) and fluorescence 
in situ hybridization (FISH) (Osborne et al. 2004). However, these methods are limited 
to one-point or partial genome-oriented detection and are incapable of the de novo 
detection of genome-wide chromatin interactions (Simonis et al. 2007).
To address whether and how DNA elements bound by protein factors interact through A  
long-range chromatin looping in a genome-wide and unbiased manner, we conceived a 
new strategy, which we called ChIA-PET. We applied ChIA-PET to characterize ERa- 
bound chromatin interactions in oestrogen-treated human breast adenocarcinoma cells 
(MCF-7), and generated the first human chromatin interactome map (A ChIA-PET 
visualization browser is provided at http://cms1.gis.a-star.edu.sg (username ‘guest’, 
password ‘gisimsgtb’) for viewing the ERa ChIA-PET map). Furthermore, using active 
promoter and transcriptional marks such as trimethylation of lysine 4 on histone H3 
(H3K4me3) and RNA polymerase II (RNAPII) from ChIP sequencing as well as gene 
expression microarray data, we show that ERa-bound chromatin interactions are func­
tionally involved in regulating specific genes.
R e s u l t s
The ChIA-PET method
In ChIA-PET, long-range chromatin interactions are captured by crosslinking with 
formaldehyde. Sonicated DNA—protein complexes are enriched by ChIP Tethered 
DNA fragments in each of the chromatin complexes are connected with DNA linkers 
by proximity ligation, and paired-end tags (PETs) are extracted for sequencing. The 
resulting ChIA-PET sequences are mapped to reference genomes to reveal relationships 
between remote chromosomal regions brought together into close spatial proximity by 
protein factors (Fig. 1a and Supplementary Fig. 1).
ChIA-PET proximity ligation generates two types of ligation products: self-ligation of
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Figure 1. ChIA-PET method with validations. a, ChIA-PET diagram. DNA fragments in soni­
cated, ChIP-enriched chromatin complexes were processed by linker ligation, proximity ligation, 
PET extraction, sequencing, and mapping to reveal interacting loci. b, ChIA-PET browser tracks: 
1, H3K4me3 ChIP-Seq; 2, RNAPII ChIP-Seq; 3, ERa (orange) and FoxAl ChIP-chip (green) 
(Lupien et al. 2008); 4, ERa ChIA-PET density; 5, inter-ligation PETs. Inset: 3C validation of 
interacting ERaBSs (purple) and controls (blue) under ethanol control (ET) and induction with 
oestrogen (E2). The error bars are s.e.m. c, 4C validation, showing 4C bait region (blue) and 
interaction targets (purple bars). d, Validation by FISH, showing increased P2—P1 interactions 
under E2 induction with background normalization (P3/P2). FISH probe genomic locations 
(P1, P2 and P3) are indicated.
128
the same DNA fragments and inter-ligation between different DNA fragments. PET 
sequences derived from self-ligation products are mapped in the reference genome with­
in a 3-kilobase (kb) span, demarcating ChIP DNA fragments, similar to the standard 
ChIP-Sequencing method (Wei et al. 2006, Lin et al. 2007). Tethered DNA fragments 
in individual chromatin complexes can also ligate with each other, and the mapping 
results of such inter-ligation PET sequences would reveal if they are intrachromosomal 
(both tags of each PET are from the same chromosome) or interchromosomal (the tags 
are from different chromosomes). Singleton PETs are presumed experimental noise, and 
overlapping PET clusters are considered enriched putative binding sites or interaction 
events (Supplementary Fig. 2).
To test the ChIA-PET strategy, we constructed two ChIA-PET libraries from inde­
pendent ERa ChIP-enriched oestrogen-treated MCF-7 chromatin preparations, and 
generated two replicate pilot datasets (IHM001H and IHM001N) using Roche/454 
pyrosequencing. Our analysis showed that both ChIA-PET libraries produced compa­
rable putative binding sites and interactions. To assess levels of false positive chromatin 
interactions, we created a negative control ChIP-PET library (IHM043) from the same 
ChIP sample, wherein the DNA was reverse crosslinked before proximity ligation. We 
also analysed a previously reported cloning-based ChIP-PET library (SHC007) (Lin et 
al. 2007). Both libraries generated abundant binding sites but no interactions. As an 
additional control, we used IgG, which binds to chromatin nonspecifically, to perform a 
mock ChIA-PET analysis (IHM062), and only a few binding sites and interactions were 
identified (Table 1, Supplementary Figs 2 and 3 and Supplementary Note 1).
In proximity ligation-based analyses including 3C, the level of non-specific chimaer- 
ic DNA ligations between different chromatin complexes can be high and thus may 
confound data analysis. To address this, we designed linker nucleotide barcodes in the 
ChIA-PET method to specifically identify such chimaeric ligation PETs in another 
ERa ChIA-PET replicate. Linker barcoding analysis suggests that chimaeric ligations 
are random and do not overlap with each other to form false positive interactions (Table 
1, Supplementary Fig. 4 and Supplementary Note 2). A possible complication is that 
ChIP-enriched loci with more DNA fragments would result in proportionally higher 
chances of inter-ligations, leading to false-positive interactions comprising randomly 
overlapping inter-ligation PETs among highly-enriched ChIP DNA fragments. Hence, 
we devised a statistical scheme to calculate such probabilities and neutralize the potential 
ChIP-enrichment bias (Supplementary Methods; validations are given in Supplemen-
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ATable 1. Summary statistics of library PET sequences.
ChIA-PET data mapped at satellites and structural variation sites were removed.
*Self-ligation PET clusters for identifying binding sites (FDR < 0.01, PET count at least 5). 
tInter-ligation PET clusters for identifying interactions include at least two (small-scale) or three 
(chimaeras and large-scale analysis) overlapping PETs (FDR < 0.05). Interchromosomal interac­
tions were subjected to manual curation.
tOne interaction has a genomic span of less than 5 kb, suggesting that it results from extra-long 
self-ligation PETs, and the other has a genomic span of more than 10 Mb and PET counts of 
only 2, and so could be non-specific.
tary Fig. 5).
Together, these libraries indicate that the prevalent chromatin interactions (Supplemen­
tary Fig. 2d—g) identified by ERa ChIA-PET data depend on proximity ligations of 
chromatin complexes and are neither technical artefacts of ligations between random 
DNA fragments nor mapping errors.
ERa-bound chromatin interactome map
Next we generated a large ERa ChIA-PET dataset (IHM001F) with 3.2 x 107 PET 
sequences by Illumina GAII paired-end sequencing (Table 1 and Supplementary Meth­
ods) for comprehensive analyses of ERa binding and chromatin interactions in oe­
strogen-treated MCF-7 cells. O f 4.6 x 106 uniquely mapped PET sequences, 1.2 x 106
Self-ligation Intrachromosome
inter-ligation
Interchromosome
inter-ligation
Library
Code
Library
identity
Total PET Unique
PET
PET PET
clusters*
PET PET
clusterst
PET PET
clusterst
Sm all-scale testin g  o f  the ChIA-PET m eth od
IHM 001N ChIA-PET 715,369 271,648 78,706 2,701 16,677 176 176,265 0
IHM 001H ChIA-PET 764,899 293,754 103,740 3,405 17,718 215 172,296 0
IHM043 ChIP-PET 1,118,509 745,251 634,993 1,158 7,386 2 t 102,872 1
SHC007 ChIP-PET 361,241 214,668 192,511 489 2,196 0 19,961 0
IHM062 ChIA-PET
(IgG)
436,248 217,708 40,847 0 11,254 0 165,607 0
A nalysis o f  chim aeras
IHH015M ChIA-PET
(AA+BB)
4,246,429 2,049,719 953,384 3,909 129,492 2,183 966,843 3
IHH015C ChIA-PET
(chimaeras)
5,904,476 1,790,714 15,490 35 98,805 0 1,676,419 0
Large-scale ChIA-PET analysis
IHM001F ChIA-PET 31,828,194 4,638,633 1,249,081 14,560 234,400 1,451 3,155,152 15
IHH015F ChIA-PET 19,590,581 6,125,099 1,841,684 6,665 348,057 3,543 3,935,358 4
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(27%) were self-ligation PETs. Among the self-ligation PETs, 16.7% clustered to form 
overlapping PET groups, representing 14,468 putative ERa-binding sites (ERaBSs) 
(false discovery rate FDR < 0.01, PET count per ERaBS at least 5; Supplementary 
Table 1). O f the inter-ligation PETs, 2.3 x 105 (5.1% of uniquely aligned PETs) were 
intrachromosomal and 3.2 x 106 (68%) were interchromosomal (Table 1). After sta­
tistical analyses in which we discarded singleton inter-ligation PETs as either very weak 
interactions or background noise, defined clusters from overlapping inter-ligation PETs, 
corrected for ChIP enrichment biases and filtered out obviously false interactions due 
to structural variations in the MCF-7 genome (Supplementary Methods), we identified 
a large set of 1,451 intrachromosomal and a small set of 15 interchromosomal overlap­
ping clusters consisting of three or more inter-ligation PETs per cluster (FDR < 0.05). 
These represent paired inter-ligating ChIP DNA fragments, which indicate potential 
distant chromatin interactions bound by ERa (Supplementary Table 2).
Each chromatin interaction detected by an inter-ligation PET cluster features two anchor 
regions (interacting loci) and a loop (the intermediate genomic span between the two 
anchors), and is therefore called a ‘duplex interaction’ (Supplementary Table 2). Most 
anchors (1,893/2,008 = 94%) involve self-ligation PET-defined ERaBSs (FDR < 0 .01). 
Many nearby duplex interactions are interconnected, linking three or more anchors 
into ‘daisy-chain’ aggregated complex interactions (Fig. 1b—d and Supplementary Fig. 
6). For example, multiple duplex interactions with three ERaBSs in the SIAH2 region 
interconnect to form a complex interaction. Hence, we further assembled 1,036 du­
plex interactions into 274 complex interactions based on overlapping of interaction 
anchors (Supplementary Methods). The remaining interactions (415) were standalone 
duplex interactions. In all, we identified 689 ERa-bound chromatin interaction regions 
(Supplementary Table 3).
To verify the ChIA-PET results, we validated several new ERaBSs identified in this 
study by ChIP-quantitative polymerase chain reaction (qPCR) (Supplementary Fig. 7), 
as well as putative intrachromosomal interaction sites (20 genomic loci) by 3C, ChIP- 
3C, 4C and FISH experiments (three examples are shown in Fig. 1; others are shown in 
Supplementary Figs 8—11 and Supplementary Tables 4 and 5). Moreover, the 3C and 
FISH experiments showed higher levels of chromatin interactions in oestrogen-treated 
conditions than in untreated conditions, indicating that the interactions are oestrogen­
dependent. We also examined three putative interchromosomal interactions by FISH; 
however, none of them were positive (Supplementary Table 4 and Supplementary Note
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3), suggesting that most ERa-bound intrachromosomal interactions were genuine, 
whereas the putative interchromosomal interactions were false positives or were too 
weak to be validated.
Taken together, the ERaBS and chromatin interactions identified by ChIA-PET data 
constitute a whole-genome chromatin interaction map bound by ERa. The genomic 
spans of most duplex interactions (86%) are less than 100 kb, about 13% are from 
100 kb to 1 megabase (Mb), and less than 1% are more than 1 Mb. Complex interac­
tions extend genomic span by connecting multiple duplex interactions. Many complex 
interactions (47%) have genomic spans in the range 100 kb to 1 Mb, with a few that are 
more than 1 Mb (Supplementary Fig. 12 and Supplementary Table 3).
To determine the reproducibility of this chromatin interactome map, we generated an 
additional ERa ChIA-PET library by using a different antibody against ERa (Welbo- 
ren et al. 2009). For this biological replicate (IHH015F), we obtained 2.0 ' 107 PET 
sequences (Table 1 and Supplementary Methods). Overall, the two ERa ChIA-PET 
libraries were very similar, with many overlapping ERaBSs and intrachromosomal in­
teractions but few interchromosomal interactions (Table 1 and Supplementary Tables 1 
and 2). The ERaBSs identified in these two libraries showed high reproducibility, espe­
cially for highly enriched binding peaks. The 2,513 ERaBSs with at least 50 PET counts 
per cluster (high enrichment) overlapped with more than 70% of the ERaBSs in the 
replicate ChIA-PET library (Supplementary Table 6). Furthermore, these high-enrich- 
ment ERaBSs intersected well with previously reported ERa binding maps (Lupien et 
al. 2008, Welboren et al. 2009) (Fig. 2a and Supplementary Fig. 13). High-enrichment 
ERaBSs are therefore more reliable than low-enrichment sites. Many intrachromosomal 
interaction regions are detected in both replicate libraries. Highly abundant chromatin 
interactions are mostly reproducible. O f the top 100 most abundant chromatin interac­
tions in IHM001F, 86 were found in IHH015F (more analyses are given in Supplemen­
tary Table 7). Furthermore, all interactions previously identified and validated in this 
study are found in both replicate libraries (Supplementary Table 5). Conversely, none of 
the putative interchromosomal interactions were reproducible.
Taken together, our results demonstrate that the ChIA-PET method is highly reliable. 
Furthermore, our data suggest that ERa functions primarily by means of an intrachro­
mosomal mechanism. Our subsequent analyses therefore focused on intrachromosomal 
interactions. Downstream analyses for both ChIA-PET replicate libraries showed simi­
lar results; for simplicity, we discuss our results here using IHM001F, but results for
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IHH015F are given in Supplementary Note 4.
We examined how many ERaBSs are involved in complex and duplex interactions, or 
in no interactions (Fig. 2b—d). Our analysis showed that high-enrichment ERaBSs are 
much more frequently involved in interactions (53%) than are low-enrichment ERaBSs 
(only 9%) (Fig. 2e and Supplementary Fig. 13), suggesting that high-confidence and
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Figure 2. ERaBS reproducibility and association with chromatin interactions. a, Numbers of 
ERaBSs identified with different ChIP enrichment cutoffs and reproducibility analyses as mea­
sured by overlapping with another ChIA-PET dataset (IHH015F), ChIP-Seq (Welboren et al. 
2009) and ChIP-chip (Carroll et al. 2005) data. Left: low-enrichment ERaBSs, 11,955 (5—49 
PETs per site). Right: high-enrichment ERaBSs, 2,513 (50 or more PETs per site). b—d, Ex­
amples of ERaBSs involved in complex interactions (b), duplex interactions (c) and no interac­
tions (d) (singleton inter-ligation PETs only (right) or no inter-ligation PETs (left)). e, ERaBS 
distribution in different categories of interactions as exemplified in b—d. Left: low-enrichment 
ERaBSs. Right: high-enrichment ERaBSs.
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strong ERaBSs are more likely than weaker ERaBSs to be involved in chromatin in­
teractions. To gain a better understanding of ERaBSs with respect to ERa target genes, 
we analysed how many ERaBSs are proximal or distal to gene promoters, based on a 
cutoff of 5 kb from transcription start sites (TSS) of University of California Santa Cruz 
(UCSC) gene database (Hsu et al. 2006). O f 2,342 ERaBSs involved in chromatin 
interactions, 387 (17%) were proximal and 1,955 (83%) were distal to TSSs (Supple­
mentary Fig. 14). We also observed the same ratio for non-interacting ERaBSs: 2,043 
(17%) were proximal and 10,175 (83%) were distal. Most ERaBSs are therefore distal 
to gene TSSs, which is in agreement with previous studies (Carroll et al. 2006, Lin et al. 
2007, Welboren et al. 2009).
A
Chromatin interaction and transcriptional regulation
To investigate the functions of ERaBSs and ERa-bound chromatin interactions in 
transcription activation, we generated genome-wide maps of H3K4me3 and RNAPII 
ChIP-Seq data from MCF-7 cells under oestrogen induction (Supplementary Meth­
ods). H3K4me3 is a histone modification that specifically marks active promoters (Bar­
ski et al. 2007), and the presence of RNAPII is strong evidence for genes that are actively 
transcribing (Phatnani & Greenleaf 2006). We also analysed previously reported FoxA1 
ChIP-Chip data (Lupien et al. 2008), because FoxA1 is an important cofactor of ERa 
(Carroll et al. 2005, Lupien et al. 2008). Generally, H3K4me3, RNAPII and FoxA1 
marks showed enrichment around ERaBSs in our analyses (Fig. 3a). When we com­
pared interacting ERaBSs with non-interacting ERaBSs, we found a significant enrich­
ment gradient of RNAPII and FoxA1 binding around ERaBSs: most association was 
with ERaBSs involved in complex-interactions, followed by duplex-interactions, and 
lastly no-interactions (Fig. 3a and Supplementary Fig. 15a; significance tests are shown 
in Supplementary Note 5).
Next we examined the H3K4me3, RNAPII and FoxA1 marks with respect to ERaBSs 
proximal or distal to gene promoters and their involvement in chromatin interac­
tions. Proximal ERaBSs, whether involved in interactions or not, were highly enriched 
in H3K4me3, but this was not true of distal ERaBSs, which was expected because 
H3K4me3 is a known mark for promoter regions (Fig. 3b and Supplementary Fig. 15b; 
significance tests are shown in Supplementary Note 5). Proximal ERaBSs were also 
highly enriched with RNAPII marks, but the enrichment for both proximal and distal
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aFigure 3. Association of ERa-bound chromatin interactions with functional marks. a, Associa­
tion of ERaBSs in complex-interaction (left), duplex-interaction (middle) and no-interaction 
(right) categories with RNAPII, H3K4me3 and FoxA1 functional marks. The left y-axis is “Rela­
tive tag density” for H3K4me3 and RNAPII ChIP-Seq data; the right y-axis is “ChIP-chip in­
tensity” for FoXA1 ChIP-chip data.] b, Association of proximal and distal interacting (left) and 
non-interacting (right) ERaBSs with RNAPII (top) and H3K4me3 (bottom) functional marks.
ERaBSs involved in interactions was significantly higher than that of the proximal and 
distal ERaBSs that are not involved in interactions. Intriguingly, although RNAPII 
showed less enrichment around distal interacting ERaBSs compared with proximal 
ERaBSs, the enrichment was significantly higher than that with distal non-interact­
ing ERaBSs. Conversely, FoxA1 binding was more enriched around distal ERaBSs 
than around proximal ERaBSs, and most enriched around interacting distal ERaBSs 
(Supplementary Fig. 15c), and differences were statistically significant (significance 
tests are shown in Supplementary Note 5). This indicates that RNAPII and FoxA1, but 
not H3K4me3, predict interactions at distal ERaBSs, and suggests that RNAPII and
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FoxA1 participate in tethering chromatin interactions. Whereas RNAPII is strongly as­
sociated with ERaBSs for transcription activation, FoxA1 is more directly correlated 
with the regulatory function of ERa at distal ERaBSs. At least six interacting ERaBSs 
bracket the FOXA1 gene, signifying ERa-mediated chromatin interactions may regulate 
FOXA1 (Fig. 2b), further supporting the hypothesis that FoxA1 and ERa may regulate 
each other (Laganiere et al. 2005).
Subsequently, we examined the 689 ERa-bound chromatin interaction regions with 
regard to looping structure and gene transcription. We envisage that multiple ERaBSs 
may function as ‘anchor’ regions forming chromatin looping structures in three-dimen­
sional space (Fig. 4a). Genes close to interaction anchors are considered to be ‘anchor 
genes’, and genes in the interaction loop regions and faraway from anchors to be ‘loop 
genes’. We annotated the interaction regions in relation to UCSC gene database tran­
scripts (Hsu et al. 2006) (a gene may have multiple transcripts; here we report tran­
script numbers, but gene numbers are given in Supplementary Note 6). A gene was 
considered to be associated with a chromatin interaction region if the TSS of a gene 
was within 20 kb of the interaction boundaries (Supplementary Fig. 14), a parameter 
that includes many known and validated ERa target genes. Most interaction regions 
(393/689 = 57%) were associated with ‘anchor genes’ (TSS to interaction anchor within 
20 kb). Altogether, 1,575 ‘anchor genes’ and 3,767 ‘loop genes’ (TSS more than 20 kb 
away from interaction anchors) were assigned to interaction regions (Supplementary 
Tables 3 and 8). Using the same distance parameter (20 kb), we assigned 11,790 genes 
to 12,126 standalone ERaBSs not involved in interactions (Supplementary Note 6).
Within interaction regions with at least one anchor gene there are 1,073 distal ERaBSs 
and 387 proximal ERaBSs (less than 5 kb to TSS), and all distal ERaBSs (5' or 3' to 
the gene promoter) are looped to anchor genes through connections with proximal 
ERaBSs. Many interaction regions include multiple genes, such as the keratin gene 
cluster (Fig. 1c) and the NR2F2 locus (Fig. 1d), whereas others include only single 
genes, such as SIAH2 (Fig. 1b). Distal ERaBSs are stronger than proximal ERaBSs; 
this is the inverse of RNAPII marks, which are stronger at gene promoters than at distal 
regions (Supplementary Fig. 16; examples are shown in Fig. 1 and Supplementary Fig. 
17). ^ese observations suggest that direct ERa binding might be initiated primarily 
at one or multiple distal sites, which then subsequently recruit other binding sites as 
anchors to form an interaction complex to ultimately engage the transcriptional ma­
chinery at gene promoters.
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Figure 4. Proposed ERa-bound chroma­
tin interaction and transcription regula­
tion mechanism. a, Distal ERaBSs interact 
with proximal sites, forming chromatin 
loops. Anchor genes (green and blue) are 
close to interaction anchors with concen­
trated active transcriptional machinery (red 
shading). Other genes far from interaction 
centres (grey) are less active. b, Expression 
microarray data (oestrogen induction from 
0 to 48 h; red denotes activation, and green 
repression) for interaction anchor genes, 
loop genes and genes near no-interaction 
ERaBSs, with all other UCSC genes (Hsu 
et al. 2006). ‘All genes’ denotes back­
ground. c, ChIA-PET interactions data at 
the FOS/JDP2/BATF loci. Transcription 
activities are shown by H3K4me3/RNAPII 
ChIP-Seq and RT—qPCR analysis (bottom 
panels, oestrogen induction from 0 to 24 
h; the y-axis is Relative Expression, fold of 
increase over ET control). ^ e  error bars are 
s.e.m. and the y-axis is fold of increase over 
ET control.
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In addition, we found 296 interaction regions with no associated anchor genes. Al­
though 41 regions contain loop genes, the remaining 255 have no associated UCSC 
genes assigned to them. Although some interaction regions could be noise or non-func­
tional, some interactions are near gene promoters just outside the 20 kb cutoff, and 
further sequencing might extend the interaction data to the promoters. The presence of 
H3K4me3, RNAPII marks and RT—qPCR data at the interaction anchor sites suggests 
that some interactions could be involved in regulating yet-to-be identified transcripts,
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such as computationally predicted genes and non-coding RNA species (Supplementary 
Fig. 18). Alternatively, such interactions could be associated with maintaining chroma­
tin structures or other unknown functions.
To understand whether genes associated with ERa-bound interactions are regulated 
by oestrogen, we analysed expression profiles of several interaction-associated genes by 
RT—qPCR over a time course of oestrogen induction (Supplementary Methods). All 
anchor genes examined are upregulated by oestrogen induction (Supplementary Fig. 
8). We extended our analysis to all interaction associated genes with the use of whole- 
genome gene expression microarrays (Fig. 4b). Most ‘anchor genes’ are upregulated 
(60%), particularly at early time points, in comparison with ‘loop genes’ (48%), in­
dicating that ‘anchor genes’ are significantly associated with gene upregulation (two­
tailed p = 1.25 x 10-16; Fig. 4c, Supplementary Note 7, Supplementary Table 9 and 
Supplementary Fig. 19). In addition, RNAPII marks are associated more with ‘anchor 
genes’ (39%) than with ‘loop genes’ (26%) (two-tailed p = 10-19). Conversely, genes as­
signed to ERaBSs not involved in interactions (on the basis that the gene promoters are 
within 20 kb of no-interaction ERaBSs) have very similar expression profiles to that of 
the background control (all UCSC genes not associated with interactions), indicating 
that genes associated with no-interaction ERaBSs are less activated than genes associ­
ated with interaction ERaBSs (significance tests are shown in Supplementary Note 7). 
Hence, some standalone ERaBSs could be noise, whereas others could involve non­
looping mechanisms such as the recruitment of secondary coactivators for downstream 
functions (Carroll et al. 2005).
Within the anchor gene category, many (495/1,575 = 31%) gene entries have 5' and 
3' ends within interaction boundaries. Such entries, called ‘enclosed anchor genes’, fre­
quently occupy the entirety of short interaction loops, engage multiple anchor sites 
around or within the gene, tend to have intense RNAPII marks covering the entire gene 
(examples are shown in Fig. 2b, c and Supplementary Fig. 20) and are preferentially as­
sociated with RNAPII marks and gene upregulation as indicated by expression microar­
rays (Supplementary Note 7 and Supplementary Table 9).
Taken together, our data show an association between chromatin interactions and gene 
transcriptional activation: enclosed anchor genes are closely correlated with upregula- 
tion as measured by gene expression microarray data and RNAPII ChIP-Seq peaks; less 
closely correlated are non-enclosed anchor genes, loop genes even less so, and genes not 
associated with interactions are much less so. These results suggest that gene-centric
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Figure 5. ERa-bound chromatin interactions are required for transcription activation. a, Ge­
nome browser at the GREB1 locus showing data tracks: 1 and 2, H3K4me3 and RNAPII ChIP- 
Seq; 3 and 4, RNAPII ChIP-qPCR scans using different RNAPII antibodies under oestrogen 
induction (E2, red) and ethanol control (ET, grey); 5, ERa (orange) and FoxA1 (green) ChIP­
chip (Carroll et al. 2006); 6, ChIA-PET density; 7, interaction data. b—d, siRNA knockdown 
experiments. MCF-7 cells were transfected with siRNA against ERa (siERa) or control (siCtrl), 
and then analysed by western blot analysis with ERa and calnexin (control) antibodies (b); 
RT—qPCR on GREB1 expression (c); and 3C assays at GREB1 (d): siERa knockdown abolishes 
chromatin interactions and turns off transcription. The error bars are s.e.m. and y-axis of c is 
“Relative Expression” and the y-axis of d is “Normalized Interaction”.
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interaction structures may enclose a compartment for concentrating ERa and transcrip­
tion-related proteins at target genes.
ERa-bound interactions may coordinate transcriptional regulation for multiple genes 
involved in the same functional pathways. At the keratin gene cluster interaction loci 
(Fig. 1c), enclosed anchor genes such as KRT8 and KRT18 are actively transcribing, as 
demonstrated by RNAPII and H3K4me3 marks, whereas the loop genes such as KRT72 
and KRT75, which are mainly keratins expressed in hair cells that do not have a func­
tion in mammary epithelial cells such as MCF-7, are mostly inactive (Supplementary 
Note 8). Another example is the complex interaction that encompasses the three genes 
FOS, JDP2 and BATF (Fig. 4c), which encode the dimerization partners of JU N  to 
form the AP-1 transcription factors. AP-1 is important in regulating oestrogen-receptor- 
dependent transcription by functioning either as a DNA tethering partner or as an 
ERa cofactor (Kushner et al. 2000). In this complex interaction, FOS and BATF are 
enclosed anchor genes and are upregulated as shown by RNAPII marks and RT—qPCR, 
whereas JDP2 is a loop gene and is downregulated as shown by RT—qPCR and de­
creased RNAPII occupancy. ^ e  promoter of JDP2 is marked by H3K4me3, a common 
feature found in many loop genes (Supplementary Table 9). JDP2 and other loop genes 
could be ‘poised’ for activation if they were to escape from the interaction loop. Long- 
range transcriptional regulation by ERa may therefore be a fine-tuning mechanism that 
evolved to regulate specific sets of related genes differentially.
To determine functionally whether some ERa-associated interaction regions are de­
pendent on ERa, we used short interfering RNA (siRNA) to knock down the level of 
ERa protein in MCF-7 cells (Supplementary Methods) and then measured whether 
the interactions and gene transcription were affected. ERa-specific siRNA (siERa) ef­
ficiently decreased the amount of ERa protein and effectively abolished the interactions 
as demonstrated by a set of 3C assays at the GREB1 locus (Fig. 5). Furthermore, siERa 
blocked GREB1 transcription as determined by RT—qPCR. Similar results were also 
previously shown at the TFF1 site (Pan et al. 2008). Together, these data suggest that at 
least some of the regulatory long-range chromatin interactions identified by ERa ChIA- 
PET data are mediated by ERa.
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D i s c u s s i o n
We demonstrated the ChIA-PET mapping strategy is an unbiased whole-genome ap­
proach for the de novo analysis of chromatin interactions, and hence is a major tech­
nological advance in our ability to study higher-order organization of chromosomal 
structures and functions. The ChIA-PET interaction data greatly increase the accuracy 
of assigning distal TFBSs to target genes, and globally addresses the three-dimensional 
chromatin interaction mechanism by which distal TFBSs regulate transcription. We 
postulate the following primary mechanism for E R a function: E R a protein dimers are 
recruited to multiple and primarily distal ERaBSs, which interact with one another 
and possibly with other factors such as FoxA1 and RNAPII to form chromatin looping 
structures around target genes; such topological architectures may partition individual 
genes into subcompartments of nuclear space such as interaction-anchor-associated 
genes and interaction-loop-associated genes for differential transcriptional activation 
or repression. We further speculate that tightly enclosed chromatin interaction centres 
could help achieve and maintain high local concentration o f transcription components 
for efficient cycling o f transcriptional machinery on target gene templates (a summary of 
results is given in Supplementary Information, and more discussion in Supplementary 
Note 9).
We expect that this global chromatin interactome map and the ChIA-PET assay will 
be a valuable starting point for future studies o f the three-dimensional architecture of 
transcription biology in whole-genome contexts.
M e t h o d s  s u m m a r y
M CF-7 cells grown in hormone-depleted medium were treated with 17^-oestradiol 
(‘oestrogen’, E2) for 45 min before being crosslinked with 1% formaldehyde for 10 min. 
ChIA-PET libraries were constructed by first performing ChIP with H C-20 antibody 
(Santa Cruz) or Mab-NRF3A6-050 antibody (Diagenode) (Welboren et al. 2009) 
against ERa. DNA fragments in ChIP complexes were then ligated to biotinylated 
half-linkers (linker ligation) containing flanking MmeI restriction sites. ^ e  complexes 
were further ligated under dilute conditions (proximity ligation). PETs were extracted 
from the ligation products by digestion with MmeI. Released biotinylated PETs were 
purified by streptavidin-coated magnetic beads, ligated to adaptors, and amplified by
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PCR. Gel-purified amplicons of PET templates were sequenced by Roche/454 and/or 
Illumina paired-end sequencing. PET sequences were mapped to the human reference 
genome (hg18). Binding sites and interactions were identified by using a readout of 
overlap PETs. To correct for ChIP enrichment bias, we formulated a statistical analysis 
framework to calculate the probability o f the formation o f inter-ligation PETs between 
two regions if ligations between DN A  fragments occur by chance. Interactions were 
further collapsed into complex interactions if they shared interaction anchors. UCSC 
genes were assigned to interaction regions if they were within 20 kb o f interaction re­
gions. To characterize ERa-bound interactions and associated genes functionally, we 
conducted gene expression microarray experiments in a time course with and without 
E2 treatment, and generated genome-wide maps of H3K4me3 (ab8580; Abcam) and 
RNAPII (serine-5 phosphorylation antibody, ab5131; Abcam) ChIP-Seq data by using 
Illumina GA single-read sequencing. Interaction-associated genes were annotated with 
expression microarray data and RNAPII and H3K4me3 ChIP-Seq peaks. Validation ex­
periments included ChIP-qPCR, 3C, ChIP-3C, 4C, FISH and RT—qPCR. For siRNA 
studies, E R a ON-TARGETplus SMARTpool siRNA (Dharmacon) was transfected 
into M CF-7 cells with Lipofectamine 2000 (Invitrogen). Sequences used in experiments 
are listed in Supplementary Table 10.
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S u m m a r y
Almost 40 years ago the estrogen receptor was discovered, a protein found in breast tu­
mors whose quantity could predict the response to endocrine disruption (Jensen et al., 
1971; McGuire, 1973). In the 40 years since, our knowledge of the estrogen receptor 
has increased dramatically. We now know that the E R a is a ligand dependent transcrip­
tion factor regulating a large number of target genes (Charpentier et al., 2000; Green et 
al., 1986; Greene et al., 1986). This also led to the discovery and development of tamox­
ifen in the late 60’s as an antifertility agent, and its use as an anti-breast cancer drug since 
the 70s (as reviewed in Jordan, 2003). We now have detailed knowledge of many aspects 
of estrogen signaling. Many genes have been identified involved in different processes 
that are regulated by the ERa. In this thesis we set out to gain insight in the network of 
binding sites and target genes governed by the E R a as well as the effect of specific ER 
modulators (SERMS) like tamoxifen on this network.
Chapter 1 is a review outlining the available methods and data on E R a binding site 
and target gene analysis at the start o f this PhD project. It reviews the different tech­
niques used so far and the advances made in elucidating E R a mediated regulation at 
that time.
In chapter 2 we identify on a truly genome-wide scale E R a binding sites using genome- 
wide ChIP-chip. In addition we determine for the first time the genome-wide effects of 
tamoxifen on E R a binding. We show that E R a binding is distributed throughout the 
genome and that only a small percentage binds in promoter regions. Furthermore, we 
observed that tamoxifen liganded E R a is able to bind to a large number of E R a bind­
ing sites and that these sites are a distinct, partially overlapping group compared to E2 
sites.
In chapter 3 we use Illumina high throughut sequencing coupled to ChIP (ChIP-Seq) 
to profile E R a binding in the absence of ligand or when liganded with E2. We identified 
13.173 E R a binding sites and provided new information on cis-acting elements. We 
compare the data obtained by ChIP-Seq with the data obtained by ChIP-chip described 
in chapter 1. We find that ChIP-Seq is more sensitive, less prone to bias, cheaper and 
quicker than ChIP-chip.
We extended our ChIP-Seq data extensively in chapter 4. We performed additional ex­
periments and obtained ChIP-Seq profiles of tamoxifen and fulvestrant liganded ERa. 
We show that tamoxifen or fulvestrant partially affect E R a binding but that antagonist
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loaded E R a is still able to bind DNA, although to a smaller number of sites. In addition 
we show that there is a group ligand specific interaction sites. By using RNA polymerase 
2 ChIP-Seq we show that the large number o f E R a binding sites regulate a much small­
er number of genes. Furthermore we show that promoter proximal enrichment of RNA 
polymerase 2 (PPEP or pausing) occurs frequently in M CF-7 cells, but only on a limited 
number o f E2 responsive genes. Tamoxifen and fulvestrant both prevent the recruitment 
and loading o f RNA polymerase 2 on the promoter and coding body of E2 upregulated 
genes. O n E2 repressed genes tamoxifen and fulvestrant act differently. Tamoxifen acts 
as an agonist at E2 repressed genes while fulvestrant acts as an agonist and can increase 
RNA polymerase 2 occupancy.
Several genome-wide ChIP-profiles have been published. Differences are present in the 
binding site profile and the subsequent conclusions drawn. In chapter 5 we perform 
ChIP-Seq using different antibodies against the ERa; F3A6, HC-20, Dia050 and a con­
trol. The profiles of both the monoclonal F3A6 and Dia050 overlap to a large extend. 
The polyclonal HC-20 also shows a large overlap with both monoclonal antibodies but 
also detects a large number o f other sites. O ur analysis shows that these sites specific 
to the polyclonal H C-20 antibody are primarily low affinity sites. ChIP-Seq using the 
H C-20 antibody in an E R a negative cell line showed that these sites are not due to cross 
reactivity. Subsequent m otif analysis of the different profiles revealed great differences in 
the presence and enrichment of sequence motifs, indicating that the choice of antibody 
greatly influences the ChIP profile and the conclusions drawn from that data.
In the chapter 6 we perform an extensive review of the data available on the E R a and 
the state o f affairs on this subject at the end of the PhD project. We discuss the develop­
ments in the techniques used to gain insight in the E R a binding site and target genes 
network. Furthermore, we discuss how the complex interplay between receptor, ligand, 
DN A  sequence, post-translational modifications, chromatin context and D NA  looping 
result in transcriptional regulation. We give an overview o f the advances made in the 
identification of the E R a binding site and target gene network including the recent ge­
nome-wide E R a ChIP profiling studies and their clinical applications. Future develop­
ments such as ChIA-PET, which not only identifies transcription factor binding but also 
long range interactions between enhancers and promoter regions, are also discussed.
In the addendum , we describe the development of a new strategy to identify on a global 
scale chromatin interactions, called chromatin analysis by paired-end tag sequencing 
(ChIA-PET). We used this technique to map the complete chromatin interaction net-
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work governed by the ERa. We showed that most of the high affinity, high confident 
E R a binding sites are anchored via looping to gene promoters often at great distances of 
each other. Most likely, the E R a will bring genes together to coordinately regulate their 
transcription. We find that the position o f a gene in the chromatin loop correlates with 
gene transcriptional activation and propose that chromatin interactions are a primary 
mechanism for regulating transcription in the mammalian genome.
In conclusion, the studies described in this thesis have provided new data and insights 
in the binding site and target gene network o f the E R a using high throughput ChIP 
profiling. Although a large body of data is available, still a lot is unknown such as the ki­
netics of E R a mediated regulation or its behavior in other cell systems like primary cells. 
W ith the current rate of development in high throughput sequencing, a vast amount 
S of data will become available in the near future. New technologies such as ChIA-PET, 
which not only identify transcription factor binding but also long distance interactions 
between enhancers and promoters, will provide more insight in the highly complex net­
work that regulates transcription. The challenges in the near future lie in analyzing and 
integrating these data and distilling new biologically relevant insights.
P e r s p e c t i v e s
The coordinated regulation of E R a target genes is a complex process dependent on 
transcription factors, coregulatory proteins, DNA elements, histon modifications and 
chromatin modifying complexes. The recent and fast moving advances in technology 
have given us the ability to gather large amounts of data. In 2000 the first ChIP-chip 
paper was published by Ren and coworkers (Ren et al., 2000). Initially spotted arrays 
were used containing several thousands o f probes covering usually promoter regions. 
Commercial promoter arrays became available a few years later. The first paper to use 
a chromosome wide tiling array, where probes are present at set intervals spanning hu­
man chromosome 21 and 22, was published in 2004 (Cawley et al., 2004). A true 
genome-wide ChIP-chip experiment was performed on E R a by Carroll and coworkers 
and published in 2006 (Carroll et al., 2006). W ithin 5 or 6 years microarray technology 
developed from user created spotted arrays containing thousands o f probes, to commer­
cially available sets o f genome-wide tiling arrays, containing around 15 million probes. 
Notwithstanding this rapid development, microarrays have important intrinsic draw­
backs. First of all, it is very expensive to perform microarrays experiments genome-wide.
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Second, probes have to be designed from a known genome sequence, and will differ in 
melting temperature, nucleotide composition and uniqueness. This results in different 
annealing behavior and cross-hybridization. High throughput sequencing lacks this bias 
and has developed as quickly if not quicker as microarrays. Initially ChIP-cloning was 
used, where the C hIP’ed fragments were cloned and then sequenced, a labor-intensive 
approach with limiter throughput. Later an approach for sequencing transcript, SAGE, 
was adapted to be used for ChIP, so called paired-end di-tag approach. Here on both 
sides of a fragment the first 18 bp are sequenced, and fragments are ligated to each other 
to limit the number of fragments to be sequenced, a technique known as ChIP-PET. In 
2006 the first ChIP-PET paper was published by Wei and coworkers, a total of around 
40,000 fragments was sequenced (Wei et al., 2006). W ith the development of the Illu­
mina high throughput sequencing the number o f fragments that could be sequenced in­
creased dramatically resulting in the development o f ChIP coupled to high throughput 
sequencing, ChIP-Seq. The first ChIP-Seq paper by Robertson was published in 2007, 
only two years after the ChIP-PET study (Robertson et al., 2007). A total of ~47 million 
fragments were sequenced. The developments in first microarray and later sequencing 
technology have been very rapid. The ChIP method itself is also subject to improve­
ment, illustrated by the development of ChIA-PET. N ot only can we map the bind­
ing o f a transcription factor to a specific region, but it is now also possible to identify 
chromatin on a global scale (Fullwood et al., 2009). At the start of this study microarray 
based technologies had just started and no genome-wide profiling had been done. D ur­
ing the study microarrays have almost become obsolete for the use o f ChIP profiling and 
sequencing based technologies were introduced and have progressed rapidly.
The genome usually represented in a two-dimensional linear way, a line going from left 
to right containing genes and promoters. In reality, genomes are ordered in complex 
three-dimensional structures packed in the nucleus. This three-dimensional structure 
is dynamic and the interaction o f chromatin regions is a regulated process. To truly 
understand what is occurring during transcriptional regulation the chromatin interac­
tions and the three-dimensional structure must be taken into account. Technological 
advances such as high throughput sequencing and ChIA-PET will allow us to paint a 
picture of what is really happening in the nucleus. A better understanding will hopefully 
enable us to intervene in this system when regulation goes wrong like it does in cancer. 
This thesis illustrates how quickly these techniques develop. The story o f the E R a is far 
from complete, but the work in this thesis provides a global insight in the E R a network 
will help to clarify its complex role in normal physiology and cancer.
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S a m e n v a t t i n g
Ongeveer 40 jaar geleden is de oestrogeen receptor ontdekt, een eiwit dat aanwezig is in 
borsttumoren. Er werd toen aangetoond dat de aanwezigheid van de oestrogeen recep­
tor kan voorspellen of het verstoren van de hormoonbalans effect heeft op de groei van 
de borsttumor. In de 40 jaar na deze ontdekking zijn we veel meer over de oestrogeen 
receptor te weten gekomen. We weten nu dat de E R a een ligand afhankelijke transcrip- 
tiefactor is die een groot aantal doelwit genen reguleert. Al deze informatie heeft aan de 
basis gestaan van de ontdekking van tamoxifen in de jaren ‘60. Tamoxifen werd initieel 
gebruikt als een anticonceptiemiddel en werd vanaf de jaren ‘70 gebruikt voor de behan­
deling van borstkanker. Sinds die tijd is er veel kennis opgedaan over de verschillende 
aspecten van de oestrogeen signalering. We weten nu dat de oestrogeen receptor behalve 
in borstkanker ook belangrijke processen reguleert in bijvoorbeeld de baarmoeder, bot, 
hart, bloedvaten en hersenen. Ook zijn er genen geïdentificeerd die gereguleerd worden 
door de oestrogeen receptor en die in deze processen een rol spelen. In dit proefschrift is 
onderzoek gedaan naar dit netwerk van genen en bindingsplaatsen, met aan het hoofd 
van dit netwerk de oestrogeen receptor. Verder is er gekeken naar het effect van oestro- 
geen receptor modulators zoals tamoxifen, op dit netwerk.
In hoofdstuk 1 wordt beschreven welke gegevens er aan het begin van dit project bes­
chikbaar waren over E R a bindingsplaatsen en doelwit genen en welke methoden er zijn 
om deze te identificeren. Dit hoofdstuk bespreekt verder de verschillende technieken 
die er tot dan toe gebruikt zijn en de vooruitgang die geboekt is in het onderzoek naar 
E R a signalering.
In hoofdstuk 2 hebben we voor het eerst E R a bindingsplaatsen geïdentificeerd in het 
hele genoom, door gebruik te maken van genoom-brede ChIP-chip. We hebben ook 
voor het eerst het effect van tamoxifen op de binding van E R a op deze genoom-brede 
schaal bekeken. We laten zien dat de binding van E R a verdeeld is over het hele genoom 
en dat maar een klein gedeelte bindt in de promoter regio’s. Verder laten we zien dat 
tamoxifen gebonden E R a nog steeds kan binden aan een groot gedeelte van de E R a 
bindingsplaatsen en dat deze een groep vormen die gedeeltelijk overlapt met de E2 ge­
bonden E R a bindingsplaatsen.
In hoofdstuk 3 gebruiken we Illumina sequentie analyse gekoppeld aan ChIP (ChIP- 
Seq) om een veel gedetailleerder genoom-breed profiel te maken van E R a binding. Dit 
is gedaan in zowel de aan- als afwezigheid van E2. We hebben 13.173 E R a bindingsp-
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laatsen gevonden en hebben nieuwe gegevens over cis elementen beschreven. Ook heb­
ben we onze ChIP-Seq data vergeleken met de ChIP-chip data uit hoofdstuk 1. Hieruit 
blijkt dat ChIP-Seq gevoeliger, nauwkeuriger en goedkoper is dan ChIP-chip.
We hebben de ChIP-Seq data uitgebreid in hoofdstuk  4. Door extra experimenten 
hebben we een ChIP-Seq profiel van E R a binding verkregen wanneer deze gebonden 
is met tamoxifen of met fulvestrant. Verder laten we zien dat tamoxifen en fulvestrant 
de binding van E R a aan het DN A  gedeeltelijk beïnvloed. Echter, E R a kan nog steeds 
binden aan het D N A  maar dan wel aan een kleiner aantal bindingsplaatsen. Ook laten 
we zien dat er een groep van bindingsplaatsen is die specifiek zijn voor bepaalde ligan­
den. Uit een ChIP-Seq experiment voor RNA polymerase 2 blijkt dat de grote groep van 
E R a bindingsplaatsen een veel kleiner aantal genen reguleert en dat verrijking van RNA 
polymerase 2 op de promoters (PPEP of pausing genoemd) vaak voorkomt in M CF-7 S 
cellen, maar wel slechts op een beperkt aantal van E2 gereguleerde genen. Tamoxifen en 
fulvestrant zorgen ervoor dat RNA polymerase 2 niet meer kan binden aan de promoter 
of het coderend gedeelte van E2 omhoog gereguleerde genen. Op omlaag gereguleerde 
genen gedragen tamoxifen en fulvestrant zich verschillend. Tamoxifen zorgt ervoor dat 
deze genen omlaag gereguleerd blijven terwijl fulvestrant er juist voor zorgt dat deze 
weer omhoog gereguleerd worden, en functioneert daar dus als een antagonist.
Er zijn al verschillende genoom-brede ChIP profielen gepubliceerd. Opvallend is dat 
er redelijk wat verschil zit in deze profielen en daardoor ook in de conclusies van deze 
onderzoeken. In hoofdstuk  5 hebben we onderzocht of het antilichaam dat gebruikt is 
om de profielen te maken de oorzaak is van deze verschillen. Hiervoor hebben we ER a 
ChIP-Seq profielen gemaakt met drie verschillende antilichamen. het F3A6, Dia050 
en het H C-20 antilichaam. Hieruit blijkt dat het profiel van het F3A6 en het Dia050 
antilichaam voor een groot deel overeenkomen. Het profiel van het polyklonale HC-20 
antilichaam overlapt bijna volledig met het profiel van de twee monoklonale antilicha- 
men en bevat ook een groot aantal bindingsplaatsen die niet in de andere profielen 
voorkomen. Onze analyse van deze bindingsplaatsen specifiek voor HC-20 laat zien 
dat deze voornamelijk bindingsplaatsen zijn met lage affiniteit voor ERa. We hebben 
ChIP-Seq gedaan met HC-20 en een E R a negatieve cel lijn waaruit blijkt dat de HC-20 
bindingsplaatsen echt zijn en niet komen door kruisreactiviteit. M otief analyse van de 
verschillende profielen laat zien dat er grote verschillen zitten in de aanwezigheid en ver­
rijking van sequentiemotieven. Hieruit blijkt dat de keuze van het antilichaam van groot 
belang is voor het ChIP profiel en de conclusies die daaruit getrokken worden.
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In hoofdstuk 6 bespreken we uitgebreid de beschikbare data over E R a en de status van 
het E R a onderzoek aan het einde van dit project. De technieken die beschikbaar zijn om 
inzicht te verkrijgen in het E R a bindingsplaats en doelwitgen netwerk worden bespro­
ken. Verder bespreken we hoe de ingewikkelde samenwerking tussen receptor, ligand, 
DN A  sequentie, post-translationele modificaties, lokale chromatine status en DN A  lus­
sen uiteindelijk leidt tot de regulatie van transcriptie. We geven een overzicht van de 
vooruitgang die geboekt is in de identificatie van het E R a bindingsplaats en doelwitgen 
profiel inclusief de recentelijk verschenen genoom-brede studies. Ook bespreken wat hier­
van toepasbaar is in de kliniek. ChIA-PET, een techniek waarmee de interacties tussen 
verschillende DNA gebieden geïdentificeerd kan worden, wordt ook besproken.
In het addendum wordt de ontwikkeling van de nieuwe technologie ChIA-PET be­
schreven. Hiermee kunnen de interacties tussen chromatine regio’s op een genoom- 
brede schaal geïdentificeerd worden. We hebben deze techniek gebruikt om het complete 
netwerk van interacties in kaart te brengen die onder invloed van de E R a plaatsvinden. 
We laten zien dat de meeste van de sterke en betrouwbaarste E R a bindingsplaatsen via 
lussen in het DNA verankerd zijn aan promoters, vaak over grote afstanden. De E R a 
brengt genen hoogstwaarschijnlijk bij elkaar waardoor de expressie van gecoördineerd 
kan worden. De positie van een gen in de lus correleert met de transcriptionele activiteit. 
Hieruit blijkt dat het zeer goed mogelijk is dat deze interacties tussen chromatine regio’s 
een belangrijk en essentieel mechanisme zijn waarmee expressie gereguleerd wordt.
Samenvattend hebben de studies die in dit proefschrift beschreven staan nieuwe ge­
gevens en inzichten in het bindingsplaats en doelwitgen netwerk van de E R a verschaft. 
Ondanks dat er al veel gegevens beschikbaar zijn is er nog steeds veel onbekend over 
bijvoorbeeld de kinetiek van regulatie door de E R a of hoe de regulatie plaatsvindt in 
andere cellen zoals bijvoorbeeld primaire cellen. Door de zeer snelle ontwikkelingen 
in sequentieanalyse zal de hoeveelheid data in de nabije toekomst drastisch toenemen. 
Door nieuwe technieken zoals ChIA-PET krijgen we ook meer inzicht in het complexe 
netwerk tussen promoters, enhancers en de chromatine regio’s onderling. De uitdag­
ingen in de toekomst liggen dan ook vooral in het analyseren van al deze data en het 
extraheren van biologisch relevante inzichten.
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